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A B S T R A C T
Background
Aggressive, agitated or violent behaviour due to psychosis constitutes an emergency psychiatric treatment where fast-acting interventions
are required. Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation.
Objectives
To examine whether oral risperidone alone is an effective treatment for psychosis-induced aggression or agitation.
Search methods
We searched the Cochrane Schizophrenia Group’s Study-Based Register of Trials (up to April 2017); this register is compiled by
systematic searches of major resources (including AMED, BIOSIS CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries
of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings. There are no language, date,
document type, or publication status limitations for inclusion of records into the register.
Selection criteria
Randomised controlled trials (RCTs) comparing rapid use of risperidone and other drugs, combinations of drugs or placebo for people
exhibiting aggression or agitation (or both) thought to be due to psychosis.
Data collection and analysis
We independently inspected all citations from searches, identified relevant abstracts, and independently extracted data from all included
studies. For binary data we calculated risk ratio (RR) and for continuous data we calculated mean difference (MD), all with 95%
confidence intervals (CI) and used a fixed-effect model. We assessed risk of bias for the included studies and used the GRADE approach
to produce a ’Summary of findings’ tables.
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Main results
The review now contains data from nine trials (total n = 582) reporting on five comparisons. Due to risk of bias, small size of trials,
indirectness of outcome measures and a paucity of investigated and reported ’pragmatic’ outcomes, evidence was graded as very-low
quality. None of the included studies provided useable data on our primary outcome ’tranquillisation or asleep’ by 30 minutes, repeated
need for tranquillisation or any economic outcomes. Data were available for our other main outcomes of agitation or aggression,
needing restraint, and incidence of adverse effects.
Risperidone versus haloperidol (up to 24 hours follow-up)
For the outcome, specific behaviour - agitation, no clear difference was found between risperidone and haloperidol in terms of efficacy,
measured as at least 50% reduction in the Positive and Negative Syndrome Scale - Psychotic Agitation Sub-score (PANSS-PAS) (RR
1.04, 95% CI 0.86 to 1.26; participants = 124; studies = 1; very low-quality evidence) and no effect was observed for need to use
restraints (RR 2.00, 95% CI 0.43 to 9.21; participants = 28; studies = 1; very low-quality evidence). Incidence of adverse effects was
similar between treatment groups (RR 0.94, 95% CI 0.54 to 1.66; participants = 124; studies = 1; very low-quality evidence).
Risperidone versus olanzapine
One small trial (n = 29) reported useable data for the comparison risperidone versus olanzapine. No effect was observed for agitation
measured as PANSS-PAS endpoint score at two hours (MD 2.50, 95% CI -2.46 to 7.46; very low-quality evidence); need to use
restraints at four days (RR 1.43, 95% CI 0.39 to 5.28; very-low quality evidence); specific movement disorders measured as Behavioural
Activity Rating Scale (BARS) endpoint score at four days (MD 0.20, 95% CI -0.43 to 0.83; very low-quality evidence).
Risperidone versus quetiapine
One trial reported (n = 40) useable data for the comparison risperidone versus quetiapine. Aggression was measured using theModified
Overt Aggression Scale (MOAS) endpoint score at two weeks. A clear difference, favouring quetiapine was observed (MD 1.80, 95%
CI 0.20 to 3.40; very-low quality evidence). No evidence of a difference between treatment groups could be observed for incidence of
akathisia after 24 hours (RR 1.67, 95% CI 0.46 to 6.06; very low-quality evidence). Two participants allocated to risperidone and one
allocated to quetiapine experienced myocardial ischaemia during the trial.
Risperidone versus risperidone + oxcarbazepine
One trial (n = 68) measured agitation using the Positive and Negative Syndrome Scale - Excited Component.(PANSS-EC) endpoint
score and found a clear difference, favouring the combination treatment at one week (MD 2.70, 95% CI 0.42 to 4.98; very low-quality
evidence), but no effect was observed for global state using Clinical Global Impression - Improvement (CGI-I) endpoint score at one
week (MD -0.20, 95% CI -0.61 to 0.21; very-low quality evidence). Incidence of extrapyramidal symptoms after 24 hours was similar
between treatment groups (RR 1.59, 95% CI 0.49 to 5.14; very-low quality evidence).
Risperidone versus risperidone + valproic acid
Two trials compared risperidone with a combination of risperidone plus valproic acid. No clear differences between the treatment
groups were observed for aggression (MOAS endpoint score at three days: MD 1.07, 95% CI -0.20 to 2.34; participants = 54; studies
= 1; very low-quality evidence) or incidence of akathisia after 24 hours: RR 0.75, 95% CI 0.28 to 2.03; participants = 122; studies =
2; very low-quality evidence).
Authors’ conclusions
Overall, results for the main outcomes show no real effect for risperidone. The only data available for use in this review are from
nine under-sampled trials and the evidence available is of very low quality. This casts uncertainty on the role of risperidone in rapid
tranquillisation for people with psychosis-induced aggression. High-quality pragmatic RCTs are feasible and are needed before clear
recommendations can be drawn on the use of risperidone for psychosis-induced aggression or agitation.
P L A I N L A N G U A G E S U M M A R Y
Risperidone as a means of calming people who are aggressive or agitated due to psychosis
Background
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People with psychosis may experience hearing voices (hallucinations) or abnormal thoughts (delusions), which can make the person
frightened, distressed, and agitated. Experiencing such emotions can sometimes lead to aggressive behaviour. This poses a challenge
and dilemma for staff. Mental health professionals have to diagnose and deliver the best available treatment to prevent the risk of harm
to both the patient and/or others, the faster the better. Risperidone is a medication taken by mouth, widely used for treating people
manage the symptoms of psychosis. As well as being an antipsychotic (preventing psychosis), it also could calm people down or help
them to sleep.
Aim of the review
This review looks at whether the antipsychotic, risperidone, could be a fast, effective treatment for people who are agitated or aggressive
as a result of having psychosis.
Searches
The Information Specialist of Cochrane Schizophrenia ran searches of their specialised register for randomised trials that looked at
the effects of giving risperidone alone compared with giving either placebo (dummy treatment) or other treatments to people who are
aggressive or agitated as a results of having psychosis. The latest date of searching was April 2017.
Results
Nine studies, with 582 participants, are included in the review but the information provided is poor in quality and tended to provide
information only partially relevant to the main aim of this review, particularly a lack of information regarding immediate (i.e. under
one hour after treatment) calming effects and the need for repeated tranquillisation. Economic data were also not reported. In the
trials, risperidone was compared to other antipsychotics, which included haloperidol, olanzapine and quetiapine. The review found
risperidone was no better or worse than haloperidol for calming aggression within 24 hours, and that two weeks after treatment,
people receiving risperidone had higher (worse) scores on scales measuring levels of aggression than those receiving quetiapine. Both
these results, however, were graded as very low-quality evidence. One small study found a combination of antipsychotics (risperidone
plus oxcarbazepine) was better than risperidone alone at reducing levels of agitation but these data were collected after one week and
again, this evidence was rated as very low quality. No clear differences in the incidence of side effects such as movement disorders were
observed.
Conclusions
The review authors conclude that at the moment, there is weak, unclear evidence regarding the use of risperidone for calming people
who are aggressive due to psychosis, and no firm conclusions can be made. Therefore, health professionals and people with mental
health problems are left without clear evidence-based guidance. However, good quality trials are possible and more research is needed
to help people dealing with psychosis-induced aggression consider and understand which medication is better at calming aggression,
has fewer side effects and works quickly.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
RISPERIDONE compared to OTHER ANTIPSYCHOTIC: a. HALOPERIDOL for psychosis- induced aggression or agitation (rapid tranquillisation)
Patient or population: psychosis-induced aggression or agitat ion (rapid tranquillisat ion)
Setting: Psychiatric acute care units.
Intervention: RISPERIDONE
Comparison: OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with OTHER
ANTIPSYCHOTIC: a.
HALOPERIDOL
Risk with RISPERI-
DONE
Tranquillisat ion or
asleep by 30 minutes -
not measured
- - - - -
Repeated need for tran-
quillisat ion within 24
hours - not measured
- - - - -
Specif ic behaviour: ag-
itat ion, up to 24 hours
(PANSS-PAS response)
assessed with: ≥50%
reduct ion on PANSS-
PAS baseline score
Study populat ion RR 1.04
(0.86 to 1.26)
124
(1 RCT)
⊕©©©
VERY LOW 123
758 per 1.000 788 per 1.000
(652 to 955)
Global outcome: need
for addit ional measures
assessed with: use of
restraints
Study populat ion RR 2.00
(0.43 to 9.21)
28
(1 RCT)
⊕©©©
VERY LOW 2345
143 per 1.000 286 per 1.000
(61 to 1.000)
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Adverse ef fects: up to
24 hours
assessed with: one or
more AEs
Study populat ion RR 0.94
(0.54 to 1.66)
124
(1 RCT)
⊕©©©
VERY LOW 123
290 per 1.000 273 per 1.000
(157 to 482)
Economic outcomes -
not measured
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Risk of bias - rated ’very serious’: high risk of performance and ’select ive report ing’ bias. Def init ion of the outcomes are not
consistent between the mult iple publicat ions.
2 Imprecision - rated ’serious’: Opt imal Information Size (OIS) criterion not met.
3 Only one study available.
4 Risk of bias - rated ’very serious’: high risk of attrit ion bias and ’select ive report ing’ bias.
5 Indirectness - rated ’serious’: provided outcome is at a t ime point (4 days) dif f erent f rom those of primary importance in this
sett ing.
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B A C K G R O U N D
Description of the condition
Aggression has been defined by NICE 2005 as a willingness to
inflict harm, whether behavioural or verbally expressed, and re-
gardless of whether physical harm is sustained. Violence has been
described as the intentional use of physical force whether threat-
ened or actual, against oneself, another person, a group, or com-
munity, that results in, or is likely to result in injury, death, psy-
chological harm, maldevelopment or deprivation (WHO 2002;
Wright 2002). Aggression is not a diagnosis in itself, but can be
a feature of several mental health conditions. There is a well-es-
tablished significant relationship between psychosis and violence
(Arseneault 2000; Brennan 2000; Fazel 2006). Agitated or violent
behaviour constitutes roughly 10% of all emergency psychiatric
treatment (Tardiff 1982). Overall, the prevalence of violence in
people who have schizophrenia, major depression or manic/bipo-
lar disorder is about 11% to 13%. An even higher percentage of
people with alcoholism (25%) or substance misuse (35%) have,
at some stage, presented with violence or aggression. Even when
additional factors such as alcohol and drug use are taken into ac-
count, psychotic symptoms such as delusions or hallucinations
are significantly and strongly associated with aggressive and vio-
lent behaviour (Swanson 1990). Low GABA (gamma-aminobu-
tyric acid) and serotonin levels in various parts of the brain have
been suggested to be associated with aggressive behaviour whilst
enhanced norepinephrine and dopamine levels with increased ag-
gression (Bazire 2009).
Description of the intervention
There are many guidelines that describe the management of peo-
ple with aggression and violence. (APA 2004; Addington 2005;
NICE 2015).NICE guidelines recommend preventative measures
such as observation, de-escalation and use of p.r.n. (i.e.: pro re nata,
as needed) medication should initially be used. If these measures
fail to calm the agitated individual, restrictive measures including
seclusion and manual/mechanical restraint, may be pursued. In-
dividuals unable or unwilling to consent to treatment may require
rapid tranquillisation with lorazepam on its own or intramuscular
haloperidol combined with intramuscular promethazine.
Risperidone was the first novel second-generation antipsychotic
and has been widely available since the 1990s (C23H27FN4O2,
Figure 1). The main pharmacological activities of risperidone in-
clude serotonin 5-HT2 receptor blockade and dopamine D2 an-
tagonism (Megens 1994), and it has therefore been suggested
that atypical antipsychotics could have an anti-aggressive effect
(Buckley 1999). Risperidone is licensed in the UK for the treat-
ment of psychotic conditions in which positive or negative symp-
toms are prominent, to maintain clinical improvement during
continuation therapy in patients who have shown an initial treat-
ment response, and for the treatment of mania in bipolar disorder
(BNF 2017).
Figure 1. Risperidone structure
Risperidone and aripiprazole are the only two antipsychotics hav-
ing FDA (Food and Drug Administration) approval for irritabil-
ity associated with autistic disorder in children (Mathis 2009).
Risperidone is also licensed in the UK for psychosis, persistent
aggression in conduct disorder and severe aggression in autism
in children (BNF 2017). A Cochrane review on atypical antipsy-
chotics for aggression and psychosis in Alzheimer’s disease found
that the adverse events associated with risperidone may outweigh
the benefits and suggested that risperidone should only be used
for treating aggression in those with dementia when there is severe
distress or risk of physical harm (Ballard 2006). Risperidone is now
licensed in the UK at a low dose for the short-termmanagement of
aggression in Alzheimer dementia which is unresponsive to non-
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pharmacological interventions (BNF 2017). Katz 1999 also found
that 1 mg/day of risperidone was useful in controlling aggression
in severe dementia.
Risperidone has atypical properties especially at lower doses but
can become more ’conventional’ at high doses (Stahl 2008).
Risperidone has been found to be associated with more adverse ef-
fects such as extrapyramidal side effects, hyperprolactinaemia and
sexual dysfunction than other antipsychotics (Tran 1997). A dou-
ble-blind study looking at risperidone use in schizophrenia found
that although hyperprolactinaemia is significantly associated with
long-term risperidone use, symptoms related to high prolactin lev-
els are rare (Conley 2001). Risperidone has been found to cause
weight gain, but the link is not as significant as with olanzapine
(Conley 2001) and clozapine (Wirshing 1999). Respiridone may
cause a disproportionate increase in weight gain in adolescents
compared to adults, which is a key area in non-compliance in this
group (Fleischhaker 2007). Risperidone was the first atypical an-
tipsychotic that became available in a long-term depot injectable
formulation lasting for two weeks. Such dosage formulations may
improve compliance, and if compliance is enhanced, may lead to
better long-term outcomes. The difficulty is patient volunteers are
generally co-operative and studies therefore do not address effi-
cacy of depot injection in the non-compliant patient population.
(Sampson 2016).
How the intervention might work
Among the atypical antipsychotics, risperidone has one of the sim-
plest pharmacological profiles and comes closest to a serotonin-
dopamine antagonist. Risperidone is a benzisoxazole derivative
which blocks dopamine2 receptors and 5HT2 receptors (with a
high ratio of serotonin to D2 receptor blockade). It also blocks
alpha1 and alpha2 adrenoceptors, H1 receptors, and has no effect
on beta adrenoceptors, muscarinic cholinoceptors or peptidergic
receptors (Janssen 1988). Psychosis is considered to be associated
with disturbances in the activity of neurotransmitters, dopamine in
particular, in the brain. Risperidone has therefore been suggested
to work by blocking the receptors in the brain that dopamine acts
on, which prevents the excessive activity of dopamine and helps
to control aggression or agitation. Czobor 1995 suggested that the
combination of risperidone on the serotonergic and dopaminergic
systems may underlie risperidone’s effect on hostility.
Aleman 2001 found some evidence that risperidone is useful
in reducing aggression in schizophrenia; although there is some
conflicting evidence, risperidone may have less of a sedative ef-
fect than conventional antipsychotics, which in turn suggests the
anti-aggressive effects of risperidone is not mediated by sedation.
Compared with conventional antipsychotics such as haloperidol,
risperidone produces some significantly better results according to
Positive and Negative Syndrome Scale (PANSS) scores (Hunter
2003).
Why it is important to do this review
Mental health problems impose a significant burden in develop-
ing countries (Shah 2000). As about 1% of any population suf-
fers from schizophrenia (Sartorius 1972), and around 80% of the
world live in developing countries (CIA 2008), most care of peo-
ple with serious mental illnesses such as schizophrenia must take
place in these low- and middle-income country situations. There
is no evidence that the prevalence of psychiatric emergencies dif-
fer across the globe and it seems reasonable to assume that most
episodes of severe aggression and agitation in people with severe
mental health problems will be taking place in low- and middle-
income countries. In many of these countries expensive antipsy-
chotic drugsmay be available, but they are generally not affordable
(WPA 2008).
Aronson 1997 conducted a review looking at the cost-effectiveness
and quality of life of patients before and after commencing risperi-
done treatment and found that risperidone improved symptoms
of psychosis, decreased the need for hospitalisation and improved
quality of life. Viale 1997 also investigated the cost-effectiveness
of risperidone before and after commencing treatment in patients
with schizophrenia and found days in hospital were reduced by
26%, but there was a 3.4% increase in total psychiatric healthcare
costs.
The fast-dissolving risperidone tablet formulation may be useful
to ensure administration. These ’orodispersible’ tablets are an op-
tion in acutely agitated psychosis (Normann 2006), and can be as
effective as an alternative to intramuscular antipsychotics (Currier
2001). Despite being regularly used for the management of psy-
chosis-induced agitation, we know of no systematic reviews on
the use of risperidone in the emergency situation. This is one of a
series of linked reviews (Table 1).
O B J E C T I V E S
To examine whether risperidone is an effective treatment for psy-
chosis-induced aggression or agitation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all relevant randomised controlled trials (RCTs). If
a trial had been described as ’double-blind’ but had implied ran-
domisation and the demographic details of each group had been
similar, wewould have included it.We excluded quasi-randomised
studies, such as those allocated by using alternate days of the week.
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Types of participants
People exhibiting aggression or agitation (or both) thought to be
due to psychosis, regardless of age and sex. Studies that also in-
volved people with other diagnoses, such as drug or alcohol in-
toxication, organic problems including dementia, non-psychotic
mental illnesses or learning disabilities, were included as long as
the majority of participants (> 50%) were experiencing psychosis.
We are interested in making sure that information is as relevant
to the current care of people with schizophrenia as possible, so, if
reported, would clearly highlight the current clinical state (acute,
early post-acute, partial remission, remission) as well as the stage
(prodromal, first episode, early illness, persistent). In addition,
where possible, we would report whether the studies primarily
focused on people with particular problems (for example, negative
symptoms, treatment-resistant illnesses).
Types of interventions
1. Risperidone
Given alone, any dose and mode of administration.
2. Other antipsychotic medications
Given alone, any dose and mode of administration.
3. Placebo
Active or non-active.
Types of outcome measures
Where possible, we grouped outcomes by time: by 30 minutes,
up to two hours, up to four hours, up to 24 hours, and over 24
hours.
Primary outcomes
1. Not tranquil or asleep
1.1 Not tranquil or asleep - by up to 30 minutes
2. Adverse events
Secondary outcomes
1. Tranquillisation or asleep
1.1 Not tranquil
1.2 Not asleep
1.3 Time to tranquillisation/sleep
1.4 Time to tranquillisation
1.5 Time to sleep
2. Specific behaviours
2.1 Self-harm, including suicide
2.2 Injury to others
2.3 Agitation
2.3.1 Another episode of agitation by 24 hours
2.3.2 No clinically important change in agitation
2.3.3 Any change in agitation
2.4 Aggression
2.4.1 Another episode of aggression by 24 hours
2.4.2 No clinically important change in aggression
2.4.3 No change in aggression
2.4.4 Average endpoint aggression score
2.4.5 Average change in aggression scores
3. Global outcomes
3.1 No overall improvement
3.2 Use of additional medication
3.3 Use of restraints/seclusion
3.4 Relapse - as defined by each study
3.5 Recurrence of violent incidents
3.6 Needing extra visits from the doctor
3.7 Refusing oral medication
3.8 Not accepting treatment
3.9 Average endpoint score
3.10 Average change score
3.11 Average dose of drug
4. Service outcomes
4.1 Duration of hospital stay
4.2 Re-admission
4.3 No clinically important engagement with services
4.4 No engagement with services
4.5 Average endpoint engagement score
4.6 Average change in engagement scores
5. Mental state
5.1 No clinically important change in general mental state
5.2 No change in general mental state
5.3 Average endpoint general mental state score
5.4 Average change in general mental state scores
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6. Adverse effects
6.1 Death
6.2 Any general adverse effects
6.3 Any serious specific adverse effects
6.4 Average endpoint general adverse effect score
6.5 Average change in general adverse effect scores
6.6 Clinically important change in specific adverse effects
6.7 Any change in specific adverse effects
6.8 Average endpoint specific adverse effects
6.9 Average change in specific adverse effects
7. Leaving the study early
7.1 For specific reasons
7.2 For general reasons
8. Satisfaction with treatment
8.1 Recipient of treatment not satisfied with treatment
8.2 Recipient of treatment average satisfaction score
8.3 Recipient of treatment average change in satisfaction scores
8.4 Informal treatment provider not satisfied with treatment
8.5 Informal treatment providers’ average satisfaction score
8.6 Informal treatment providers’ average change in satisfaction
scores
8.7 Professional providers not satisfied with treatment
8.8 Professional providers’ average satisfaction score
8.9 Professional providers’ average change in satisfaction scores
9. Acceptance of treatment
9.1 Not accepting treatment
9.2 Average endpoint acceptance score
9.3 Average change in acceptance score
10. Quality of life
10.1 No clinically important change in quality of life
10.2 Not any change in quality of life
10.3 Average endpoint quality of life score
10.4 Average change in quality of life scores
10.5 No clinically important change in specific aspects of quality
of life
10.6 No change in specific aspects of quality of life
10.7 Average endpoint specific aspects of quality of life
10.8 Average change in specific aspects of quality of life
11. Economic outcomes
11.1 Direct costs
11.2 Indirect costs
Outcomes used for ’Summary of findings’ table
Weused theGRADEapproach to interpret findings (Schünemann
2011) and used GRADEpro GDT to create ’Summary of findings’
tables. These tables provide outcome-specific information con-
cerning the overall quality of evidence from each included study
in the comparison, the magnitude of effect of the interventions
examined, and the sum of available data on all outcomes we rated
as important to patient-care and decision making. We included
the following outcomes in the ’Summary of findings’ table:
1. tranquillisation or asleep - by 30 minutes;
2. repeated need for rapid tranquillisation - within 24 hours;
3. specific behaviours - agitation or aggression;
4. global state - needing restraints or seclusion;
5. adverse events - serious adverse effects (not death);
6. economic outcomes.
For assessments of the overall quality of evidence for each outcome
that included pooled data from RCTs only, we downgraded the
evidence from ’high quality’ by one level for ’serious’ (or by two
for ’very serious’) study limitations (risk of bias), indirectness of
evidence, inconsistency, imprecision of effect estimates or potential
publication bias.
Search methods for identification of studies
No language restriction was applied within the limitations of the
search tools.
Electronic searches
Cochrane Schizophrenia Group Study-Based Register of
Trials
The Information Specialist searched the register (up to 12 April
2017) using the following phrase:
(*rispe* or *9-OH-risperid* or *r 64766* in intervention of
STUDY) AND (*aggress* or *violen* or *agitation* or *tranq*
in title, abstract, index terms of REFERENCE or intervention of
STUDY)
In such a study-based register, searching the major concept re-
trieves all the synonyms and relevant studies because all the stud-
ies have already been organised based on their interventions and
linked to the relevant topics.
This register is compiled by systematic searches of major re-
sources (including AMED, BIOSIS, CINAHL, Embase, MED-
LINE, PsycINFO, PubMed, and registries of clinical trials) and
their monthly updates, handsearches, grey literature, and confer-
ence proceedings (see Group s Module). There are no language,
date, document type, or publication status limitations for inclu-
sion of records into the register.
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Searching other resources
1. Reference searching
We inspected references of all included studies for further relevant
studies.
2. Personal contact
Where necessary, we contacted the first author of each included
study for information regarding unpublished trials.
Data collection and analysis
Selection of studies
1. 2017 search
Review authors EGO and MH independently inspected all ab-
stracts of studies identified as above to identify potentially relevant
reports. Where disagreement occurred, we resolved it by discus-
sion, or where there was still doubt, we acquired the full article for
further inspection and further discussion with CEA. We acquired
the full articles of relevant reports for re-assessment and to make a
final decision on inclusion (see Criteria for considering studies for
this review for this review). Once we had obtained the full articles,
EGO and MH independently inspected all reports and indepen-
dently decided whether they met the inclusion criteria. EGO and
MH were not blinded to the names of the authors, institutions
or journal of publication. Where difficulties or disputes arose, we
discussed them with CEA and if a decision could not be reached,
we added these studies to those awaiting assessment and contacted
the authors of the papers for clarification.
2. 2015 search
Review author KM independently inspected all records identified
in the search for potential relevance.Where difficulties or disputes
arose, KM discussed them with CEA .
3. 2011 and 2013 searches
Review authors UA and FR independently inspected all ab-
stracts of studies identified as above to identify potentially
relevant reports. In addition, to ensure reliability, HJ (see
Acknowledgements) inspected a random sample of these abstracts,
comprising 10% of the total. Where disagreement occurred, we
resolved it by discussion, or where there was still doubt, we ac-
quired the full article for further inspection and further discussion
with CEA. We acquired the full articles of relevant reports for re-
assessment and to make a final decision on inclusion (see Criteria
for considering studies for this review for this review). Once we
had obtained the full articles, UA and FR independently inspected
all reports and independently decided whether they met the in-
clusion criteria. UA and FR were not blinded to the names of the
authors, institutions or journal of publication. Where difficulties
or disputes arose, we discussed them with HJ and CEA and if we
had been unable to reach a decision, we would have added these
studies to those awaiting assessment and contacted the authors of
the papers for clarification.
Data extraction and management
1. Extraction
1.1 2017 search
Review authors EGO andMH independently extracted data from
all included studies. Again, any disagreement was discussed, deci-
sions documented and, if necessary, we contacted the authors of
studies for clarification. If there had been any remaining problems,
we would have consulted with CEA to help clarify issues and these
final decisions would have been documented. We extracted data
presented only in graphs and figures whenever possible, but we
only included the data if both EGO and MH independently had
the same result; we used Plot Digitizer open source software for
data extraction from figures, following instructions provided by
Kadic 2016. We attempted to contact authors through an open-
ended request in order to obtain missing information or for clarifi-
cation whenever necessary. If studies had beenmulti-centre, where
possible, we would have extracted data relevant to each compo-
nent centre separately.
1.2 2011 and 2013 searches
Review authors UA and FR independently extracted data from
all included studies. In addition, to ensure reliability, HJ inde-
pendently extracted data from a random sample of these studies.
Again, we discussed any disagreement, documented decisions and,
if necessary, we contacted the authors of studies for clarification.
With any remaining problems, CA helped to clarify issues and
we documented these final decisions. The need did not arise, but
we had planned to extract data presented only in graphs and fig-
ures whenever possible while only including the data if two review
authors independently had the same result. We had also planned
to attempt to contact authors through an open-ended request in
order to obtain missing information or for clarification whenever
necessary, and to extract data relevant to each component of multi-
centre studies separately if we had found such studies.
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2. Management
2.1 Forms
We extracted data onto standard, pre-designed, simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
a) the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000);
b) the measuring instrument has not been written or modified by
one of the trialists for that particular trial; and
c) the instrument should be a global assessment of an area of func-
tioning and not sub-scores which are not, in themselves, validated
or shown to be reliable. However there are exceptions, we included
sub-scores from mental state scales measuring positive and nega-
tive symptoms of schizophrenia.
Ideally, the measuring instrument should either be i. a self-re-
port or ii. completed by an independent rater or relative (not the
therapist). We realise that this is not often reported clearly; in
Description of studies we noted if this was the case or not.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data: change
data can remove a component of between-person variability from
the analysis; however, calculation of change needs two assessments
(baseline and endpoint), which can be difficult to obtain in un-
stable and difficult-to-measure conditions such as schizophrenia.
We decided primarily to use endpoint data, and only use change
data if the former were not available. If necessary, we combined
endpoint and change data in the analysis, as we preferred to use
mean differences (MDs) rather than standardisedmean differences
(SMDs) throughout (Deeks 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we applied the following standards
to relevant continuous data before inclusion.
For endpoint data from studies including fewer than 200 partici-
pants:
a) when a scale started from the finite number zero, we subtracted
the lowest possible value from the mean, and divided this by
the standard deviation (SD). If this value was lower than one, it
strongly suggests that the data are skewed. We excluded these data
and entered them as ’other data’. If this ratio was higher than one
but less than two, there is suggestion that the data are skewed: we
entered these data and tested whether their inclusion or exclusion
would change the results substantially. If such data changed the
results we entered them as ’other data’; if they did not change the
results substantially, we used these data in the analyses. Finally, if
the ratio was larger than two, we included these data, because it is
less likely that they are skewed (Altman 1996; Higgins 2011).
b) if a scale starts from a positive value (such as the Positive and
Negative Syndrome Scale (PANSS), which can have values from
30 to 210 (Kay 1986)), we modified the calculation described
above to take the scale starting point into account. In these cases
skewed data are present if 2 SD > (S − S min), where S is the
mean score and ’S min’ is the minimum score.
Please note: we planned to enter all relevant data from studies of
more than 200 participants in the analysis irrespective of the above
rules, because skewed data pose less of a problem in large studies.
We entered all relevant change data, as when continuous data are
presented on a scale that includes a possibility of negative values
(such as change data), it is difficult to tell whether or not data are
skewed.
2.5 Common measurement
To facilitate comparison between trials we aimed, where relevant,
to convert variables that can be reported in different metrics, such
as days in hospital (mean days per year, per week or per month)
to a common metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS) (Overall 1962),
or the PANSS (Kay 1986), this could be considered as a clinically
significant response (Leucht 2005; Leucht 2005a). If data based
on these thresholds were not available, we used the primary cut-
off presented by the original authors.
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
risperidone. Where keeping to this made it impossible to avoid
outcome titles with double-negatives (e.g. ’Not un-improved’), we
reported data where the left of the line indicated an unfavourable
outcome. If needed in order to improve readability, we switched
labels on the X axis and stated it in a note accompanying the graph.
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Assessment of risk of bias in included studies
For the 2017 search review authors EGO and MH independently
assessed risk of bias within the included studies by using criteria
described in theCochraneHandbook for Systematic Reviews of Inter-
ventions to assess trial quality (Higgins 2011a). This set of criteria
is based on evidence of associations between overestimate of effect
and high risk of bias of the article such as sequence generation,
allocation concealment, blinding, incomplete outcome data, and
selective reporting.
If the raters had disagreed, we would have made the final rating
by consensus, with the involvement of CEA. Where inadequate
details of randomisation and other characteristics of trials were
provided, we attempted to contact authors of the studies in order
to obtain further information. If non-concurrence had occurred,
we would have reported this.
We noted the level of risk of bias in the text of the review and in
the text and ’Summary of findings’ tables.
For the 2011 and 2013 searches, UA and FRundertook assessment
of risk of bias as above.
Measures of treatment effect
1. Binary data
For binary outcomes we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI), as it has been
shown that RR is more intuitive than odds ratios (Boissel 1999);
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000). Although the number needed to treat for an ad-
ditional beneficial outcome (NNTB) and the number needed to
treat for an additional harmful outcome (NNTH), with their CIs
are intuitively attractive to clinicians, they are problematic to cal-
culate and interpret in meta-analyses (Hutton 2009). For binary
data presented in the ’Summary of findings’ tables we, where pos-
sible, we calculated illustrative comparative risks.
2. Continuous data
For continuous outcomes we estimated the mean difference (MD)
between groups. We preferred not to calculate effect size measures
(standardised mean difference (SMD)). However if scales of very
considerable similarity were used, we presumed there was a small
difference in measurement, and we calculated effect size and trans-
formed the effect back to the units of one or more of the specific
instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra-class correlation (ICC) in clustered studies, leading to a
’unit of analysis’ error (Divine 1992) whereby P values are spuri-
ously low, CIs unduly narrow and statistical significance overesti-
mated. This causes type I errors (Bland 1997; Gulliford 1999).
If clustering had not been accounted for in primary studies, we
would have presented data in a table, with a (*) symbol to indicate
the presence of a probable unit of analysis error. We would have
attempted to contact the first authors of studies to obtain intra-
class correlation coefficients (ICCs) for their clustered data and
to adjust for this by using accepted methods (Gulliford 1999).
If clustering had been incorporated into the analysis of primary
studies, wewould have presented these data as if from a non-cluster
randomised study, but adjusted for the clustering effect. We have
sought statistical advice and have been advised that the binary data
as presented in a report should be divided by a ’design-effect’. This
is calculated using themean number of participants per cluster (m)
and the ICC [Design effect = 1+(m-1)*ICC] (Donner 2002). If
the ICC was not reported it was assumed to be 0.1 (Ukoumunne
1999). If cluster studies had been appropriately analysed taking
into account ICCs and relevant data documented in the report,
synthesis with other studies would have been possible using the
generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence, on entry to the second phase the
participants can differ systematically from their initial state despite
a wash-out phase. For the same reason cross-over trials are not ap-
propriate if the condition of interest is unstable (Elbourne 2002).
As both effects are very likely in severe mental illness, if we had
included cross-over studies, we would only have used data from
the first phase of cross-over studies.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for we would not reproduce
these data or use themwithin analyses. If, however,more than 50%
of those in one arm of a study were lost, but the total loss was less
than 50%, we would address this within the ’Summary of findings’
tables by down-rating quality. Finally, we would also downgraded
quality within the ’Summary of findings’ tables should the loss be
25% to 50% in total.
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2. Binary
In the case where attrition for a binary outcome was between 0%
and 50% and where these data were not clearly described, we
presented data on a ’once-randomised-always-analyse’ basis (an
intention-to-treat (ITT) analysis). Those leaving the study early
were all assumed to have the same rates of negative outcome as
those who completed. We used the rate of those who stayed in the
study - in that particular arm of the trial - and applied this also to
those who did not. We undertook a sensitivity analysis to test how
prone the primary outcomes were to change when data only from
people who completed the study to that point were compared to
the ITT analysis using the above assumptions.
3. Continuous
3.1 Attrition
We used data where attrition for a continuous outcome was be-
tween 0% and 50%, and data only from people who completed
the study to that point were reported.
3.2 Standard deviations
If standard deviations (SDs) were not reported, we tried to obtain
the missing values from the authors. If these were not available,
where there were missing measures of variance for continuous
data, but an exact standard error (SE) and CIs available for group
means, and either P value or t value available for differences in
mean, we could calculate SDs according to the rules described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). When only the SE is reported, SDs are calculated
by the formula SD = SE *
√
(n). The Cochrane Handbook for
Systematic Reviews of Interventions presents detailed formulae for
estimating SDs from P, t or F values, CIs, ranges or other statistics
(Higgins 2011). If these formulae do not apply, we could calculate
the SDs according to a validated imputation method which is
based on the SDs of the other included studies (Furukawa 2006).
Although some of these imputation strategies can introduce error,
the alternative would be to exclude a given study’s outcome and
thus to lose information. Nevertheless, we would have examined
the validity of the imputations in a sensitivity analysis that excludes
imputed values.
3.3 Assumptions about participants who left the trials early
or were lost to follow-up
Various methods are available to account for participants who left
the trials early or were lost to follow-up. Some trials just present
the results of study completers; others use the method of last ob-
servation carried forward (LOCF); while more recently, methods
such as multiple imputation or mixed-effects models for repeated
measurements (MMRM) have become more of a standard. While
the latter methods seem to be somewhat better than LOCF (Leon
2006), we feel that the high percentage of participants leaving the
studies early and differences between groups in their reasons for
doing so is often the core problem in randomised schizophrenia
trials. We therefore determined not to exclude studies based on
the statistical approach used. However, by preference we planned
to use the more sophisticated approaches, i.e. we would have used
MMRM or multiple-imputation to LOCF, and would only have
presented completer analyses if some kind of ITT data were not
available at all. Moreover, we planned to address this issue in the
item ’Incomplete outcome data’ of the ’Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying situations or people which we had
not predicted would arise. Where such situations or participant
groups arose, we fully discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlying methods which we had
not predicted would arise. Where such methodological outliers
arose, we fully discussed these.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 statistic alongside the Chi2 P value. The I2 statistic provides an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of I2
depends on i. magnitude and direction of effects and ii. strength of
evidence for heterogeneity (e.g. P value from Chi2 test, or a CI for
I2). An I2 estimate greater than or equal to 50% accompanied by a
statistically significant Chi2 statistic, was interpreted as evidence of
substantial levels of heterogeneity (Deeks 2011). Where substan-
tial levels of heterogeneity were found in the primary outcome,
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we explored reasons for the heterogeneity (Subgroup analysis and
investigation of heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results ( Egger 1997).
These are described in Chapter 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Sterne 2011).
1. Protocol versus full study
We tried to locate protocols of included randomised trials. If the
protocol was available, we compared outcomes in the protocol
and in the published report. If the protocol was not available,
we compared outcomes listed in the methods section of the trial
report with actually reported results.
2. Funnel plot
We are aware that funnel plots may be useful in investigating
reporting biases but are of limited power to detect small-study
effects. We decided not to use funnel plots for outcomes where
there were 10 or fewer studies, or where all studies were of similar
size. In future versions of this review, if funnel plots are possible,
we will seek statistical advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model. It puts added weight onto small studies
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
We chose the fixed-effect model for analyses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
We did not anticipate any subgroup analyses.
2. Investigation of heterogeneity
If inconsistency was high, we reported it. First, we investigated
whether data were entered correctly. Second, if data were correct,
we visually inspected the graph and successively removed outly-
ing studies to see if homogeneity was restored. For this review, we
decided that should this occur with data contributing to the sum-
mary finding of no more than around 10% of the total weighting,
we would present the data. If not, we would not pool data but
would discuss the issues. We know of no supporting research for
this 10% cut-off but are investigating the use of prediction inter-
vals as an alternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity
were obvious, we stated hypotheses regarding these for future re-
views or versions of this review. We did not anticipate undertaking
analyses relating to these.
Sensitivity analysis
We planned that if there were substantial differences in the direc-
tion or precision of effect estimates in any of the sensitivity anal-
yses listed below, we would not add data from the lower-quality
studies to the results of the higher-quality trials, but would present
these data within a subcategory. If their inclusion did not result in
a substantive difference, they would remain in the analyses.
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they had been
described in some way as to imply randomisation. For the primary
outcomes we would have included these studies, and if there was
no substantive difference when these implied randomised studies
were added to those with better description of randomisation, then
we would have used all data from the implied studies.
2. Assumptions for lost binary data
Where assumptions had to bemade regardingpeople lost to follow-
up (see Dealing with missing data), we compared the findings of
the primary outcomes where we used our assumption compared
with completer data only. If there was a substantial difference, we
reported results and discussed them but continued to employ our
assumption.
Where assumptions had to be made regarding missing SDs data
(see Dealing with missing data), we compared the findings on
primary outcomes where we used our assumption compared with
complete data only. We undertook a sensitivity analysis to test
how prone results were to change when completer data only were
compared with the imputed data using the above assumption. If
there was a substantial difference, we reported results and discussed
them but continued to employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials that were judged to be
at high risk of bias across one or more of the domains of randomi-
sation (see Assessment of risk of bias in included studies) for the
meta-analysis of the primary outcome/s. If the exclusion of trials
at high risk of bias did not substantially alter the direction of effect
or the precision of the effect estimates, thenwe included data from
these trials in the analysis.
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4. Imputed values
We also would have undertaken a sensitivity analysis to assess the
effects of including data from trials where we used imputed val-
ues for ICC in calculating the design effect in cluster-randomised
trials if included. If substantial differences had been noted in the
direction or precision of effect estimates in any of the sensitivity
analyses listed above, we would not pool data from the excluded
trials with the other trials contributing to the outcome, but would
have presented them separately.
5. Fixed and random effects
We synthesised data using a fixed-effect model; however, we also
synthesised data for the primary outcomes using a random-effects
model to evaluate whether this altered the significance of the result.
R E S U L T S
Description of studies
For substantive descriptions of studies please see the
Characteristics of included studies, Characteristics of studies
awaiting classification, and Characteristics of excluded studies.
Results of the search
Electronic searches up to April 2017 identified 850 records of po-
tentially eligible studies. After an initial screening of these records
(checking titles and abstracts), the full-text articles of 92 records
(referring to 70 studies) were obtained. From these 70 studies, 57
(76 records) were excluded with reasons, four studies (four records
were placed in awaiting assessment) and nine studies (12 records)
were included. Please see Figure 2 for summary of the searches up
to April 2017.
Figure 2. Search results - up to April 2017
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Included studies
Details of the included studies in the review are provided in the
Characteristics of included studies table. Searches undertaken be-
tween 2011 and 2015 identified three studies for inclusion (Lim
2010; Walther 2014; Yao 2010). In 2017, we identified six addi-
tional studies for inclusion (Dai 2012; Jin 2013; Li 2013; Wang
2012; Wang 2013; Zhou 2013).
1. Length of studies
The duration of the studies ranged from 24 hours (Lim 2010) to
eight weeks (Dai 2012; Li 2013; Yao 2010).
2. Participants
2.1 Clinical state
Participants presented with acute exacerbation of psychotic symp-
toms. All the studies focused on people whose psychosis had pri-
marily triggered agitation (Lim 2010; Walther 2014; Wang 2012;
Zhou 2013) or aggressive behaviour (Dai 2012; Jin 2013; Li 2013;
Wang 2013; Yao 2010).
2.2 Diagnosis
Eighty-nine per cent of participants (n = 520) had a diagnosis of
schizophrenia. Other diagnosis included schizoaffective disorder
(n = 6, 1%), bipolar I disorder with or without psychotic symp-
toms (n = 43, 7%), schizophreniform disorder (n = 10, 2%), and
psychotic disorder not otherwise specified (n = 3, 1%).
2.3 Exclusions
Reported exclusion criteria included pregnant or lactating women,
people with serious medical illnesses, people who had used certain
medications (e.g. antipsychotics, long-acting antipsychotics, ben-
zodiazepines) within a specified period prior to enrolment, people
with a known allergy or hypersensitivity to the study drugs, and
people with alcohol or psychoactive substance use disorder.
2.4 Age
Six studies reported age range and a mean age (Dai 2012; Jin
2013; Li 2013; Walther 2014; Wang 2012; Yao 2010), one study
reported an age range (Lim 2010), and two studies reported a
mean age (Wang 2013; Zhou 2013). Age ranges varied from the
narrowest being 20-30 years (Dai 2012) to the largest one being
of 18-65 (Jin 2013; Lim 2010); mean ages varied from the lowest
being of 25.3 (Dai 2012) years to the highest 39.4 years (Jin 2013).
2.5 Sex
The studies included a total of 353 male participants and 229
female participants.
3. Study size
The study sizes varied with the smallest study having 40 partic-
ipants (Dai 2012) and the largest randomising 124 people (Lim
2010).
4. Setting
In all the included studies, participants presented at psychiatric
emergency departments and were newly admitted inpatients.
5. Interventions
A total of five comparisons were identified in the included studies:
three comparisons involved a single drugwhilst the other two com-
parisons involved a combination. Unfortunately, only two com-
parisons (’risperidone versus haloperidol’, and ’risperidone versus
valproic acid’) could benefit from more than one study as source
of data; moreover, as for the first comparison this held true for a
single outcome only (’leaving the study early’).
Involved daily doses of risperidone started from 1 mg (Dai 2012;
Li 2013; Wang 2013; Yao 2010) or 2 mg (Lim 2010; Walther
2014) to a maximum of 4 mg (Zhou 2013) or 6 mg (Dai 2012;
Li 2013; Lim 2010; Walther 2014; Wang 2013; Yao 2010). In
one study (Wang 2012), authors declared a titration without a
specification on the intended doses, reporting only a mean daily
administered dose (4.2 mg ± 0.35mg). In Jin 2013 dosages were
not specified.
5.1 Versus antipsychotics
Haloperidol intramuscular (IM) dose was in the 5 mg to 15 mg
range (Lim 2010), whilst as for the oral formulation it was a fixed
dose of 15mg (Walther 2014).Olanzapinewas given as a fixeddose
of 20 mg, oral (Walther 2014). Quetiapine flexible dose started
from 100 mg/day and then increased to 400 mg to 500 mg/day
with a maximum dose of 750 mg/day (Dai 2012).
5.2 Versus combinations
In the risperidone +oxcarbazepine comparison (Wang 2012), daily
administered dose of risperidone and oxcarbazepine were, respec-
tively, of 4.1 mg ± 0.4 mg (oral formulation) and 1.20 g ± 0.42 g
(oral formulation).
As for the risperidone + valproic acid comparison, magnesium
valproate was administered at 500 mg/day (Yao 2010), within the
750 mg to 1000 mg/day range (Jin 2013; Li 2013), or with a
mean dose of 800 mg ± 50 mg/day (Li 2013); sodium valproate
daily administered dose was in the 600 mg to 1200 mg/day range
(Wang 2013) or of 400 mg twice daily (intravenous formulation
(Zhou 2013).
6. Outcomes
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The majority of the included studies provided binary data with
respect to “specific behaviour - agitation” outcome, “global state”
outcome, “mental state” outcome, “adverse effects” outcome, and
“leaving the study early” outcome. The majority of trials that em-
ployed continuous scales measured “specific behaviour - agitation”
outcome, “specific behaviour - aggression” outcome, “mental state”
outcome, and “adverse effects - movement disorders” outcome.
The various rating scales, fromwhichwewere able to obtain usable
data, are listed below.
6.1 Specific behaviour - agitation
a. Positive and Negative Syndrome Scale - Excited
Component (PANSS-EC)
The PANSS-EC is a five-item scale (excitement, tension, hostility,
uncooperativeness, and poor impulse control). The items are rated
from one (not present) to seven (extremely severe). Scores range
from five to 35, with mean scores ≥ 20 indicating agitation. A
high score indicates high levels of agitation (Montoya 2011).
b. Positive and Negative Syndrome Scale - Psychotic Agitation
Subscale (PANSS-PAS)
The PANSS-PAS is a five-item scale (excitement, hallucinatory be-
haviour, hostility, uncooperativeness, and poor impulse control).
The items are rated from one (not present) to seven (extremely
severe), with total scores ranging from five to 35. A high score
indicates high levels of psychotic agitation (Currier 2000).
6.2 Specific behaviour - aggression
a. Modified Overt Aggression Scale (MOAS)
The OAS (Yudofsky 1986) is a 16-item rating scale which aims to
measure the intensity of verbal and physical aggression. Clinicians
are required to comment on the duration of the aggressive incident
as well as the intervention required to control it. High scores are
indicative of higher levels of aggression.
6.3 Global state
a. Clinical Global Impression (CGI)
The CGl (Guy 1976) is not a diagnostic tool but rather, enables
clinicians to quantify the severity of symptoms of any mental
health problem at one point in time. Clinicians are then able to
use this to track whether there has been any improvement or wors-
ening of symptoms over time. A seven-point rating scale is used
with high scores indicating increased severity or less recovery.
b. Clinical Global Impression - Improvement (CGI-I)
The CGI-I (Guy 1976) enables clinicians to assess whether a per-
son’s symptoms have improved or worsened following an inter-
vention. Based on the clinicians judgement, a rating on a seven-
point scale is given from one (very much improved) to seven (very
much worse). Low scores indicate greater improvement.
c. Clinical Global Impression - Severity (CGI-S)
The CGI-S (Guy 1976) requires clinicians to consider the severity
of a person’s symptoms in relation to the clinicians past experience
of people with the same diagnosis. Clinicians then have to give
a rating from one (normal) to seven (extremely ill). High scores
indicate increased severity.
6.4 Mental state
a. Brief Psychiatric Rating Scale (BPRS)
The Brief Psychiatric Rating Scale was originally developed by
Overall and Gorham (Overall 1962) as a 14-item scale to measure
the severity of a range of psychiatric symptoms, including psy-
chosis. This rating scale items evolved over time and now consists
of 24 items which can be rated on a seven-point scale from ‘not
present’ to ‘extremely severe’. A high score would suggest poor
mental health. It is not clear for the majority of the studies in-
cluded in this review, which version of the BPRS was used.
b. Positive and Negative Syndrome Scale (PANSS)
The PANSS was developed and published by Kay, Flszbein and
Opler (Kay 1986). The PANSS is designed as a brief interview,
whereby the severity of 30 symptoms of schizophrenia can be as-
sessed on a scale of one to seven. A high score would indicate more
severe symptoms. The PANSS can be divided into separate sub
scales by focusing on the statements relating to positive symptoms
(e.g. hallucinations), negative symptoms (e.g. social withdrawal)
or general psychopathology (e.g. anxiety and uncooperativeness).
6.5 Adverse effects
a. Abnormal Involuntary Movement Scale (AIMS)
The AIMS (Guy 1976) is a 12-items scale which records the oc-
currence of tardive dyskinesia. The first 10 items are rated from
one to five, whilst the last two items are dichotomous items (yes,
no).
b. Barnes Akathisia Scale (BAS)
The BAS scale was developed by Barnes 1989 and includes items
which aim to rate both the observable symptoms which charac-
terise akathisia such as restless movements and also the person’s
subjective experience, including any distress. The items are rated
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from zero = normal to three = severe. There is also an item for
rating global severity from zero (absent) to five (severe). A high
score indicates high levels of akathisia.
c. Simpson-Angus Scale (SAS)
The SAS (Simpson 1970) is a 10-item scale which measures drug
induced parkinsonism (extrapyramidal side effects). Each item is
scored from zero to four. A high score would indicate increased
levels of parkinsonism.
d. Treatment Emergent Symptom Scale (TESS)
The TESS (Guy 1976) is a six-item scale which is used to assess
the occurrence and intensity of treatment-related adverse effects.
A high score indicates worse symptoms.
7. Missing outcomes
Not one of the studies evaluated tranquillisation within 30 min-
utes, satisfaction with care, acceptance of treatment, quality of life,
or economic outcomes.
8. Funders
One of the nine included studies received sponsorship from a
pharmaceutical company.
Excluded studies
In total 59 studies had to be excluded: 12 studies were ex-
cluded based on their method of allocation (Beck 1997; Buckley
1997; Currier 2000; Greenspan 2005; Hatta 2008; Hovens 2005;
Lewis 2006; Li 2014; Pei 2009; Potkin 2005; Schooler 2003;
Villari 2008); 35 studies were excluded based on the charac-
teristics of their participants, who were not experiencing a psy-
chosis-induced aggression or agitation (Belenkaya 2005; Citrome
2001; Briken 2002; Buitelaar 2001; Citrome 2004; Chan 2013;
Czobor 1995; Francey 2007; Han 2005; He 2005; Huaqiang
2009; ISRCTN11736448 2003; Kane 2003; Kirwan 2002;
Kolivakis 2002; Lieberman 2001; Liu 2010; NCT00174200
2005; NCT00203775 2005; NCT00205699 2005; Citrome
2007; NCT00485498 2003; Ou 2007; Peng 2009; Swanson
2008; Tang 2007; Temputrn 2007; Tosic Golubovic Suzana 2009;
Veser 2006; Wan 2005; Wang 2004; Wang 2006; Wei 2010; Xi
2010; Xuan 2007). For 11 studies the intervention under investi-
gation did not meet our inclusion criteria (Conde 2011; Currier
2004; Fang 2012; Hong 2014; Hou 2011; Jiang 2012; Liu 2012;
Wang 2015; Zhang 2012; Zheng 2010; Zhou 2012); one study
was excluded because the study terminated too early due to diffi-
culties in recruiting participants (NCT00418873 2007).
Risk of bias in included studies
Please see the relevant ’Risk of bias’ tables in the Characteristics of
included studies, Figure 3 and Figure 4.
Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 4. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All nine studies were reported as randomised. In Dai 2012, Jin
2013, Li 2013, Wang 2013, Yao 2010, and Zhou 2013 randomi-
sation is stated but no informations on randomisation procedures
and allocation process were given. For the studies that did report
further details, methods are described as randomnumber sequence
(Wang 2012), pre-defined randomisation code (Lim 2010), and
randomisation in blocks (Walther 2014).
Blinding
None of the studies were double-blind with two studies (Lim 2010
and Wang 2012) reporting to be open-label . Only two studies
reported being rater-blind (Lim 2010; Walther 2014).
Incomplete outcome data
There was no evidence of attrition bias for seven studies (Dai
2012; Li 2013; Lim 2010; Wang 2012; Wang 2013; Yao 2010;
Zhou 2013). In Jin 2013, two participants left the study early due
to adverse effects (without any procedure in order to take into
account attrition bias), whilst in Walther 2014, nine people were
excluded due to refusal to provide post-hoc consent.
Selective reporting
In Lim 2010, Walther 2014 and Yao 2010, there was evidence of
selective reporting, since several outcomes - despite being stated
in the methods - are not reported or reported only partially.
Other potential sources of bias
A study being sponsored by a pharmaceutical company does not
automatically indicate bias, but indicates a level of risk for un-
certainty. One study was sponsored by Janssen Phamaceutica Ko-
rea (Lim 2010). Although Walther 2014 stated that their study
was unfunded, several authors were affiliated with Novartis, As-
traZeneca, Bristol-Myers Squibb, Janssen, Servier, Eli Lilly, Zeller
Medical, and Sandoz. Eight out of the nine studies had a very
small sample size (Dai 2012; Jin 2013; Li 2013; Walther 2014;
Wang 2012; Wang 2013; Yao 2010; Zhou 2013).
Effects of interventions
See: Summary of findings for the main comparison
RISPERIDONE compared to OTHER ANTIPSYCHOTIC: a.
HALOPERIDOL for psychosis-induced aggression or agitation
(rapid tranquillisation); Summary of findings 2RISPERIDONE
compared to OTHER ANTIPSYCHOTIC: b. OLANZAPINE
for
psychosis-induced aggression or agitation (rapid tranquillisation);
Summary of findings 3 RISPERIDONE compared to OTHER
ANTIPSYCHOTIC: c. QUETIAPINE for psychosis-induced
aggression or agitation (rapid tranquillisation); Summary of
findings 4 RISPERIDONE compared to COMBINATION: a.
RISPERIDONE + OXCARBAZEPINE for psychosis-induced
aggression or agitation (rapid tranquillisation); Summary of
findings 5 RISPERIDONE compared to COMBINATION:
b. RISPERIDONE + VALPROIC ACID for psychosis-induced
aggression or agitation (rapid tranquillisation)
See: Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5.
1. COMPARISON 1: RISPERIDONE versus OTHER
ANTIPSYCHOTIC: a. HALOPERIDOL
Two studies (n =152) compared risperidonewith haloperidol (Lim
2010; Walther 2014).
1.1 Specific behaviour - agitation
There were no clear differences in terms of Positive And Negative
Syndrome Scale - Psychotic Agitation Sub-score (PANSS-PAS) re-
sponse rate up to 24 hours (risk ratio (RR) 1.04, 95% confidence
interval (CI) 0.86 to 1.26; participants = 124; studies = 1; Analysis
1.1) and PANSS-PAS rating scales up to two hours (mean differ-
ence (MD) 0.40, 95% CI -4.42 to 5.22; participants = 28; studies
= 1; Analysis 1.2), up to 24 hours (MD 0.20, 95% CI -3.96 to
4.36; participants = 28; studies = 1; Analysis 1.3), and over 24
hours (at 48 hours, MD 1.50, 95% CI -1.36 to 4.36; participants
= 28; studies = 1; at 72 hours, MD 1.40, 95% CI -1.62 to 4.42;
participants = 28; studies = 1; at 96 hours, MD 2.90, 95% CI -
0.34 to 6.14; participants = 28; studies = 1; Analysis 1.4).
1.2 Global outcome
No clear differences were identified in terms of need for benzo-
diazepines (RR 0.88, 95% CI 0.34 to 2.27; participants = 124;
studies = 1), need for seclusion room (RR 0.33, 95% CI 0.01 to
7.55; participants = 28; studies = 1), and use of restraints (RR
2.00, 95% CI 0.43 to 9.21; participants = 28; studies = 1; Analysis
1.5).
1.3 Adverse effects
A similar proportion of participants experienced one or more ad-
verse effects, thus resulting in no clear differences between treat-
ment groups (RR 0.94, 95% CI 0.54 to 1.66; participants = 124;
studies = 1; Analysis 1.7).
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More people allocated to risperidone experienced insomnia, with-
out clear differences (RR 13.00, 95% CI 0.75 to 225.90; partici-
pants = 124; studies = 1), while a similar number of patients expe-
rienced somnolence (RR 1.29, 95% CI 0.51 to 3.24; participants
= 124; studies = 1; Analysis 1.8).
No clear differences resulted between risperidone and haloperidol
in terms of movement disorders, both when considering the pro-
portion of people experiencing extrapyramidal symptoms up to 24
hours (RR 0.63, 95% CI 0.22 to 1.80; participants = 124; studies
= 1; Analysis 1.9), or continuous scale scores such as Behavioural
Activity Rating Scale (BARS) (MD -0.60, 95% CI -1.56 to 0.36;
participants = 28; studies = 1) and SAS (MD -0.40, 95% CI -3.00
to 2.20; participants = 28; studies = 1; Analysis 1.11).
Risperidone and haloperidol were similar for adverse events such
as headache (RR 0.75, 95% CI 0.18 to 3.21; participants = 124;
studies = 1) and dizziness (RR 1.00, 95% CI 0.26 to 3.82; partic-
ipants = 124; studies = 1) up to 24 hours (Analysis 1.12).
1.4 Leaving the study early
A comparable proportion of participants left the study early due
to any reason (RR 2.20, 95% CI 0.51 to 9.48; participants = 152;
studies = 2; I2 = 59%), due to adverse effects (RR 0.50, 95%
CI 0.05 to 5.37; participants = 124; studies = 1), or due to lack
of efficacy (RR 9.00, 95% CI 0.53 to 152.93; participants = 28;
studies = 1; Analysis 1.13).
2. COMPARISON 2: RISPERIDONE versus OTHER
ANTIPSYCHOTIC: b. OLANZAPINE
One study (n = 29) compared risperidone with olanzapine
(Walther 2014). Unsurprisingly with such a small study, no dif-
ference between the compared drugs for any of the considered
outcomes could be observed.
2.1 Specific behaviour - agitation
There were no clear differences in PANSS-PAS endpoint scores
up to two hours (MD 2.50, 95% CI -2.46 to 7.46; participants
= 29; studies = 1; Analysis 2.1), up to 24 hours (MD 0.90, 95%
CI -3.40 to 5.20; participants = 29; studies = 1; Analysis 2.2), and
over 24 hours (at 48 hours, MD -1.20, 95% CI -5.15 to 2.75;
participants = 29; studies = 1; at 72 hours, MD -0.30, 95% CI -
4.47 to 3.87; participants = 29; studies = 1; at 96 hours, MD 2.10,
95%CI -1.41 to 5.61; participants = 29; studies = 1; Analysis 2.3).
2.2 Global outcome
No clear differences were found when comparing risperidone and
olanzapine in terms of need for seclusion room (RR 0.36, 95% CI
0.02 to 8.07; participants = 29; studies = 1) and use of restraints
(RR 1.43, 95% CI 0.39 to 5.28; participants = 29; studies = 1;
Analysis 2.4).
2.3 Adverse effects
Comparison in terms of BARS (MD 0.20, 95% CI -0.43 to 0.83;
participants = 29; studies = 1) and SAS scores (MD 1.80, 95% CI
-0.63 to 4.23; participants = 29; studies = 1) resulted in no clear
difference (Analysis 2.6).
2.4 Leaving the study early
More people allocated to risperidone left the study early due to
lack of efficacy, but there was no clear difference between treat-
ment groups for this outcome (RR 2.14, 95% CI 0.46 to 9.93;
participants = 29; studies = 1; Analysis 2.7).
3. COMPARISON 3: RISPERIDONE versus OTHER
ANTIPSYCHOTIC: c. QUETIAPINE
One study (n = 40) compared risperidone with quetiapine (Dai
2012).
3.1 Specific behaviour - aggression
A clear difference at Modified Overt Aggression Scale (MOAS)
endpoint score could be seen at two weeks favouring participants
allocated to quetiapine (MD 1.80, 95% CI 0.20 to 3.40; partici-
pants = 40; studies = 1), whilst this was not the case at four weeks
(MD 0.90, 95% CI -0.44 to 2.24; participants = 40; studies = 1),
at six weeks (MD 0.70, 95% CI -0.29 to 1.69; participants = 40;
studies = 1), and at eight weeks (MD 0.55, 95% CI -0.40 to 1.50;
participants = 40; studies = 1). (Analysis 3.1).
3.2 Mental state
There was no clear difference observed in the ’no response’ out-
come of the PANSS rating scale at eight weeks (RR 1.00, 95%
CI 0.16 to 6.42; participants = 40; studies = 1; Analysis 3.2). No
clear differences were found as for the other dichotomous outcome
(Analysis 3.3).
PANSS total endpoint scores and sub-scale endpoint scores (pos-
itive symptoms, negative symptoms, general psychopathology)
were collected at two, four, six and eight weeks. Only PANSS pos-
itive symptoms sub-scale endpoint scores at four weeks resulted in
a clear difference in favour of quetiapine (MD 1.70, 95% CI 0.01
to 3.39; participants = 40; studies = 1; Analysis 3.4).
3.3 Adverse effects
No clear differences could be observed between risperidone and
quetiapine for a list of different adverse effects: blurred vision (RR
0.50, 95% CI 0.10 to 2.43; participants = 40; studies = 1; Analysis
3.5), somnolence (RR 0.60, 95% CI 0.17 to 2.18; participants
= 40; studies = 1; Analysis 3.6), tachycardia (RR 4.00, 95% CI
0.49 to 32.72; participants = 40; studies = 1; Analysis 3.7), nausea
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and vomiting (RR 1.00, 95% CI 0.07 to 14.90; participants =
40; studies = 1; Analysis 3.8), akathisia (RR 1.67, 95% CI 0.46
to 6.06; participants = 40; studies = 1), hypermyotonia (RR 7.00,
95% CI 0.95 to 51.80; participants = 40; studies = 1; Analysis
3.9), headache (RR 1.00, 95% CI 0.16 to 6.42; participants =
40; studies = 1), liver function tests (LFTs) elevation (RR 1.00,
95% CI 0.07 to 14.90; participants = 40; studies = 1), weight gain
(RR 4.00, 95% CI 0.49 to 32.72; participants = 40; studies = 1),
and agitation (RR 3.50, 95% CI 0.83 to 14.83; participants = 40;
studies = 1; Analysis 3.10).
4. COMPARISON 4: RISPERIDONE versus
COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
One study (n = 68) compared risperidone with the ’risperidone +
oxcarbazepine’ combination (Wang 2012).
4.1 Specific behaviour - agitation
Therewas a clear difference in the Positive AndNegative Syndrome
Scale - Excited Component (PANSS-EC) endpoint scores at one
week (MD 2.70, 95% CI 0.42 to 4.98; participants = 68; studies
= 1; Analysis 4.1) in favour of the combination.
4.2 Global outcome
Comparison at one week in terms of Clinical Global Impression -
Improvement (CGI-I) (MD -0.20, 95% CI -0.61 to 0.21; partic-
ipants = 68; studies = 1) and Clinical Global Impression - Severity
(CGI-S) endpoint scores (MD 0.20, 95% CI -0.25 to 0.65; par-
ticipants = 68; studies = 1) resulted in no clear difference (Analysis
4.2).
4.3 Mental state
There was a clear difference between Brief Psychiatric Rating Scale
(BPRS) endpoint scores at one week (MD 5.20, 95% CI 1.04 to
9.36; participants = 68; studies = 1) in favour of the combination
(Analysis 4.5).
4.4 Adverse effects
In the combination group a total number of 47 adverse effects were
registered compared to a total of 40 adverse effects in participants
allocated to risperidone. (Analysis 4.6).
There was a clear difference in the number of participants experi-
encing excessive sedation in favour of risperidone. (RR 0.06, 95%
CI 0.00 to 0.92; participants = 68; studies = 1; Analysis 4.8).
Risperidone and combination groups were comparable in terms
of the number of participants that were experiencing various ad-
verse effects at four weeks: dry mouth (RR 2.12, 95% CI 0.81
to 5.55; participants = 68; studies = 1) and constipation at four
weeks (RR 1.30, 95% CI 0.62 to 2.72; participants = 68; studies
= 1) (Analysis 4.7); tachycardia (RR 1.24, 95% CI 0.46 to 3.30;
participants = 68; studies = 1; Analysis 4.9); nausea (RR 2.12, 95%
CI 0.20 to 22.31; participants = 68; studies = 1; Analysis 4.10),
extrapyramidal symptoms (EPS) (RR 1.59, 95% CI 0.49 to 5.14;
participants = 68; studies = 1) and tremor (RR 0.85, 95% CI 0.25
to 2.89; participants = 68; studies = 1) (Analysis 4.11); headache
(RR 0.07, 95% CI 0.00 to 1.19; participants = 68; studies = 1)
and skin rash (RR 0.35, 95% CI 0.01 to 8.37; participants = 68;
studies = 1) (Analysis 4.12).
5. COMPARISON 5: RISPERIDONE versus
COMBINATION: b. RISPERIDONE + VALPROIC ACID
Five studies (n = 307) compared risperidone with the ’risperidone
+ valproic acid’ combination (Jin 2013; Li 2013; Wang 2013; Yao
2010; Zhou 2013).
5.1 Specific behaviour - agitation
PANSS-EC endpoint scores were comparable between risperidone
and combination at three days (MD -0.11, 95% CI -2.98 to 2.76;
participants = 54; studies = 1); a clear difference in favour of the
combination was identified at five days (MD 5.47, 95% CI 2.64
to 8.30; participants = 54; studies = 1) and seven days (MD 5.11,
95% CI 2.51 to 7.71; participants = 54; studies = 1; Analysis 5.1).
Endpoint scores at PANSS-EC at two weeks (MD 0.09, 95% CI
-0.90 to 1.08; participants = 63; studies = 1) and at four weeks
(MD 0.17, 95% CI -0.85 to 1.19; participants = 63; studies = 1)
could not show a difference between the compared drugs (Analysis
5.2).
5.2 Specific behaviour - aggression
Risperidone and ’risperidone + valproic acid’ combination were
comparable both at three days (MD 1.07, 95% CI -0.20 to 2.34;
participants = 54; studies = 1) and five days (MD 0.38, 95% CI -
0.83 to 1.59; participants = 54; studies = 1) in terms of Modified
Overt Aggression Scale (MOAS) endpoint scores. A clear differ-
ence in favour of the combination could be identified at seven days
(MD 3.32, 95% CI 2.07 to 4.57; participants = 54; studies = 1),
at two weeks (MD 1.13, 95% CI 0.23 to 2.02; participants = 128;
studies = 2; I2 = 25%), at four weeks (MD 1.57, 95% CI 0.75 to
2.39; participants = 128; studies = 2; I2 = 0%), and at six weeks
(MD 1.47, 95% CI 0.83 to 2.11; participants = 68; studies = 1),
whilst being comparable at eight weeks (MD 1.00, 95% CI -0.11
to 2.11; participants = 60; studies = 1;Analysis 5.2).
5.3 Mental state
Five participants allocated to risperidone and three participants
allocated to the combination showed no clinical response based on
the PANSS score (< 30% reduction from baseline score) at eight
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weeks (RR 1.67, 95% CI 0.44 to 6.38; participants = 62; studies
= 1; Analysis 5.3).
However, when looking at PANSS endpoint scores, a clear differ-
ence favouring the combination could be seen at two weeks (MD
3.48, 95% CI 1.88 to 5.08; participants = 253; studies = 4; I2 =
80%), at four weeks (MD 5.45, 95%CI 3.81 to 7.08; participants
= 253; studies = 4; I2 = 70%), at six weeks (MD 9.90, 95% CI
7.42 to 12.37; participants = 130; studies = 2; I2 = 92%) and at
eight weeks (MD 5.83, 95% CI 4.12 to 7.54; participants = 122;
studies = 2; I2 = 58%).
High I2 values that should be translated into inconsistency of find-
ings between the studies; data at two, four and six weeks had Chi
2 P values statistically significant, showing evidence of substan-
tial levels of heterogeneity (Assessment of heterogeneity; Section
9.5.2, Higgins 2011). We investigated for input errors and found
that data were entered correctly. At the visual inspection of the
forest plots we identified Wang 2013 as an outlying study for the
two and four weeks pooled data analyses and removed it to see if
homogeneity was restored. PANSS endpoint scores at two weeks
(MD 2.50, 95% CI 0.78 to 4.21; participants = 185; studies = 3;
I2 = 62%, Chi2 = 5.23, P = 0.07) showed a I2 value > 50% with a
Chi2 P value non statistically significant, whilst at four weeks (MD
4.52, 95% CI 2.76 to 6.29; participants = 185; studies = 3; I2 =
21%, Chi2 = 2.55, P = 0.28) I2 value resulted being <50% accom-
panied by a non statistically significant Chi2 P value. Given the
concordance of direction of effects, the summary effect resulting
statistically significant even by removal of the outlying study, and
that the relative weights of this last were 13.3% and 14.2%, (re-
spectively, two and four weeks), we decided to present the pooled
data (Subgroup analysis and investigation of heterogeneity).
Sub-scale continuous data showed a clear difference at PANSS
positive symptoms sub-scale in favour of the combination at four
weeks (MD2.75, 95%CI 1.86 to 3.64; participants = 191; studies
= 3; I2 = 76%), six weeks (MD 4.40, 95% CI 1.40 to 7.40; partic-
ipants = 68; studies = 1), and eight weeks (MD 1.70, 95% CI 0.71
to 2.69; participants = 60; studies = 1), despite being comparable
at two weeks (MD 0.64, 95% CI -0.24 to 1.53; participants =
191; studies = 3; I2 = 81%; Analysis 5.4).
Again, we investigated for input errors and that data were entered
correctly. At the visual inspection of the graphs, Li 2013 could
be identified as an hypothetical outlying study. By removing it, I2
values resulted < 50% and Chi2 P values resulted non statistically
significant (two weeks: I2 = 2%, Chi2 = 1.02, P = 0.31; four weeks:
I2 = 0%, Chi2 = 0.36, P = 0.55). Given the relative weights of
the outlying study being 68.8% at two weeks and 69.8% at four
weeks, we decided not to consider pooled data and wait for more
studies and data.
PANSS negative symptoms sub-scale could not show clear differ-
ences at two weeks (MD 0.29, 95% CI -0.57 to 1.15; participants
= 128; studies = 2; I2 = 65%), four weeks (MD 1.23, 95% CI -
0.16 to 2.62; participants = 128; studies = 2; I2 = 59%), and eight
weeks (MD 1.30, 95% CI -0.02 to 2.62; participants = 60; studies
= 1); a clear difference was observed at six weeks only, favouring
the combination (MD 3.80, 95% CI 1.07 to 6.53; participants =
68; studies = 1).
PANSS general psychopathology sub-scale showed clear differ-
ences in favour of the combination at four weeks (MD 1.14, 95%
CI 0.04 to 2.23; participants = 128; studies = 2; I2 = 50%), six
weeks (MD 6.50, 95% CI 4.06 to 8.94; participants = 68; studies
= 1), and eight weeks (MD 1.60, 95% CI 0.43 to 2.77; partici-
pants = 60; studies = 1); at two weeks data did not show a clear
difference between the compared drugs (MD 0.93, 95% CI -0.07
to 1.93; participants = 128; studies = 2; I2 = 66%) (Analysis 5.4).
5.4 Adverse effects
In the combination group a total number of 20 adverse effects were
registered, compared to the 16 total adverse effects experienced by
participants allocated to risperidone (Analysis 5.5).
Two participants allocated to risperidone and one allocated to the
combination suffered from myocardial ischaemia (RR 2.00, 95%
CI 0.19 to 20.93; participants = 62; studies = 1; Analysis 5.6).
Risperidone and combination groups resulted in comparable in
terms of probability of experiencing blurred vision (RR 1.00, 95%
CI 0.37 to 2.68; participants = 122; studies = 2; I2 = 0%), dry
mouth (RR 1.64, 95%CI 0.76 to 3.54; participants = 129; studies
= 2; I2 = 78%; Analysis 5.7); insomnia (RR 2.00, 95% CI 0.19
to 20.77; participants = 54; studies = 1), somnolence (RR 0.85,
95% CI 0.44 to 1.63; participants = 121; studies = 2; I2 = 0%;
Analysis 5.8); decreased blood pressure (RR 0.75, 95% CI 0.18 to
3.10; participants = 68; studies = 1), tachycardia (RR 1.48, 95%
CI 0.83 to 2.67; participants = 251; studies = 4; I2 = 35%), T-wave
changes in ECG (RR 2.00, 95% CI 0.19 to 20.77; participants
= 54; studies = 1; Analysis 5.9); constipation (RR 1.11, 95% CI
0.70 to 1.76; participants = 189; studies = 3; I2 = 6%), nausea
(RR 0.70, 95% CI 0.29 to 1.71; participants = 122; studies = 2;
I2 = 0%; Analysis 5.10); EPS (RR 1.35, 95% CI 0.76 to 2.39;
participants = 121; studies = 2; I2 = 91%), akathisia (RR 0.75,
95% CI 0.28 to 2.03; participants = 122; studies = 2; I2 = 0%),
tremor (RR 1.20, 95% CI 0.40 to 3.56; participants = 68; studies
= 1; Analysis 5.11); headache (RR 0.94, 95% CI 0.53 to 1.68;
participants = 243; studies = 4; I2 = 0%), weight gain (RR 1.50,
95% CI 0.47 to 4.78; participants = 60; studies = 1), oedema
(RR 0.34, 95% CI 0.01 to 8.13; participants = 63; studies = 1),
leukopenia (RR 0.34, 95% CI 0.01 to 8.13; participants = 63;
studies = 1), and liver function tests elevation (RR 0.60, 95% CI
0.15 to 2.40; participants = 116; studies = 2; I2 = 0%; Analysis
5.13).
Treatment Emergent Symptom Scale (TESS) endpoint scores did
not find a clear difference in movement disorders between the
compared groups at three days (MD -0.04, 95% CI -1.35 to 1.27;
participants = 54; studies = 1), five days (MD -0.11, 95% CI -
1.55 to 1.33; participants = 54; studies = 1), and at seven days
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(MD -0.51, 95% CI -1.88 to 0.86; participants = 54; studies = 1;
Analysis 5.12).
5.5 Leaving the study early
Two participants allocated to the combination and none of those
allocated to risperidone left the study early due to adverse effects
(RR 0.21, 95% CI 0.01 to 4.13; participants = 63; studies = 1;
Analysis 5.14).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
RISPERIDONE compared to OTHER ANTIPSYCHOTIC: b. OLANZAPINE for psychosis- induced aggression or agitation (rapid tranquillisation)
Patient or population: psychosis-induced aggression or agitat ion (rapid tranquillisat ion)
Setting: Psychiatric acute care units.
Intervention: RISPERIDONE
Comparison: OTHER ANTIPSYCHOTIC: b. OLANZAPINE
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with OTHER
ANTIPSYCHOTIC: b.
OLANZAPINE
Risk with RISPERI-
DONE
Tranquillisat ion or
asleep by 30 minutes -
not measured
- - - - -
Repeated need for tran-
quillisat ion within 24
hours - not measured
- - - - -
Specif ic behaviour: agi-
tat ion, up to 2 hours
assessed with: PANSS-
PAS endpoint score
MD 2.5 higher
(2.46 lower to 7.46
higher)
- 29
(1 RCT)
⊕©©©
VERY LOW 123
Global outcome: need
for addit ional measures
assessed with: use of
restraints
Study populat ion RR 1.43
(0.39 to 5.28)
29
(1 RCT)
⊕©©©
VERY LOW 1234
200 per 1.000 286 per 1.000
(78 to 1.000)
Adverse ef fects: move-
ment disorder
assessed with: BARS
endpoint score
MD 0.20 higher
(0.43 lower to 0.83
higher)
- 29
(1 RCT)
⊕©©©
VERY LOW 1234
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Economic outcomes -
not measured
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Risk of bias - rated ’very serious’: high risk of attrit ion bias and ‘select ive report ing’ bias.
2 Only one study available.
3 Imprecision - rated ’very serious’: Opt imal Information Size (OIS) criterion not met.
4 Indirectness - rated ’serious’: provided outcome is at a t ime point (4 days) dif f erent f rom those of primary importance in this
sett ing.
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RISPERIDONE compared to OTHER ANTIPSYCHOTIC: c. QUETIAPINE for psychosis- induced aggression or agitation (rapid tranquillisation)
Patient or population: psychosis-induced aggression or agitat ion (rapid tranquillisat ion)
Setting: Inpat ient ward.
Intervention: RISPERIDONE
Comparison: OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with OTHER AN-
TIPSYCHOTIC: c. QUE-
TIAPINE
Risk with RISPERI-
DONE
Tranquillisat ion or
asleep by 30 minutes -
not measured
- - - - -
Repeated need for tran-
quillisat ion within 24
hours - not measured
- - - - -
Specif ic behaviour - ag-
gression, over 24 hours
assessed with: MOAS
endpoint score at 2
weeks
MD 1.80 higher
(0.20 higher to 3.40
higher)
- 40
(1 RCT)
⊕©©©
VERY LOW 123
Global outcome - not
measured
- - - - -
Adverse ef fects: move-
ment disorders over 24
hours
assessed with:
akathisia
Study populat ion RR 1.67
(0.46 to 6.06)
40
(1 RCT)
⊕©©©
VERY LOW 123
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150 per 1.000 251 per 1.000
(69 to 909)
Economic outcomes -
not measured
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; MD: mean dif ference; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Only one study available.
2 Indirectness - rated ’serious’: provided outcome is at a t ime point (2 weeks) dif f erent f rom those of primary importance in
this sett ing.
3 Imprecision - rated ’very serious’: Opt imal Information Size (OIS) criterion not met.
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RISPERIDONE compared to COMBINATION: a. RISPERIDONE + OXCARBAZEPINE for psychosis- induced aggression or agitation (rapid tranquillisation)
Patient or population: psychosis-induced aggression or agitat ion (rapid tranquillisat ion)
Setting: Inpat ient ward.
Intervention: RISPERIDONE
Comparison: COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with COMBINA-
TION: a. RISPERIDONE
+ OXCARBAZEPINE
Risk with RISPERI-
DONE
Tranquillisat ion or
asleep by 30 minutes -
not measured
- - - - -
Repeated need for tran-
quillisat ion within 24
hours - not measured
- - - - -
Specif ic behaviour: agi-
tat ion, over 24 hours
assessed with: PANSS-
EC endpoint score
MD 2.70 higher
(0.42 higher to 4.98
higher)
- 68
(1 RCT)
⊕©©©
VERY LOW 1234
Global Outcome: aver-
age scores, over 24
hours
assessed with: CGI-I
endpoint score
MD 0.20 lower
(0.61 lower to 0.21
higher)
- 68
(1 RCT)
⊕©©©
VERY LOW 1234
Adverse ef fects: move-
ment disorders, over 24
hours
assessed with: EPS
Study populat ion RR 1.59
(0.49 to 5.14)
68
(1 RCT)
⊕©©©
VERY LOW 1234
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114 per 1.000 182 per 1.000
(56 to 587)
Economic outcomes -
not measured
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; MD: mean dif ference;RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Risk of bias - rated ’very serious’: high risk for performance bias and detect ion bias.
2 Only one study available.
3 Indirectness - rated ’serious’: provided outcome is at a t ime point (1 week) dif f erent f rom those of primary importance in
this sett ing.
4 Imprecision - rated ’very serious’: Opt imal Information Size (OIS) criterion not met.
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RISPERIDONE compared to COMBINATION: b. RISPERIDONE + VALPROIC ACID for psychosis- induced aggression or agitation (rapid tranquillisation)
Patient or population: psychosis-induced aggression or agitat ion (rapid tranquillisat ion)
Setting: Inpat ient ward.
Intervention: RISPERIDONE
Comparison: COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with COMBINA-
TION: b. RISPERIDONE
+ VALPROIC ACID
Risk with RISPERI-
DONE
Tranquillisat ion or
asleep by 30 minutes -
not measured
- - - - -
Repeated need for tran-
quillisat ion within 24
hours - not measured
- - - - -
Specif ic behaviour - ag-
gression, over 24 hours
assessed with: MOAS
endpoint score at 3
days
The mean specif ic be-
haviour - aggression,
over 24 hours was 0
MD 1.07 higher
(0.20 lower to 2.34
higher)
- 54
(1 RCT)
⊕©©©
VERY LOW 123
Global outcome - not
measured
- - - - -
Adverse ef fects: move-
ment disorders, over 24
hours
assessed with:
akathisia
Study populat ion RR 0.75
(0.28 to 2.03)
122
(2 RCTs)
⊕©©©
VERY LOW 23
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66 per 1.000 49 per 1.000
(18 to 133)
Economic outcomes -
not measured
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval;MD: mean dif ference;RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Only one study available.
2 Indirectness - rated ’serious’: provided outcome is at a t ime point (3 days) dif f erent f rom those of primary importance in this
sett ing.
3 Imprecision - rated ’very serious’: Opt imal Information Size (OIS) criterion not met.
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D I S C U S S I O N
Summary of main results
1. COMPARISON 1: RISPERIDONE versus OTHER
ANTIPSYCHOTIC: a. HALOPERIDOL
Two studies were included (Lim 2010;Walther 2014), with a total
number of 152 participants (risperidone, n = 76; haloperidol, n
= 76); although two potential sources of data were available, only
one outcome could benefit from both (’leaving the study early’).
We did expect to find more relevant studies since haloperidol has
an historical role in drug development research and still could
be indicated as the ’common comparator’ when designing ran-
domised controlled trials (RCTs). Moreover, available outcomes
were rated of very low quality (Summary of findings for the main
comparison), due to high risk of attrition and ’selective reporting’
bias, small sample size and indirectness of outcome measures. No
data concerning ’tranquillisation or asleep’, repeated need for tran-
quillisation and economic outcomes were available.
1.1 Agitation, global outcome
Risperidone and haloperidol showed similar results in agitation
measurement scales and global outcomes such as need for benzo-
diazepine, need for seclusion room or use of restraints.
Interestingly, dichotomous data on efficacy outcomes provided no
strong evidence of a difference between oral risperidone and intra-
muscular administration of haloperidol; even if higher-quality ev-
idence is needed to draw any firm conclusion, patients preference
and best interest should be taken into consideration in treatment
decision making when delivering a tailored therapy.
1.2 Adverse effects
Analyses provides no strong evidence that the intervention yielded
any differences in terms of adverse effects.
1.3 Leaving the study early
A comparable number of participants allocated to either risperi-
done or haloperidol left the study early.
2. COMPARISON 2: RISPERIDONE versus OTHER
ANTIPSYCHOTIC: b. OLANZAPINE
Only one study was included (Walther 2014), with a total number
of 29 participants (risperidone, n = 14; olanzapine, n = 15). Due
to high risk of attrition and ’selective reporting’ bias, the small
sample size and the indirectness of the outcomemeasures, available
outcomes were rated of very low quality (Summary of findings 2).
No data concerning ’tranquillisation or asleep’, repeated need for
rapid tranquillisation and economic outcomes were available.
Analyses provides no strong evidence that risperidone has an effect
any different than olanzapine for any of the considered outcomes:
’specific behaviour - agitation’, ’global outcome’, ’adverse effects’,
’leaving the study early’.
3. COMPARISON 3: RISPERIDONE versus OTHER
ANTIPSYCHOTIC: c. QUETIAPINE
Only one studywas included (Dai 2012), with a total number of 40
participants (risperidone, n = 20; quetiapine, n = 20). Due to small
sample size and the indirectness of the outcomemeasures, available
outcomes were rated of very low quality (Summary of findings 3).
No data concerning ’tranquillisation or asleep’, repeated need for
rapid tranquillisation, ’global state’ and economic outcomes were
available. No data were available on the ’rapid tranquillisation’
topic: the first time point at which data were collected was at two
weeks.
Data analyses provide no strong evidence that risperidone has an
effect clinically significantly different than quetiapine for almost
all the outcomes: ’specific behaviour - aggression’, ’mental state’,
’adverse effects’.
4. COMPARISON 4: RISPERIDONE versus
COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Only one study was included (Wang 2012), with a total number of
68 participants (risperidone, n = 33; risperidone + oxcarbazepine,
n = 35). Due to high risk of performance and detection bias,
small sample size and indirectness of outcome measures, available
outcomes were rated of very low quality (Summary of findings 4);
no data concerning ’tranquillisation or asleep’, repeated need for
tranquillisation and economic outcomes were available.
4.1 Agitation, global outcome, mental state
As for the available ’agitation’ and ’mental state’ outcomes
(PANSS-EC and BPRS endpoint scores, respectively), we could
find evidences of differences in favour of the combination, with no
strong evidence of any difference for the ’global outcome’. How-
ever, it has to be noted that available data were collected at seven
days, a timing far too late to be informative for the ’rapid tran-
quillisation’ topic. Moreover, the quality of evidence was very low
due to aforementioned risks.
4.2 Adverse effects
Very low quality of evidence was found that ’risperidone + ox-
carbazepine’ combination yielded to higher number of ’excessive
sedation’ adverse events (zero events occurred in the risperidone
group,whilst nine eventswere reported for the combination group;
Analysis 4.8). Interestingly, since we do not have further details
on data and the latter have not been collected to multiple time
points, we could not exclude that this evidence is just another way
to read the higher efficacy one (Analysis 4.1; Analysis 4.5).
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The ideal concept of ’tranquillisation’ is to find a way to get people
calm without causing sedation. Even if this last could be necessary
within the first hours, it could not be justified in the later days (if
no other aggression or agitation episodes occurred).
No strong evidence of any difference could be observed as for the
other collected adverse events.
5. COMPARISON 5: RISPERIDONE versus
COMBINATION: b. RISPERIDONE + VALPROIC ACID
Five studies were included (Jin 2013; Li 2013; Wang 2013; Yao
2010; Zhou 2013), with a total number of 307 participants
(risperidone, n = 153; risperidone + valproic acid, n = 154). Avail-
able outcomeswere rated of very lowquality (Summary of findings
5), due to small sample size and indirectness of outcome measures.
No data concerning ’tranquillisation or asleep’, repeated need for
tranquillisation and economic outcomes were available.
5.1 Agitation, aggression
As for available efficacy outcomes on agitation, continuous data
analyses provides no strong evidence of different efficacy between
risperidone and the ’risperidone + valproic acid’ combination at
three days; when focusing on later time points, a clear difference
in favours of the combination at five and seven days, but not at
two and four weeks, could be seen.
Concerning continuous data on aggression, evidence of a clear dif-
ference could be observed in favour of the combination at five and
seven7 days, two, four, and six weeks. However, mean difference
(MD) and confidence interval (CI) values should be taken into
account to evaluate clinically significance. At eight weeks a strong
evidence of any difference between the compared drugs could not
be provided.
5.2 Mental state
Very low quality of evidence of a clear difference in PANSS end-
point scores favouring the combination could be observed (sub-
group analyses were carried out for PANSS endpoint scores data at
two and four weeks); this held true for the later time points (mainly
six and eight weeks) of positive symptoms, negative symptoms
and general psychopathology sub-scales; PANSS positive symp-
toms sub-scale endpoint scores data at two and four weeks could
not be pooled due to high heterogeneity.
It has to be highlighted, however, that available dataweremeasured
starting from the second week: no evidence could be found con-
cerning time points relevant to the ’rapid tranquillisation’ topic.
5.3 Adverse effects
Data analyses provide no strong evidence of any difference in terms
of adverse effects between risperidone and the ’risperidone + val-
proic acid’ combination. However, in one study (Yao 2010), three
episodes of myocardial ischaemia were observed: an association
between the drug administration and the event could not be found
throughout the relevant paper, nor more information about their
cardiovascular baseline risk (presumably not high since age range
of participants recruited in the study was between 17 and 42 years,
with a mean age of 26.9 years).
5.4 Leaving the study early
No strong evidence of any difference in terms of ’leaving the study
early’ outcome could be observed.
Overall completeness and applicability of
evidence
1. Completeness
We identified nine relevant studies and all reported only a few
outcomes: only two comparisons could benefit from more than
one study as data source and - even more surprisingly - as for the
haloperidol comparison this held true only for a single outcome;
themost represented comparison is the one comparing risperidone
with ’risperidone + valproic acid’ combination (five studies). No
study reported data regarding the ’tranquillisation or asleep’ out-
come, service outcomes, satisfaction with treatment, acceptance of
treatment, quality of life, or economic outcomes. Three included
studies suffered from ’selective reporting’ bias, thus further limit-
ing available data. Protocols were not available for all the included
studies.
2. Applicability
All of the included studies were more of the explanatory type of
study rather the practical/pragmatic and easily applicable to real-
world practice one (Thorpe 2009).
Included studies were conducted in three different countries
(China, seven; Korea, one; Switzerland, one) and in psychiatric
inpatient and emergency admission settings.
Rapid tranquillisation is often used to achieve a fast resolution of
this clinical state that could otherwise result in injury to self or
others, hence preventing prolonged physical restraint of people,
which should be seen as the very last available resource. It was
therefore surprising and disappointing that few studies measured
agitation and aggression outcomes at time points that one would
associate with ’rapid tranquillisation’. The first available time point
is at two hours (Walther 2014), with seven studies having set
time points greater than 24 hours (three days, Zhou 2013; one
week, Wang 2012; two weeks, Dai 2012; Jin 2013; Li 2013;
Wang 2013; Yao 2010). In Lim 2010, outcomes are stated to be
measured as early as 30 minutes but, unfortunately, only 24 hours
measurements were provided.
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Quality of the evidence
1. General
All of the included studies were published after the first
CONSORT guidance (1996); no studies complied with this in-
ternationally agreed standard. Disappointingly, a large proportion
of data was rendered unusable, which could have been avoided
had the trials been better reported.
2. Specific
All nine studies were randomised, but details were vaguely re-
ported and none was double-blinded. Three studies suffered from
’selective reporting’ bias. Data from more than one source were
available for two comparisons only. These factors strongly limit
the quality of the available evidence and this can be evinced in the
’Risk of bias’ and ’Summary of findings’ tables; all of the selected
outcomes to be included in th ’Summary of findings’ tables were
rated as ’very low’ quality.
Potential biases in the review process
We followed the protocol and conducted a thorough search and
adhered to our pre-specified inclusion and exclusion criteria when
inspecting citations. It is possible that we have failed to identify
small relevant studies, but we feel that it is unlikely that we would
have missed large studies that would make a substantial difference
to the findings from this review. Given the small number of in-
cluded studies, review authors EGO and MH independently in-
spected all citations obtained from the search and extracted the
data to minimise bias.
In order to further limit the risk for potential biases and improve
the overall quality of the work, we followed the recommenda-
tions of theCochrane Editorial Unit (CEU) Screening Programme
by Dr Nuala Livingstone and the Methodological Expectations
of Cochrane Intervention Reviews (MECIR; Higgins 2016); the
systematic review was checked and verified by using the CEU
Screening Tool items. Previously excluded studies were checked
for NROD exclusion bias (no relevant outcome data exclusion
bias; Higgins 2016; Kirkham 2010): one study was retrieved.
Agreements and disagreements with other
studies or reviews
The review authors are not aware of any other studies or system-
atic reviews that have focused solely on use of risperidone alone
for people who are agitated or aggressive due to serious mental
illnesses.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with an interest in psychosis-induced
aggression or agitation
People during an acute episode of psychosis can be under tremen-
dous distress; there is currently very limited high-quality research
regarding effective and safe treatment for those episodes. It is es-
sential that people receive appropriate care based on the best avail-
able evidence. The nine trials included in this review compared
oral risperidone with intramuscular or oral single drugs (haloperi-
dol, olanzapine, quetiapine) or combinations (risperidone + ox-
carbazepine, risperidone + valproic acid). Data analyses could not
provide strong evidence of any difference between the compared
drugs when focusing on rapid tranquillisation (up to two hours,
but ideally within the first 10 minutes after getting clinical at-
tention). When checking for efficacy at medium-long terms, the
combination of risperidone + oxcarbazepine yielded a greater im-
provement in terms of levels of agitation, even if the overall quality
of evidence was rated as ’very low’. If people are at risk of need-
ing such interventions, it would seem reasonable to expect better
evidence than what research community has thus far provided.
2. For clinicians
Available evidence on the use of risperidone for people with psy-
chosis-induced aggression or agitation is strongly limited. In terms
of rapid tranquillisation of psychosis-induced aggression or agita-
tion, no strong evidence could be observed between risperidone
and compared drugs or combinations, including intramuscular
administration of haloperidol. When widening the topic of the
review to the phase after rapid tranquillisation, very low-quality
evidence of a slight advantage up to one week in favour of the
’risperidone + oxcarbazepine’ combination could be seen. Overall,
data are very scarce: it is not possible to draw firm conclusions as
to whether risperidone is more or less effective than other inter-
ventions for psychosis-induced aggression or agitation.
If researchers continue to let down the clinical community by
avoiding pragmatic studies on such an important and relevant
area like rapid tranquillisation in psychosis-induced aggression or
agitation, clinicians should formally request such investigations:
not to have good evidence in this area is always more often difficult
to justify.
3. For policy makers
This is a greatly under researched area. Currently, the use of risperi-
done alone in the management of acutely agitated or aggressive
patients could be efficacious but the evidence base for this is lack-
ing. This underpins the need for high-quality trials in the rapid
tranquillisation setting.
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Implications for research
1. General
All nine studies identified for inclusion in this review were
conducted after the Consolidated Standards of Reporting Trials
(CONSORT, Moher 2001) statement was proposed, yet the re-
porting quality was rated as very-low quality due to high risk of
performance, attrition and ’selective reporting’ bias, small size of
randomised populations, and indirectness of outcome measures.
More transparency in the reporting of randomised controlled trials
(RCTs) would enable readers to understand the design, conduct,
analysis and interpretation, and to assess the validity of results.
Although binary data are easier to interpret, where continuous
data are used some measure of variance should be provided. Data
presented in graphs should be accompanied by exact numbers and
standard deviations (SDs) in the text.
2. Specific
Large pragmatic well-designed randomised trials led by indepen-
dent researchers, which measure simple, meaningful and highly
applicable outcomes such as ’being tranquil’, ’being asleep’, ’serious
adverse effect’, ’needing additional medication’, ’further aggressive
episodes’, and ’economic outcomes’ are still required. These stud-
ies just need modest financial support and firm help from ethics
committees who should understand the need to produce good ev-
idence for practice in this difficult area of health. See Table 2 for
a suggested design for a study.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dai 2012
Methods Allocation: randomised
Blindness: not reported
Duration: 8 weeks
Participants Diagnosis: schizophrenia with aggressive behaviour (ICD-10)
N = 40
Age: mean 25.3 years; range 20-30 years.
Sex: 32 males, 8 females.
History: mean length of illness of 1.45 years, range from 1 month to 3 years; history
of aggressive behaviour (total score of Modified overt aggression scale more than 5 after
admission for 1 week); type of schizophrenia: 29 participants with paranoid schizophre-
nia; 5 participants with hebephrenic schizophrenia; 6 participants with unclear type
Excluded: organic psychosis, affective disorder or other psychogeny; body diseases,
epilepsy, encephalosis, alcohol or drug dependence; women in gestational or suckling
period
Setting: Dalian, China (inpatient).
Interventions 1. Risperidone: initial dose of 1 mg/day, increased to 3 mg to 4 mg/day in 7 days, then
dose adjusted according to illness condition within 1 month, maximum dose < 6 mg/
day. N = 20
2. Quetiapine: initial dose of 100 mg/day, increased to 400 mg to 500 mg/day in 7 days,
then dose adjusted according to illness condition within 1 month, maximum dose < 750
mg/day. N = 20
Trihexyphenidyl or benzodiazepines could be used as p.r.n. drugs
Outcomes Specific behaviour: aggression - MOAS endpoint score (2, 4, 6, 8 weeks; Table 3 in p.
2063)
Mental state: Clinical response (8 weeks; section 2.1 in p.2062), PANSS endpoint score
(2, 4, 6, 8 weeks; Table 2 in p.2062), PANSS positive symptoms sub-scale endpoint score
(2, 4, 6, 8 weeks; Table 2 in p.2062), PANSS negative symptoms sub-scale endpoint
score (2, 4, 6, 8 weeks; Table 2 in p.2062), PANSS general psychopathology sub-scale
endpoint score (2, 4, 6, 8 weeks; Table 2 in p.2062).
Adverse events: specific adverse events (8 weeks; Table 4 in p.2063)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “All the cases were randomly as-
signed to two group…” (p.2061)
Comments: the author described a random
component, but no more detail about ran-
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Dai 2012 (Continued)
dom methods were given
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of attrition bias
Selective reporting (reporting bias) Unclear risk Data on p.r.n. drugs usage not reported.
Protocol not available; compared to the
’methods’ section, no evidence of ’selective
reporting’ bias
Other bias High risk Small sample size
Jin 2013
Methods Allocation: randomised
Blindness: not reported
Duration: 4 weeks
Participants Diagnosis: schizophrenia with impulsive and aggressive behaviour (CCMD-3)
N = 63
Age: mean 39.4 years; range 18-65 years.
Sex: 32 males, 31 females.
History: length of illness: mean 3.3 years; PANSS total score before treatment: mean 89.
69; all patients received risperidone before enrolment
Excluded: severe heart disease, hepatic disease, renal disease or physical ailments; drug
allergies or leukopenia; epilepsy, alcohol and substance dependence
Setting: Liaoning, China (inpatient).
Interventions 1. Risperidone: dosage not stated. N = 31.
2. Risperidone + magnesium valproate sustained release tablet: risperidone dosage not
stated; magnesium valproate sustained release initial dose 500 mg/day, increased to 750
mg to 1000 mg/day over one week. N = 32
Trihexyphenidyl and propanolol could be used as p.r.n. drugs
Outcomes Specific behaviour: agitation - PANSS-EC endpoint score (2, 4 weeks; Table 1 in p.161)
.
Mental state: PANSS endpoint score (2, 4 weeks; Table 1 in p.161), PANSS positive
symptoms sub-scale endpoint score (2, 4 weeks; Table 1 in p.161).
Adverse effects: specific adverse effects (4 weeks; Table 3 in p.161)
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Jin 2013 (Continued)
Unable to use:
Adverse effects: TESS endpoint score (4 weeks; Table 2 in p.161)*.
Notes * typo input error is likely
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “All the cases were randomly as-
signed to two group…” (p.161)
Comments: the author described a random
component, but no more detail about ran-
dom methods were given
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Two participants left the study early due to
adverse effects; these data were lost
Selective reporting (reporting bias) Unclear risk Data on p.r.n. drugs usage not reported.
Protocol not available; compared to the
’methods’ section, no evidence of ’selective
reporting’ bias
Other bias High risk Small sample size
Li 2013
Methods Allocation: randomised
Blindness: not reported
Duration: 8 weeks
Participants Diagnosis: schizophrenia with aggressive behaviour (ICD-10).N = 60
Age: mean 30 years; range 18-60 years.
Sex: 31 males, 29 females
History: length of illness: mean 5.3 years; education years: mean 8 years; PANSS total
score before enrolment: mean 78.5; range more than 70; MOAS total score before
enrolment: mean 8.8; range more than 4
Excluded: severe body diseases; drug dependence; women in gestational or suckling
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Li 2013 (Continued)
period
Setting: Shanxi, China (outpatient).
Interventions 1. Risperidone: initial dose of 1 mg/day, maximum dose of 6 mg/day; mean dose of 3.3
± 1.6 mg/day. N = 30
2. Risperidone + magnesium valproate sustained release: risperidone initial dose of 1
mg/day, maximum dose of 4 mg/day; mean dose of 2.5 mg ± 1.5 mg/day; magnesium
valproate sustained release initial dose of 500 mg/day, maximum dose of 1000 mg/day;
mean dose of 800 mg ±5 0 mg/day. N = 30
Benzodiazepines could be used as p.r.n. drugs.
Outcomes Specific behaviour: agitation - MOAS endpoint score (2, 4, 8 weeks; Table 2 in p.70).
Mental state: PANSS endpoint score (2, 4, 8 weeks; Table 1 in p.70), PANSS positive
symptoms sub-scale endpoint score (2, 4, 8 weeks; Table 1 in p.70), PANSS negative
symptoms endpoint score (2, 4, 8 weeks; Table 1 in p.70), PANSS general psychopathol-
ogy endpoint score (2, 4, 8 weeks; Table 1 in p.70).
Adverse effects: specific adverse events (4 weeks; section 2.3 in p.70)
Unable to use:
Adverse effects: gastrointestinal reaction (definition too vague)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “All the cases were randomly as-
signed to two group…” (p.69)
Comments: the author described a random
component, but no more detail about ran-
dom methods
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of attrition bias
Selective reporting (reporting bias) Unclear risk Data on p.r.n. drugs usage not reported.
Protocol not available; compared to the
’methods’ section, no evidence of ’selective
reporting’ bias
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Li 2013 (Continued)
Other bias High risk Small sample size
Lim 2010
Methods Allocation: randomised
Blindness: open-label, rater blind.
Duration: 24 hours
Participants Diagnosis: DSM-IV diagnosis of schizophrenia (N = 78), bipolar disorder (N = 43),
others (N = 3)
N = 124
Age: range 18-65 years
Sex: 66 males, 58 females
History: “acute psychotic agitation in the emergency room or inpatient ward” (p.82)
Excluded: neurological disorder, severe medical disease, alcohol or other psychoactive
substance misusers, history of neuromalignant syndrome or hypersensitivity to trial med-
ications, pregnant or lactating women, people treated with antipsychotics or benzodi-
azepines within 6 hours to the start of the trial or with depot antipsychotic within one
treatment cycle of enrolment
Setting: Korea (psychiatric emergency room inpatient ward).
Interventions 1. Risperidone: oral dose 2 mg, maximum 6 mg during 24 hours. N = 62
2. Haloperidol: IM dose 5 mg, maximum 15 mg during 24 hours. N = 62
Outcomes Specific behaviour: no clinically important change in agitation (defined as PANSS-PAS*
50% reduction from the baseline score)
Use of additional medication - lorazepam.
Adverse events
Leaving the study early
Unable to use:
Mental state: PANSS Total (mean, SE/SD not reported, P values of significant findings
reported, overall F value)
Mental state: YMRS Total (mean, SE/SD/CI not reported).
Global state: CGI-S (mean, SE/SDnot reported, P values of significant findings reported,
overall F value)
Specific behaviour: Behaviorally Anchored Rating Scale (mean, SE/SD/CI not reported)
Notes 4 participants allocated to risperidone and 17 participants allocated to haloperidol re-
ceived more than previously stated maximum dose
Intramuscular injection of 4mg lorazepam or 2mg of oral lorazepamwas used as a rescue
medicine if severe extrapyramidal symptoms (EPS) had occurred. Although paper gives
information about use of additional lorazepam in 7 participants from risperidone and 8
from haloperidol group, it does not provide further details
* Authors of the manuscript use the “PANSS-EC” term but provide the items list of
PANSS-PAS; in other published studies they refers to this as an “5 item acute agitation
cluster [...] from PANSS score”
Risk of bias
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Lim 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned “according to a
predefined randomization code that was
balanced to ensure even distribution of pa-
tients in each treatment group” (p.82)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was an open-label study where one
group received IM. and the other group
received an orodispersible tablet
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study was rater-blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk There is no evidence of incomplete out-
come data. The authors give reasons for the
participants who discontinued the study
Selective reporting (reporting bias) High risk Authors report that anti-parkinsonian
drugs could be given at the lowest effective
dose, however the amount administered is
not described in the results. Several out-
comes are not reported. Protocol not avail-
able
Other bias High risk Sponsored by Janssen Phamaceutica Ko-
rea. Authors state they usedPANSS-ECbut
provide description for PANSS-PAS, while
calling this scale a “5 item acute agitation
cluster” in the other linked publications
Walther 2014
Methods Allocation: randomised.
Blindness: single.
Duration: 96 hours.
Participants Diagnosis: DSM-IV criteria for schizophrenia (n = 27), schizoaffective (n = 6), or
schizophreniform disorder (n = 10)
N = 43*
Age: mean 34 years (SD 10), range 18-55 years.
Sex: 31 males, 12 females.
History: severely agitated, admitted to acute care inpatient unit
Excluded: people who did not give post hoc informed consent, duration ill ~ 7 years,
84% free of antipsychotics or mood stabilisers at the time of study inclusion
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Walther 2014 (Continued)
Setting: Switzerland (acute care psychiatry units).
Interventions 1. Risperidone: 2 mg to 6 mg/day for 5 days, flexible dose, oral. N = 14
2. Haloperidol: 15 mg/day for 5 days, fixed dose, oral. N = 14
3. Olanzapine: 20 mg/day for 5 days, fixed dose, oral. N = 15
Additional use of up to 30 mg diazepam/day was permitted (day 1), up to 60 mg/day,
days 2-5
Outcomes Specific behaviour: PANSS-PAS score**, need for seclusion room
Leaving the study early
Lack of efficacy
Adverse effects: movement disorders (AIMS for risperidone vs haloperidol, Barnes scale,
SAS)
Unable to use:
Use of additional medication - diazepam/biperiden (data not reported by group)
Adverse effects: movement disorders (AIMS for risperidone vs olanzapine: no SD)
Notes * eligible patients were 52 patients but 9 refused to provide post-hoc consent
** scores and SE values were extracted from figures, see methods for further details; SD
values were then calculated
Authors were contacted (2nd July 2016, 9th July 2016).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed by creat-
ing 3 sets of random numbers between
1 and 60 using a computer-based re-
search randomizer (www.randomizer.org)”
(pg.125)
Allocation concealment (selection bias) Low risk “ The order of inclusion determined allo-
cation to treatment group. The randomisa-
tion list was locked in the office of the prin-
cipal investigator [...], who was engaged
neither in treatment nor in study assess-
ments” (pg.125)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All ratings were performed by 1 of 2 raters
who were blind to treatment allocation.”
(pg. 215)
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Walther 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 9 participants were excluded post-ran-
domisation due to refusal to provide post-
hoc consent; their treatment assignment
was not provided. 6 participants dropped
out but LOCF method was used to deal
with attrition bias
Selective reporting (reporting bias) High risk PANSS-PAS scores at 24, 48, 72, and 96
hours not provided.
PANSS scores at 96 hours not provided.
Number of patients that needed additional
BDZ not provided.
Number of patients that needed additional
biperiden not provided
Protocol not available.
Other bias High risk Authors declare no conflicts of interest but
all do have some affiliation with relevant
companies
Small sample size.
Wang 2012
Methods Allocation: randomised
Blindness: open-label
Duration: 4 weeks
Participants Diagnosis: schizophrenia with agitation (CCMD-3).
N = 68
Age: mean 30.5 years; range 17~60 years.
Sex: 57 males, 11 females.
History: all patients did not receive clozapine; BPRS total score > = 35 before enrolment
Excluded: severe body diseases, alcohol or drug dependence.
Setting: Liaoning, China (inpatient)
Interventions 1. Risperidone: initial dose not stated, increased to treatment dosage in 7 to 10 days,
then adjust dose according to illness condition; mean dose (4.2 ± 0.35) mg/day. N = 33
2. Risperidone + oxcarbazepine: initial dose not stated for both drugs. Risperidone in-
creased to treatment dosage in 7 to 10 days, then adjust dose according to illness condi-
tion; mean dose (4.1 ± 0.4) mg/day. Oxcarbazepine: initial dose not stated, increased to
0.9~1.8 g/day in one week, then adjust dose according to illness condition; mean dose
(1.20 ± 0.42) g/day. N = 35
Outcomes Specific behaviour: agitation - PANSS-EC endpoint score (1, 2, 4 weeks; Table 1 in p.
2957).
Mental state: BPRS endpoint score (1, 2, 4 weeks; Table 1 in p.2957).
Global outcome: CGI endpoint score (1, 2, 4 weeks; Table 1 in p.2957).
Adverse effects: specific adverse effects (4 weeks; 2.3 in p.2957)
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Wang 2012 (Continued)
Unable to use:
No clinical response (4 weeks; 2.2 in p.2957), data is available at 4 weeks only which is
not consistent with the “rapid tranquillisation” topic
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “All the cases were randomly as-
signed to two group according to random
number table” (p.2061)
Allocation concealment (selection bias) Unclear risk The author did not describe the allocation
concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open trial. The blinding of participants
and personnel not ensured
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open trial. The blinding of outcome as-
sessment not ensured.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants (3/68, 4.4%) left study early
due to poor clinical response (2participants
in
risperidone alone group), however, the au-
thor used LOCFmethodology to deal with
missing data
Selective reporting (reporting bias) Unclear risk Protocol not available; compared to the
’methods’ section, no evidence of ’selective
reporting’ bias
Other bias High risk Small sample size
Wang 2013
Methods Allocation: randomised
Blindness: not reported
Duration: 6 weeks
Participants Diagnosis: schizophrenia with aggressive behaviour (CCMD-3).
N = 68
Age: mean 37.2 years.
Sex: 43 males, 25 females.
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Wang 2013 (Continued)
History: mean length of illness of 6 years, range from 6 months to 23 years; PANSS total
score ≥ 60 before enrolment; MOAS total score ≥ 4 before enrolment
Excluded: severe heart, liver and kidney or nervous system diseases, severe body diseases;
endocrine disease, blood disease, hypertension; glaucoma; women in gestational or suck-
ling period; with severe suicide risk; with poor compliance; allergy to study drugs
Setting: Sichuan, China (inpatient).
Interventions 1. Risperidone: initial dose of 1 mg/day, dose range from 4 mg to 6 mg/day. N = 34
2. Risperidone + sodium valproate: risperidone initial dose of 1 mg/day, dose range from
4 mg to 6 mg/day. Sodium valproate initial dose of 4 mg/day, dose range from 600 mg
to 1200 mg/day. N = 34
Additional treatment with benzodiazepines or benzhexol have been used as p.r.n. drugs
Outcomes Specific behaviour: aggression - MOAS endpoint score (2, 4, 6 weeks; Table 2 in p.73).
Mental state: PANSS endpoint score (2, 4, 6 weeks; Table 1 in p.73), PANSS positive
symptoms sub-scale endpoint score (2, 4, 6 weeks; Table 1 in p.73), PANSS negative
symptoms sub-scale endpoint score (2, 4, 6 weeks; Table1 in p.73), PANSS general
psychopathology sub-scale endpoint score (2, 4, 6 weeks; Table 1 in p.73).
Adverse events: specific adverse events (6 weeks; Table 3 in p.73)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “All the cases were randomly as-
signed to twogroup…” (p.73).Comments:
the author described a randomised com-
ponent, but no more detail about random
methods were given
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome date
Selective reporting (reporting bias) Unclear risk Data on p.r.n. drugs usage not reported.
Protocol not available; compared to the
’methods’ section, no evidence of ’selective
reporting’ bias
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Wang 2013 (Continued)
Other bias High risk Small sample size
Yao 2010
Methods Allocation: randomised
Blindness: not reported
Duration: 8 weeks, follow-up 6 months on participants which had clinical response after
treatment
Participants Diagnosis: schizophrenia with aggressive behaviour (CCMD-3).
N = 62
Age: mean 26.9 years; range 17~42 years.
Sex: 33 males, 29 females.
History: length of illness: not stated;marital status: 23 unmarried, 38married; education:
3 illiterate, 53 less than Bachelor degree, 6 Bachelor degree or more
Excluded: severe physical ailments; patients received antipsychotics within 2weeks before
enrolment; patients with positive family history
Setting: Henan, China (inpatient).
Interventions 1. Risperidone: initial dose of 1 mg/day, increased to 4 mg to 6 mg/day in 7-15 days;
mean (SD): 4.98 (1.07) mg/ay. N = 31
2. Risperidone + magnesium valproate sustained release tablet: risperidone initial dose of
1 mg/day, increased to 4 mg to 6 mg/day in 7-15 days; magnesium valproate sustained
release tablet dose of 500 mg/day. N = 31
Benzodiazepines (alprazolam, 0.8 mg bed-time) could be used for participants with poor
quality of sleep as p.r.n. drugs
Outcomes Mental state: no clinical response at PANSS (8 weeks; section 2.1 in p.2714), PANSS
endpoint score (2, 4, 6, 8 weeks; Table 1 in p.2714).
Adverse effects: specific adverse effects.
Unable to use:
Global state: CGI endpoint score (not reported).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “… were randomly into…” (p.
2713)
Comments: the author described a random
component, but no more detail about ran-
dom methods
Allocation concealment (selection bias) Unclear risk Not stated
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Yao 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not state
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of attrition bias
Selective reporting (reporting bias) High risk CGI endpoint score measured at 2, 4, 6,
8 weeks but not reported. Data on p.r.
n. drugs usage not reported. Protocol not
available
Other bias High risk Small sample size.
Zhou 2013
Methods Allocation: randomised
Blindness: not reported
Duration: 7 days
Participants Diagnosis: schizophrenia with agitation (CCMD-3)
N = 54
Age: mean 26.0 years
Sex: 28 males, 26 females.
History: mean length of illness of 2.47 years; mean PANSS-EC baseline score of 21.98,
range starting from 15; mean MOAS total baseline score of 8.37
Excluded: organic diseases, alcohol or drug dependence.
Setting: Guangxi, China (inpatient).
Interventions 1. Risperidone: initial dose 1 mg/day, twice daily from day 1 to day 3, increased to 2
mg/day twice daily from the day 4 to day 7. N = 27
2. Risperidone + sodium valproate: Risperidone initial dose 1 mg/day twice daily from
the day 1 to day 3, increased to 2 mg/day twice daily from the day 4 to the day 7. Sodium
valproate: intravenous drip 400 mg twice daily from day 2 to day 4. N = 27
Benzhexol (2 mg/day) or alprazolam (0.4 mg to 0.8 mg/day) could be used when nec-
essary
Outcomes Specific behaviour - agitation: PANSS-EC endpoint score (3, 5, 7 days; Table 1 in p.
262), Specific behaviour - aggression: MOAS endpoint score (3, 5, 7 days; Table 1 in p.
262).
Adverse events: TESS endpoint score (3, 5, 7 days; Table 2 in p.262), specific adverse
events (7 days; 2.2 in p.262).
Notes
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Zhou 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “ [...] were randomly divided into
[...]” (p.261). Authors describe a random
component, but no more detail about ran-
dom methods were given
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Unclear risk Data on p.r.n. drugs usage not reported.
Protocol not available; compared to the
’methods’ section, no evidence of ’selective
reporting’ bias
Other bias High risk Small sample size
AIMS: Abnormal Involuntary Movement Scale.
BDZ: Benzodiazepine
BPRS: Brief Psychiatric Rating Scale.
CCMD: Chinese Classification of Mental Disorders.
CGI: Clinical Global Impression.
CGI-I: Clinical Global Impression - Improvement.
CGI-S: Clinical Global Impression - Severity.
CI: Confidence Interval.
DSM: Diagnostic and Statistical Manual of mental disorders.
ICD-10: International Classification of Diseases 10th edition.
IM: Intramuscular.
LOCF: Last Observation Carried Forward.
MOAS: Modified Overt Aggression Scale.
PANSS-EC: Positive and Negative Syndrome Scale - Excited Component.
PANSS-PAS: Positive and Negative Syndrome Scale - Psychotic Agitation Sub-score.
P.r.n.: Pro re nata (if needed).
SAS: Simpson-Angus Scale.
SD: Standard Deviation.
SE: Standard Error.
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TESS: Treatment Emergent Symptom Scale.
YMRS: Young Mania Rating Scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Beck 1997 Allocation: quasi-randomised
Belenkaya 2005 Allocation: randomised
Participants: patients with acute mania; not psychosis-induced aggression or agitation that required
rapid tranquillisation
Briken 2002 Allocation: randomised
Participants: schizophrenia or schizoaffective-disorder
PANSS mean score of 2.00 (SD: 1.28) and a 3-day washout period suggests improbability on
psychosis-induced aggression or agitation requiring rapid tranquillisation
Buckley 1997 Allocation: not randomised
Buitelaar 2001 Allocation: randomised
Participants: adolescents with severe aggressive behaviour and borderline intelligence or mild mental
retardation; not psychosis-induced aggression or agitation that required rapid tranquillisation
Chan 2013 Allocation: randomised
Participants: schizophrenia; not psychosis-induced aggression or agitation that required rapid tran-
quillisation
Citrome 2001 Allocation: randomised
Participants: schizophrenia and persistent aggressive behaviour; not psychosis-induced aggression or
agitation that required rapid tranquillisation
Citrome 2004 Allocation: randomised
Participants: acute exacerbation of schizophrenia; not psychosis-induced aggression or agitation that
required rapid tranquillisation
Citrome 2007 Allocation: randomised
Participants: schizophrenia patients who also exhibit problems with hostility; not psychosis-induced
aggression or agitation that required rapid tranquillisation
Conde 2011 Allocation: randomised
Participants: individuals with acute psychotic agitation.
Intervention: risperidone + clonazepam vs haloperidol + clonazepam
Currier 2000 Allocation: not randomised
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(Continued)
Currier 2004 Allocation: randomised
Participants: individuals with schizophrenia, exhibiting agitation
Intervention: risperidone + lorazepam vs haloperidol vs lorazepam
Czobor 1995 Allocation: randomised
Participants: schizophrenia; not psychosis-induced aggression or agitation that required rapid tran-
quillisation
Fang 2012 Allocation: randomised
Participants: schizophrenia exhibiting agitation
Intervention: risperidone + clonazepam vs haloperidol
Francey 2007 Allocation: randomised
Participants: first episode psychosis with low risk of self-harm or aggression; not psychosis-induced
aggression or agitation that required rapid tranquillisation
Greenspan 2005 Allocation: not randomised
Han 2005 Allocation: randomised
Participants: schizophrenia with agitation/aggression; not psychosis-induced aggression requiring
rapid tranquillisation
Hatta 2008 Allocation: not randomised
He 2005 Allocation: randomised
Participants: patients with schizophrenia; not psychosis-induced aggression or agitation that required
rapid tranquillisation
Hong 2014 Allocation: randomised
Participants: individuals with schizophrenia exhibiting agitation
Intervention: risperidone + clonazepam vs MECT
Hou 2011 Allocation: randomised
Participants: acute schizophrenia with excitement and agitation
Intervention: risperidone + lorazepam vs haloperidol + promethazine
Hovens 2005 Allocation: not randomised
Huaqiang 2009 Allocation: randomised
Participants: schizophrenia and schizophreniform psychosis and dominated with excitement and
agitation; not psychosis-induced aggression or agitation that required rapid tranquillisation
ISRCTN11736448 2003 Allocation: randomised
Participants: aggressive challenging behaviour and intellectual disability; not psychosis-induced ag-
gression or agitation that required rapid tranquillisation
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(Continued)
Jiang 2012 Allocation: randomised
Participants: patients with schizophrenia exhibiting agitation or aggression
Intervention: risperidone + clonazepam vs haloperidol
Kane 2003 Allocation: randomised
Participants: patients with schizophrenia; not psychosis-induced aggression or agitation that required
rapid tranquillisation
Kirwan 2002 Allocation: randomised
Participants: nursing home patients with dementia; not psychosis-induced aggression or agitation
that required rapid tranquillisation
Kolivakis 2002 Allocation: randomised
Participants: schizophreniform disorder and early paranoid schizophrenia; not psychosis-induced
aggression or agitation that required rapid tranquillisation
Lewis 2006 Allocation: not randomised
Li 2014 Allocation: not randomised (full text not consistent with abstract text)
Lieberman 2001 Allocation: randomised
Participants: treatment resistant patients with schizophrenia; not psychosis-induced aggression or
agitation that required rapid tranquillisation
Liu 2010 Allocation: randomised
Participants: schizophrenia with excitement and agitation in the acute stage; not psychosis-induced
aggression or agitation that required rapid tranquillisation
Liu 2012 Allocation: randomised
Participants: patients with schizophrenia exhibiting agitation or aggression
Intervention: risperidone + haloperidol vs risperidone + clonazepam vs haloperidol
NCT00174200 2005 Allocation: randomised
Participants: antipsychotic-naive, non-agitated patients diagnosed with first-episode schizophrenia
or schizophreniform disorder; not psychosis-induced aggression or agitation that required rapid
tranquillisation
NCT00203775 2005 Allocation: randomised
Participants: psychotic disorder; not psychosis-induced aggression or agitation that required rapid
tranquillisation
NCT00205699 2005 Allocation: randomised
Participants: not psychosis-induced aggression or agitation that required rapid tranquillisation
NCT00418873 2007 Allocation: randomised
Participants: aggressive schizophrenic patients in an acute ward
Intervention: risperidone vs zotepine
Outcomes: study terminated due to difficulty in recruiting participants - no usable data
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(Continued)
NCT00485498 2003 Allocation: randomised
Participants: schizophrenia; not psychosis-induced aggression or agitation that required rapid tran-
quillisation
Ou 2007 Allocation: randomised
Participants: schizophrenia with aggressive behavior; not psychosis-induced aggression or agitation
that required rapid tranquillisation
Pei 2009 Allocation: quasi-randomised
Peng 2009 Allocation randomised
Participants: people with schizophrenia who are hospitalised for the first time; not psychosis-induced
aggression or agitation that required rapid tranquillisation
Potkin 2005 Allocation: not randomised
Schooler 2003 Allocation: not randomised
Swanson 2008 Allocation: randomised
Participants: schizophrenia; not psychosis-induced aggression or agitation that required rapid tran-
quillisation
Tang 2007 Allocation: randomised
Participants: acute excitement phase of schizophrenia; not psychosis-induced aggression or agitation
Temputrn 2007 Allocation: randomised
Participants: schizoaffective disorder experiencing an acute exacerbation of psychotic symptoms; not
psychosis-induced aggression or agitation that required rapid tranquillisation
Tosic Golubovic Suzana 2009 Allocation: randomised.
Participants: people with schizophrenia or schizoaffective experiencing an acute psychotic episode;
not psychosis-induced aggression or agitation that required rapid tranquillisation
Veser 2006 Allocation: randomised
Participants: people with psychosis-induced agitation, however the study exclusion criteria included
an inability to give informed consent; not psychosis-induced aggression or agitation that required
rapid tranquillisation
Villari 2008 Allocation: quasi-randomised
Wan 2005 Allocation: randomised
Participants: people with schizophrenia and agitation/aggression; not psychosis-induced aggression
or agitation that required rapid tranquillisation
Wang 2004 Allocation: randomised
Participants: acute agitation in schizophrenia; not psychosis-induced aggression or agitation that
required rapid tranquillisation
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(Continued)
Wang 2006 Allocation: randomised
Participants: people with schizophrenia who are displaying aggressive behaviours, not acute agitation
or aggressive episodes and thus not requiring rapid tranquillisation
Wang 2015 Allocation: randomised
Participants: people with schizophrenia exhibiting agitation or aggression
Intervention: risperidone + haloperidol vs risperidone + ECT
Wei 2010 Allocation: randomised
Participants: adolescents with schizophrenia; not psychosis-induced aggression or agitation that
required rapid tranquillisation
Xi 2010 Allocation: randomised
Participants: schizophrenia with impulsive and aggressive symptoms; not psychosis-induced aggres-
sion or agitation that required rapid tranquillisation
Xuan 2007 Allocation: randomised
Participants: people with acute schizophrenia with excitement/agitation and other behavioural dis-
orders; not psychosis-induced aggression or agitation that required rapid tranquillisation
Zhang 2012 Allocation: randomised
Participants: people with schizophrenia exhibiting agitation or aggression
Intervention: risperidone + clonazepam vs haloperidol.
Zheng 2010 Allocation: randomised
Participants: people with schizophrenia who have acute psychotic agitation
Intervention: risperidone + clonazepam vs haloperidol
Zhou 2012 Allocation: randomised
Participants: people with schizophrenia exhibiting agitation or aggression
Intervention: risperidone + clonazepam vs haloperidol
ECT: electroconvulsive therapy.
MECT: modern electroconvulsive therapy.
PANSS: Positive And Negative Syndrome Scale.
SD: standard deviation.
Characteristics of studies awaiting assessment [ordered by study ID]
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Herrera 2005
Methods Allocation: randomised.
Blindness: double.
Duration: not stated.
Participants Diagnosis: psychosis with agitation and/or violence.
N = 20.
Age: not stated.
Sex: not stated.
History: not stated.
Exclusion: not stated.
Setting: psychiatric emergency department.
Interventions 1. Haloperidol: dose 10 mg/IM.
2. Risperidone: dose 2 mg/liquid.
Outcomes Specific behaviour - agitation: PANSS-EC.
Notes Conference abstract, full characteristics and outcome data not reported. Attempted to contact author
Hsu 2010
Methods Allocation: randomised.
Blindness: single.
Duration: 24 hours.
Participants Diagnosis: DSM-IV diagnosis of schizophrenia (N = 20), bipolar disorder (N = 18), schizoaffective disorder (N = 1)
, delusional disorder or others (N = 3)
N = 42.
Age: range 18-65 years.
Sex: 20 males and 22 females.
History: within 24 hours of admission - previous psychiatric history not stated
Exclusion: “pregnant or lactating women; patients with serious medical illnesses; patients with closed-angle glaucoma;
patients with an allergic reaction to olanzapine, risperidone, or haloperidol; or patients who had received a long-
acting antipsychotic agent injection within 30 days were excluded”
Setting: Taiwan (acute medical centre).
Interventions 1. Haloperidol: dose 7.5 mg/IM. N = 11.
2. Risperidone: dose 3 mg/liquid. N = 10.
3. Olanzapine: dose 10 mg/IM. N = 11.
4. Olanzapine: dose 10 mg/velotab. N = 10.
Outcomes Specific behaviour - agitation: PANSS-EC*.
Notes * attempted to contact authors to ask for any usable data.
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Lasic 2006
Methods Allocation: randomised.
Blindness: not stated.
Duration: up to 3 months.
Participants Diagnosis: ICD X diagnosis of acute exacerbation of schizophrenia or schizoaffective disorder, mania with psychotic
features, acute paranoid reaction, or delusional disorders
N = 60.
Age: ≥18 years.
Exclusion: “delirium, epilepsy, or mental retardation; intoxication or symptoms of withdrawal from alcohol or other
psychoactive substances; clinical laboratory values indicating serious medical illness; treatment with any antipsychotic
or benzodiazepine within 6 hours of screening; a history of neurolepticmalignant syndrome or knownhypersensitivity
to any of the trial medications; treatment with a depot antipsychotic within 1 treatment cycle of screening and use
of disallowed medications”
Setting: Croatia (acute psychiatric inpatient ward).
Interventions 1. Haloperidol IM (dose not reported).
2. Risperidol liquid (dose not reported).
Outcomes Specific behaviour - agitation: BARS, PANSS agitation cluster.
Mental state: PANSS.
Global state: CGI-I.
Adverse effects.
Notes Conference abstract, full characteristics and outcome data not reported. Attempted to contact author
NCT00859872
Methods Allocation: randomised.
Blindness: single.
Duration: 47 days.
Participants Diagnosis: DSM-IV diagnosis of acute exacerbation of schizophrenia or schizoaffective disorder with agitation
Age: range 18-45 years.
Sex: males and females.
History: not stated.
Exclusion: pregnant or lactating women, serious medical illness, known sensitivity to study medication, treatment
with a depot antipsychotic with 1 cycle of screening, use of disallowed medication, psychosis caused by “delirium,
epilepsy, mental retardation and affective disorder; intoxication or symptoms of withdrawal from alcohol of other
psychoactive substances.”
Setting: China (psychiatric inpatient ward).
Interventions 1. Haloperidol: dose 5 mg to 20 mg/IM/day.
2. Risperidone: dose 2 mg to 6 mg/oral/day + clonazepam: dose 4 mg to 8 mg/oral/day
Outcomes Specific behaviour - agitation: PANSS-EC.
Mental state: PANSS.
Notes Protocol, full characteristics and outcome data not reported. Unable to establish contact details at this time
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BARS: Behavioural Activity Rating Scale.
CGI-I: Clinical Global Impression - Improvement.
DSM: Diagnostic and Statistical Manual of mental disorders.
ICD: International Classification of Diseases.
IM: Intramuscular.
PANSS: Positive and Negative Syndrome Scale.
PANSS-EC: Positive and Negative Syndrome Scale - Excited Component.
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D A T A A N D A N A L Y S E S
Comparison 1. RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Specific behaviour: 1a. Agitation
- Various measures
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 PANSS-PAS response up
to 24 hours ( ≥ 50% reduction
at PANSS-PAS score)
1 124 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.86, 1.26]
2 Specific behaviour: 1b. Agitation
- Average scores - i. up to 2
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Endpoint score (PANSS-
PAS, high = worse)
1 28 Mean Difference (IV, Fixed, 95% CI) 0.40 [-4.42, 5.22]
3 Specific behaviour: 1c. Agitation
- Average scores - ii. up to 24
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Endpoint score (PANSS-
PAS, high = worse)
1 28 Mean Difference (IV, Fixed, 95% CI) 0.20 [-3.96, 4.36]
4 Specific behaviour: 1d. Agitation
- Average scores - iii. over 24
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Endpoint score at 48
hours (PANSS-PAS, high =
worse)
1 28 Mean Difference (IV, Fixed, 95% CI) 1.5 [-1.36, 4.36]
4.2 Endpoint score at 72
hours (PANSS-PAS, high =
worse)
1 28 Mean Difference (IV, Fixed, 95% CI) 1.40 [-1.62, 4.42]
4.3 Endpoint score at 96
hours (PANSS-PAS, high =
worse)
1 28 Mean Difference (IV, Fixed, 95% CI) 2.90 [-0.34, 6.14]
5 Global outcome: 1a. General -
Need for additional measures
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Need for benzodiazepine
up to 24 hours
1 124 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.34, 2.27]
5.2 Need for seclusion room 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.55]
5.3 Use of restraints 1 28 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.43, 9.21]
6 Global outcome: 1b. General -
Need for additional medication
(skewed data)
Other data No numeric data
7 Adverse effects: 1. General 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 One or more AEs up to
24 hours
1 124 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.54, 1.66]
8 Adverse effects: 2a. Specific -
Arousal level
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Insomnia up to 24 hours 1 124 Risk Ratio (M-H, Fixed, 95% CI) 13.0 [0.75, 225.90]
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8.2 Somnolence up to 24
hours
1 124 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.51, 3.24]
9 Adverse effects: 2b. Specific -
Movement disorder - i. Various
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 EPS up to 24 hours 1 124 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.22, 1.80]
10 Adverse effects: 2b. Specific -
Movement disorder - ii. Need
for biperiden
Other data No numeric data
11 Adverse effects: 2b. Specific
- Movement disorder - iii.
Average scores (skewed data)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 Endpoint scores at 96
hours (AIMS, high = worse)
1 28 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 Endpoint scores at 96
hours (BARS, high = worse)
1 28 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.56, 0.36]
11.3 Endpoint scores at 96
hours (SAS, high = worse)
1 28 Mean Difference (IV, Fixed, 95% CI) -0.40 [-1.00, 2.20]
12 Adverse effects: 2c. Specific -
Miscellaneous
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Headache up to 24 hours 1 124 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.18, 3.21]
12.2 Dizziness up to 24 hours 1 124 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.26, 3.82]
13 Leaving the study early 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 For any reason 2 152 Risk Ratio (M-H, Fixed, 95% CI) 2.2 [0.51, 9.48]
13.2 Due to adverse effects 1 124 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.37]
13.3 Lack of efficacy 1 28 Risk Ratio (M-H, Fixed, 95% CI) 9.0 [0.53, 152.93]
Comparison 2. RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Specific behaviour: 1. Agitation
- Average scores - i. Up to 2
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Endpoint score (PANSS-
PAS, high = worse)
1 29 Mean Difference (IV, Fixed, 95% CI) 2.5 [-2.46, 7.46]
2 Specific behaviour: 1. Agitation
- Average scores - ii. Up to 24
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Endpoint score (PANSS-
PAS, high = worse)
1 29 Mean Difference (IV, Fixed, 95% CI) 0.90 [-3.40, 5.20]
3 Specific behaviour: 1. Agitation
- Average scores - iii. over 24
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Endpoint score at 48
hours (PANSS-PAS, high =
worse)
1 29 Mean Difference (IV, Fixed, 95% CI) -1.20 [-5.15, 2.75]
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3.2 Endpoint score at 72
hours (PANSS-PAS, high=
worse)
1 29 Mean Difference (IV, Fixed, 95% CI) -0.30 [-4.47, 3.87]
3.3 Endpoint score at 96
hours (PANSS-PAS, high =
worse)
1 29 Mean Difference (IV, Fixed, 95% CI) 2.10 [-1.41, 5.61]
4 Global outcome: 1a. General -
Need for additional measures
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Need for seclusion room 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.02, 8.07]
4.2 Use of restraints 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.39, 5.28]
5 Global outcome: 1b. General -
Need for additional medication
(skewed data)
Other data No numeric data
6 Adverse effects: 1a. Specific -
Movement disorder - i. Meed
for biperiden
Other data No numeric data
7 Adverse effects: 1b. Specific
- Movement disorder - ii.
Average scores (skewed data)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Endpoint score (BARS,
high = worse)
1 29 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.43, 0.83]
7.2 Endpoint score (SAS, high
= worse)
1 29 Mean Difference (IV, Fixed, 95% CI) 1.80 [-0.63, 4.23]
8 Leaving the study early 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Lack of efficacy 1 29 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [0.46, 9.93]
Comparison 3. RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Specific behaviour: 1. Aggression
- Average scores - i. Over 24
hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Endpoint score at 2 weeks
(MOAS, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 1.80 [0.20, 3.40]
1.2 Endpoint score at 4 weeks
(MOAS, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.44, 2.24]
1.3 Endpoint score at 6 weeks
(MOAS, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 0.70 [-0.29, 1.69]
1.4 Endpoint score at 8 weeks
(MOAS, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 0.55 [-0.40, 1.50]
2 Mental state: 1a. No change in
general mental state
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 No response at 8 weeks (
≤ 25% reduction at PANSS
score)
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.16, 6.42]
3 Mental state: 1b. Change in
general mental state
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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3.1 Clinical response at 8
weeks (25 - 50% reduction at
PANSS score)
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.34, 5.21]
3.2 Clinical response at 8
weeks (50 - 75% reduction at
PANSS score)
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.39, 1.95]
3.3 Clinical response at 8
weeks ( ≥ 75% reduction at
PANSS score)
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.43, 2.33]
4 Mental state: 1c. Average scores -
i. Over 24 hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Endpoint score at 2 weeks
(PANSS, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 2.40 [-2.15, 6.95]
4.2 Endpoint score at 4 weeks
(PANSS, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 1.95 [-3.07, 6.97]
4.3 Endpoint score at 6 weeks
(PANSS, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 5.75 [-0.09, 11.59]
4.4 Endpoint score at 8 weeks
(PANSS, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 3.55 [-0.69, 7.79]
4.5 Endpoint score at 2 weeks
(PANSS positive symptoms
sub-scale, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 1.15 [-0.37, 2.67]
4.6 Endpoint score at 4 weeks
(PANSS positive symptoms
sub-scale, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 1.70 [0.01, 3.39]
4.7 Endpoint score at 6 weeks
(PANSS positive symptoms
sub-scale, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 2.05 [-0.15, 4.25]
4.8 Endpoint score at 8 weeks
(PANSS positive symptoms
sub-scale, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 2.25 [-0.36, 4.86]
4.9 Endpoint score at 2 weeks
(PANSS negative symptoms
sub-scale, high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 1.30 [-0.07, 2.67]
4.10 Endpoint score at
4 weeks (PANSS negative
symptoms sub-scale, high =
worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 1.31 [-0.04, 2.66]
4.11 Endpoint score at
6 weeks (PANSS negative
symptoms sub-scale, high =
worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 1.70 [-0.12, 3.52]
4.12 Endpoint score at
8 weeks (PANSS negative
symptoms sub-scale, high =
worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 2.05 [-0.06, 4.16]
4.13 Endpoint score at
2 weeks (PANSS general
psychopathology sub-scale,
high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) -1.75 [-4.73, 1.23]
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4.14 Endpoint score at
4 weeks (PANSS general
psychopathology sub-scale,
high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) -0.60 [-3.73, 2.53]
4.15 Endpoint score at
6 weeks (PANSS general
psychopathology sub-scale,
high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 1.01 [-1.88, 3.90]
4.16 Endpoint score at
8 weeks (PANSS general
psychopathology sub-scale,
high = worse)
1 40 Mean Difference (IV, Fixed, 95% CI) 1.37 [-1.30, 4.04]
5 Adverse effects: 1a. Specific -
Anticholinergic
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Blurred vision over 24
hours
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.10, 2.43]
6 Adverse effects: 1b. Specific -
Arousal
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Somnolence over 24 hours 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.17, 2.18]
7 Adverse effects: 1c. Specific -
Cardiovascular
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Tachycardia over 24 hours 1 40 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [0.49, 32.72]
8 Adverse effects: 1d. Specific -
Gastrointestinal
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Nausea and vomiting over
24 hours
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.90]
9 Adverse effects: 1e. Specific -
Movement disorders
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Akathisia over 24 hours 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.46, 6.06]
9.2 Hypermyotonia over 24
hours
1 40 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.95, 51.80]
10 Adverse effects: 1f. Specific -
Miscellaneous
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Headache over 24 hours 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.16, 6.42]
10.2 Liver Function Tests
(LFTs) elevation over 24 hours
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.90]
10.3 Weight gain over 24
hours
1 40 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [0.49, 32.72]
10.4 Agitation over 24 hours 1 40 Risk Ratio (M-H, Fixed, 95% CI) 3.5 [0.83, 14.83]
Comparison 4. RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Specific behaviour: 1. Agitation -
Average scores - i. over 24 hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Endpoint score at 1 week
(PANSS-EC, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 2.70 [0.42, 4.98]
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1.2 Endpoint score at 2 weeks
(PANSS-EC, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 2.40 [0.32, 4.48]
1.3 Endpoint score at 4 weeks
(PANSS-EC, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 2.40 [0.53, 4.27]
2 Global Outcome: 1. Average
scores - i. Over 24 hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Endpoint score at 1 week
(CGI-I, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.61, 0.21]
2.2 Endpoint score at 2 weeks
(CGI-I, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 0.5 [0.07, 0.93]
2.3 Endpoint score at 4 weeks
(CGI-I, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 0.50 [0.14, 0.86]
2.4 Endpoint score at 1 week
(CGI-S, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.25, 0.65]
2.5 Endpoint score at 2 weeks
(CGI-S, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 0.5 [0.07, 0.93]
2.6 Endpoint score at 4 weeks
(CGI-S, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 0.5 [0.14, 0.86]
3 Mental state: 1a. No change in
general mental state
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 No response at 4 weeks ( <
50% reduction BPRS score)
1 68 Risk Ratio (M-H, Fixed, 95% CI) 10.61 [1.44, 78.36]
4 Mental state: 1b. Change in
general mental state
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Clinical response at 4
weeks (50 - 75% reduction at
BPRS score)
1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.50, 0.97]
4.2 Clinical response at 4
weeks ( ≥ 75% reduction at
BPRS score)
1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.25, 2.89]
5 Mental state: 1c. Average scores -
i. Over 24 hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Endpoint score at 1 week
(BPRS, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 5.20 [1.04, 9.36]
5.2 Endpoint score at 2 weeks
(BPRS, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 6.20 [2.48, 9.92]
5.3 Endpoint score at 4 weeks
(BPRS, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 5.40 [1.84, 8.96]
6 Adverse effects: 1. General -
Total number of AEs
Other data No numeric data
7 Adverse effects: 2a. Specific -
Anticholinergic
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Dry mouth over 24 hours 1 68 Risk Ratio (M-H, Fixed, 95% CI) 2.12 [0.81, 5.55]
7.2 Constipation over 24
hours
1 68 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.62, 2.72]
8 Adverse effects: 2b. Specific -
Arousal
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Excessive sedation over 24
hours
1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.00, 0.92]
9 Adverse effects: 2c. Specific -
Cardiovascular
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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9.1 Tachycardia over 24 hours 1 68 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.46, 3.30]
10 Adverse effects: 2d. Specific -
Gastrointestinal
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Nausea over 24 hours 1 68 Risk Ratio (M-H, Fixed, 95% CI) 2.12 [0.20, 22.31]
11 Adverse effects: 2e. Specific -
Movement disorders
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 EPS over 24 hours 1 68 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [0.49, 5.14]
11.2 Tremor over 24 hours 1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.25, 2.89]
12 Adverse effects: 2f. Specific -
Miscellaneous
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Headache over 24 hours 1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.19]
12.2 Skin rash over 24 hours 1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.37]
Comparison 5. RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Specific behaviour: 1. Agitation -
average scores - i. over 24 hours
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Endpoint score at 3 days
(PANSS-EC, high = worse)
1 54 Mean Difference (IV, Fixed, 95% CI) -0.11 [-2.98, 2.76]
1.2 Endpoint score at 5 days
(PANSS-EC, high = worse)
1 54 Mean Difference (IV, Fixed, 95% CI) 5.47 [2.64, 8.30]
1.3 Endpoint score at 7 days
(PANSS-EC, high = worse)
1 54 Mean Difference (IV, Fixed, 95% CI) 5.11 [2.51, 7.71]
1.4 Endpoint score at 2 weeks
(PANSS-EC, high = worse)
1 63 Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.90, 1.08]
1.5 Endpoint score at 4 weeks
(PANSS-EC, high = worse)
1 63 Mean Difference (IV, Fixed, 95% CI) 0.17 [-0.85, 1.19]
2 Specific behaviour: 1. Aggression
- Average scores - i. over 24
hours
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Endpoint score at 3 days
(MOAS, high = worse)
1 54 Mean Difference (IV, Fixed, 95% CI) 1.07 [-0.20, 2.34]
2.2 Endpoint score at 5 days
(MOAS, high = worse)
1 54 Mean Difference (IV, Fixed, 95% CI) 0.38 [-0.83, 1.59]
2.3 Endpoint score at 7 days
(MOAS, high = worse)
1 54 Mean Difference (IV, Fixed, 95% CI) 3.32 [2.07, 4.57]
2.4 Endpoint score at 2 weeks
(MOAS, high = worse)
2 128 Mean Difference (IV, Fixed, 95% CI) 1.13 [0.23, 2.02]
2.5 Endpoint score at 4 weeks
(MOAS, high = worse)
2 128 Mean Difference (IV, Fixed, 95% CI) 1.57 [0.75, 2.39]
2.6 Endpoint score at 6 weeks
(MOAS, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 1.47 [0.83, 2.11]
2.7 Endpoint score at 8 weeks
(MOAS, high = worse)
1 60 Mean Difference (IV, Fixed, 95% CI) 1.00 [-0.11, 2.11]
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3 Mental state: 1. No change in
general mental state
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 No clinical response at 8
weeks ( < 30% reduction at
PANSS score)
1 62 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.44, 6.38]
4 Mental state: 2. Average scores -
i. over 24 hours
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Endpoint score at 2 weeks
(PANSS, high = worse)
4 253 Mean Difference (IV, Fixed, 95% CI) 3.48 [1.88, 5.08]
4.2 Sub-group analysis:
Endpoint score at 2 weeks
(PANSS, high = worse)
3 185 Mean Difference (IV, Fixed, 95% CI) 2.50 [0.78, 4.21]
4.3 Endpoint score at 4 weeks
(PANSS, high = worse)
4 253 Mean Difference (IV, Fixed, 95% CI) 5.45 [3.81, 7.08]
4.4 Sub-group analysis:
Endpoint score at 4 weeks
(PANSS, high = worse)
3 185 Mean Difference (IV, Fixed, 95% CI) 4.52 [2.76, 6.29]
4.5 Endpoint score at 6 weeks
(PANSS, high = worse)
2 130 Mean Difference (IV, Fixed, 95% CI) 9.90 [7.42, 12.37]
4.6 Endpoint score at 8 weeks
(PANSS, high = worse)
2 122 Mean Difference (IV, Fixed, 95% CI) 5.83 [4.12, 7.54]
4.7 Endpoint score at 2 weeks
(PANSS positive symptoms
sub-scale, high = worse)
3 191 Mean Difference (IV, Fixed, 95% CI) 0.64 [-0.24, 1.53]
4.8 Endpoint score at 4 weeks
(PANSS positive symptoms
sub-scale, high = worse)
3 191 Mean Difference (IV, Fixed, 95% CI) 2.75 [1.86, 3.64]
4.9 Endpoint score at 6 weeks
(PANSS positive symptoms
sub-scale, high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 4.4 [1.40, 7.40]
4.10 Endpoint score at
8 weeks (PANSS positive
symptoms sub-scale, high =
worse)
1 60 Mean Difference (IV, Fixed, 95% CI) 1.70 [0.71, 2.69]
4.11 Endpoint score at
2 weeks (PANSS negative
symptoms sub-scale, high =
worse)
2 128 Mean Difference (IV, Fixed, 95% CI) 0.29 [-0.57, 1.15]
4.12 Endpoint score at
4 weeks (PANSS negative
symptoms sub-scale, high =
worse)
2 128 Mean Difference (IV, Fixed, 95% CI) 1.23 [-0.16, 2.62]
4.13 Endpoint score at
6 weeks (PANSS negative
symptoms sub-scale, high =
worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 3.80 [1.07, 6.53]
4.14 Endpoint score at
8 weeks (PANSS negative
symptoms sub-scale, high =
worse)
1 60 Mean Difference (IV, Fixed, 95% CI) 1.30 [-0.02, 2.62]
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4.15 Endpoint score at
2 weeks (PANSS general
psychopathology sub-scale,
high = worse)
2 128 Mean Difference (IV, Fixed, 95% CI) 0.93 [-0.07, 1.93]
4.16 Endpoint score at
4 weeks (PANSS general
psychopathology sub-scale,
high = worse)
2 128 Mean Difference (IV, Fixed, 95% CI) 1.14 [0.04, 2.23]
4.17 Endpoint score at
6 weeks (PANSS general
psychopathology sub-scale,
high = worse)
1 68 Mean Difference (IV, Fixed, 95% CI) 6.5 [4.06, 8.94]
4.18 Endpoint score at
8 weeks (PANSS general
psychopathology sub-scale,
high = worse)
1 60 Mean Difference (IV, Fixed, 95% CI) 1.60 [0.43, 2.77]
5 Adverse effects: 1a. General -
Total number of AEs
Other data No numeric data
6 Adverse effects: 1b. General -
Serious
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 myocardial ischaemia (at 8
weeks)
1 62 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 20.93]
7 Adverse effects: 2a. Specific -
Anticholinergic
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Blurred vision over 24
hours
2 122 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.37, 2.68]
7.2 Dry mouth over 24 hours 2 129 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.76, 3.54]
8 Adverse effects: 2b. Specific -
Arousal
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Insomnia over 24 hours 1 54 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 20.77]
8.2 Somnolence over 24 hours 2 121 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.44, 1.63]
9 Adverse effects: 2c. Specific -
Cardiovascular
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Decreased blood pressure
over 24 hours
1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.18, 3.10]
9.2 Tachycardia over 24 hours 4 251 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.83, 2.67]
9.3 T-wave changes in ECG
over 24 hours
1 54 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 20.77]
10 Adverse effects: 2d. Specific -
Gastrointestinal
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Constipation over 24
hours
3 189 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.70, 1.76]
10.2 Nausea over 24 hours 2 122 Risk Ratio (M-H, Fixed, 95% CI) 0.7 [0.29, 1.71]
11 Adverse effects: 2e. Specific -
Movement disorders
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 EPS over 24 hours 2 121 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.76, 2.39]
11.2 Akathisia over 24 hours 2 122 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.28, 2.03]
11.3 Tremor over 24 hours 1 68 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.40, 3.56]
12 Adverse effects: 2f. Specific -
Movement disorders - Average
scores - i. Over 24 hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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12.1 Endpoint score at 3 days
(TESS, high = worse)
1 54 Mean Difference (IV, Fixed, 95% CI) -0.04 [-1.35, 1.27]
12.2 Endpoint score at 5 days
(TESS, high = worse)
1 54 Mean Difference (IV, Fixed, 95% CI) -0.11 [-1.55, 1.33]
12.3 Endpoint score at 7 days
(TESS, high = worse)
1 54 Mean Difference (IV, Fixed, 95% CI) -0.51 [-1.88, 0.86]
13 Adverse effects: 2g. Specific -
Miscellaneous
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Headache over 24 hours 4 243 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.53, 1.68]
13.2 Weight gain over 24
hours
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.47, 4.78]
13.3 Oedema over 24 hours 1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.13]
13.4 Leukopenia over 24
hours
1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.13]
13.5 Liver Function Tests
(LFTs) elevation over 24 hours
2 116 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.15, 2.40]
14 Leaving the study early 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 For any reason 1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.13]
14.2 Due to adverse effects 1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.13]
Analysis 1.1. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome 1
Specific behaviour: 1a. Agitation - Various measures.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 1 Specific behaviour: 1a. Agitation - Various measures
Study or subgroup Risperidone Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PANSS-PAS response up to 24 hours (≥ 50% reduction at PANSS-PAS score)
Lim 2010 (1) 49/62 47/62 100.0 % 1.04 [ 0.86, 1.26 ]
Subtotal (95% CI) 62 62 100.0 % 1.04 [ 0.86, 1.26 ]
Total events: 49 (Risperidone), 47 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours haloperidol Favours risperidone
(1) Authors of the manuscript use the ”PANSS-EC” term but provide the items list of PANSS-PAS; in other published studies they refers to this as an ”5 item acute
agitation cluster [...] from PANSS score”. X-axis labels of the forest plot have been switched in order to improve readability.
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Analysis 1.2. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome 2
Specific behaviour: 1b. Agitation - Average scores - i. up to 2 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 2 Specific behaviour: 1b. Agitation - Average scores - i. up to 2 hours
Study or subgroup Risperidone Haloperidol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score (PANSS-PAS, high = worse)
Walther 2014 14 11.6 (6.9) 14 11.2 (6.1) 100.0 % 0.40 [ -4.42, 5.22 ]
Subtotal (95% CI) 14 14 100.0 % 0.40 [ -4.42, 5.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours risperidone Favours haloperidol
Analysis 1.3. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome 3
Specific behaviour: 1c. Agitation - Average scores - ii. up to 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 3 Specific behaviour: 1c. Agitation - Average scores - ii. up to 24 hours
Study or subgroup Risperidone Haloperidol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score (PANSS-PAS, high = worse)
Walther 2014 (1) 14 14.4 (5.4628) 14 14.2 (5.7622) 100.0 % 0.20 [ -3.96, 4.36 ]
Subtotal (95% CI) 14 14 100.0 % 0.20 [ -3.96, 4.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.92)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours risperidone Favours haloperidol
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(1) Data were extracted from figure 1 (p.126); see methods for further details.
Analysis 1.4. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome 4
Specific behaviour: 1d. Agitation - Average scores - iii. over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 4 Specific behaviour: 1d. Agitation - Average scores - iii. over 24 hours
Study or subgroup Risperidone Haloperidol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 48 hours (PANSS-PAS, high = worse)
Walther 2014 (1) 14 11.9 (4.6397) 14 10.4 (2.8811) 100.0 % 1.50 [ -1.36, 4.36 ]
Subtotal (95% CI) 14 14 100.0 % 1.50 [ -1.36, 4.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
2 Endpoint score at 72 hours (PANSS-PAS, high = worse)
Walther 2014 (2) 14 11.2 (5.1635) 14 9.8 (2.5817) 100.0 % 1.40 [ -1.62, 4.42 ]
Subtotal (95% CI) 14 14 100.0 % 1.40 [ -1.62, 4.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
3 Endpoint score at 96 hours (PANSS-PAS, high = worse)
Walther 2014 (3) 14 12.4 (4.7519) 14 9.5 (3.9662) 100.0 % 2.90 [ -0.34, 6.14 ]
Subtotal (95% CI) 14 14 100.0 % 2.90 [ -0.34, 6.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Chi2 = 0.54, df = 2 (P = 0.76), I2 =0.0%
-4 -2 0 2 4
risperidone haloperidol
(1) Data were extracted from figure 1 (p.126); see methods for further details.
(2) Data were extracted from figure 1 (p.126); see methods for further details.
(3) Data were extracted from figure 1 (p.126); see methods for further details.
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Analysis 1.5. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome 5
Global outcome: 1a. General - Need for additional measures.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 5 Global outcome: 1a. General - Need for additional measures
Study or subgroup Risperidone Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Need for benzodiazepine up to 24 hours
Lim 2010 7/62 8/62 100.0 % 0.88 [ 0.34, 2.27 ]
Subtotal (95% CI) 62 62 100.0 % 0.88 [ 0.34, 2.27 ]
Total events: 7 (Risperidone), 8 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
2 Need for seclusion room
Walther 2014 0/14 1/14 100.0 % 0.33 [ 0.01, 7.55 ]
Subtotal (95% CI) 14 14 100.0 % 0.33 [ 0.01, 7.55 ]
Total events: 0 (Risperidone), 1 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
3 Use of restraints
Walther 2014 4/14 2/14 100.0 % 2.00 [ 0.43, 9.21 ]
Subtotal (95% CI) 14 14 100.0 % 2.00 [ 0.43, 9.21 ]
Total events: 4 (Risperidone), 2 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 1.34, df = 2 (P = 0.51), I2 =0.0%
0.01 0.1 1 10 100
Favours risperidone Favours haloperidol
Analysis 1.6. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome 6
Global outcome: 1b. General - Need for additional medication (skewed data).
Global outcome: 1b. General - Need for additional medication (skewed data)
Study Intervention Mean
(total mg of diazepam needed
during the entire study per pa-
tient)
SD N
Walther 2014 Risperidone 92.9 86.8 14
Walther 2014 Haloperidol 71.1 70.4 14
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Analysis 1.7. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome 7
Adverse effects: 1. General.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 7 Adverse effects: 1. General
Study or subgroup Risperidone Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 One or more AEs up to 24 hours
Lim 2010 17/62 18/62 100.0 % 0.94 [ 0.54, 1.66 ]
Subtotal (95% CI) 62 62 100.0 % 0.94 [ 0.54, 1.66 ]
Total events: 17 (Risperidone), 18 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
0.5 0.7 1 1.5 2
Favours risperidone Favours haloperidol
Analysis 1.8. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome 8
Adverse effects: 2a. Specific - Arousal level.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 8 Adverse effects: 2a. Specific - Arousal level
Study or subgroup Risperidone Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Insomnia up to 24 hours
Lim 2010 6/62 0/62 100.0 % 13.00 [ 0.75, 225.90 ]
Subtotal (95% CI) 62 62 100.0 % 13.00 [ 0.75, 225.90 ]
Total events: 6 (Risperidone), 0 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
2 Somnolence up to 24 hours
Lim 2010 9/62 7/62 100.0 % 1.29 [ 0.51, 3.24 ]
Subtotal (95% CI) 62 62 100.0 % 1.29 [ 0.51, 3.24 ]
Total events: 9 (Risperidone), 7 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Chi2 = 2.28, df = 1 (P = 0.13), I2 =56%
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Analysis 1.9. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome 9
Adverse effects: 2b. Specific - Movement disorder - i. Various.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 9 Adverse effects: 2b. Specific - Movement disorder - i. Various
Study or subgroup Risperidone Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 EPS up to 24 hours
Lim 2010 5/62 8/62 100.0 % 0.63 [ 0.22, 1.80 ]
Subtotal (95% CI) 62 62 100.0 % 0.63 [ 0.22, 1.80 ]
Total events: 5 (Risperidone), 8 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours risperidone Favours haloperidol
Analysis 1.10. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome
10 Adverse effects: 2b. Specific - Movement disorder - ii. Need for biperiden.
Adverse effects: 2b. Specific - Movement disorder - ii. Need for biperiden
Study Intervention Mean
(total mg of biperiden needed
during the entire study per pa-
tient)
SD N
Walther 2014 Risperidone 4.1 7.3 14
Walther 2014 Haloperidol 5.2 8.3 14
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Analysis 1.11. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome
11 Adverse effects: 2b. Specific - Movement disorder - iii. Average scores (skewed data).
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 11 Adverse effects: 2b. Specific - Movement disorder - iii. Average scores (skewed data)
Study or subgroup Risperidone Haloperidol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint scores at 96 hours (AIMS, high = worse)
Walther 2014 14 7 (0) 14 7.6 (1.6) Not estimable
Subtotal (95% CI) 14 14 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Endpoint scores at 96 hours (BARS, high = worse)
Walther 2014 14 0.3 (1.1) 14 0.9 (1.46) 100.0 % -0.60 [ -1.56, 0.36 ]
Subtotal (95% CI) 14 14 100.0 % -0.60 [ -1.56, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
3 Endpoint scores at 96 hours (SAS, high = worse)
Walther 2014 14 3 (3.7) 14 3.4 (3.3) 100.0 % -0.40 [ -3.00, 2.20 ]
Subtotal (95% CI) 14 14 100.0 % -0.40 [ -3.00, 2.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 1.12. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome
12 Adverse effects: 2c. Specific - Miscellaneous.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 12 Adverse effects: 2c. Specific - Miscellaneous
Study or subgroup Risperidone Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Headache up to 24 hours
Lim 2010 3/62 4/62 100.0 % 0.75 [ 0.18, 3.21 ]
Subtotal (95% CI) 62 62 100.0 % 0.75 [ 0.18, 3.21 ]
Total events: 3 (Risperidone), 4 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
2 Dizziness up to 24 hours
Lim 2010 4/62 4/62 100.0 % 1.00 [ 0.26, 3.82 ]
Subtotal (95% CI) 62 62 100.0 % 1.00 [ 0.26, 3.82 ]
Total events: 4 (Risperidone), 4 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
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Analysis 1.13. Comparison 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL, Outcome
13 Leaving the study early.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 1 RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL
Outcome: 13 Leaving the study early
Study or subgroup Risperidone Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 For any reason
Lim 2010 1/62 2/62 80.0 % 0.50 [ 0.05, 5.37 ]
Walther 2014 4/14 0/14 20.0 % 9.00 [ 0.53, 152.93 ]
Subtotal (95% CI) 76 76 100.0 % 2.20 [ 0.51, 9.48 ]
Total events: 5 (Risperidone), 2 (Haloperidol)
Heterogeneity: Chi2 = 2.45, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 1.06 (P = 0.29)
2 Due to adverse effects
Lim 2010 1/62 2/62 100.0 % 0.50 [ 0.05, 5.37 ]
Subtotal (95% CI) 62 62 100.0 % 0.50 [ 0.05, 5.37 ]
Total events: 1 (Risperidone), 2 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
3 Lack of efficacy
Walther 2014 4/14 0/14 100.0 % 9.00 [ 0.53, 152.93 ]
Subtotal (95% CI) 14 14 100.0 % 9.00 [ 0.53, 152.93 ]
Total events: 4 (Risperidone), 0 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 2.41, df = 2 (P = 0.30), I2 =17%
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Analysis 2.1. Comparison 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE, Outcome 1
Specific behaviour: 1. Agitation - Average scores - i. Up to 2 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE
Outcome: 1 Specific behaviour: 1. Agitation - Average scores - i. Up to 2 hours
Study or subgroup Risperidone Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score (PANSS-PAS, high = worse)
Walther 2014 14 11.6 (6.9) 15 9.1 (6.7) 100.0 % 2.50 [ -2.46, 7.46 ]
Subtotal (95% CI) 14 15 100.0 % 2.50 [ -2.46, 7.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE, Outcome 2
Specific behaviour: 1. Agitation - Average scores - ii. Up to 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE
Outcome: 2 Specific behaviour: 1. Agitation - Average scores - ii. Up to 24 hours
Study or subgroup Risperidone Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score (PANSS-PAS, high = worse)
Walther 2014 (1) 14 14.4 (5.4628) 15 13.5 (6.3517) 100.0 % 0.90 [ -3.40, 5.20 ]
Subtotal (95% CI) 14 15 100.0 % 0.90 [ -3.40, 5.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
risperidone olanzapine
(1) Data were extracted from figure 1 (p.126); see methods for further details.
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Analysis 2.3. Comparison 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE, Outcome 3
Specific behaviour: 1. Agitation - Average scores - iii. over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE
Outcome: 3 Specific behaviour: 1. Agitation - Average scores - iii. over 24 hours
Study or subgroup Risperidone Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 48 hours (PANSS-PAS, high = worse)
Walther 2014 (1) 14 11.9 (4.6397) 15 13.1 (6.158) 100.0 % -1.20 [ -5.15, 2.75 ]
Subtotal (95% CI) 14 15 100.0 % -1.20 [ -5.15, 2.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
2 Endpoint score at 72 hours (PANSS-PAS, high=worse)
Walther 2014 (2) 14 11.2 (5.1635) 15 11.5 (6.2742) 100.0 % -0.30 [ -4.47, 3.87 ]
Subtotal (95% CI) 14 15 100.0 % -0.30 [ -4.47, 3.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
3 Endpoint score at 96 hours (PANSS-PAS, high = worse)
Walther 2014 (3) 14 12.4 (4.7519) 15 10.3 (4.88) 100.0 % 2.10 [ -1.41, 5.61 ]
Subtotal (95% CI) 14 15 100.0 % 2.10 [ -1.41, 5.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 1.64, df = 2 (P = 0.44), I2 =0.0%
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(1) Data were extracted from figure 1 (p.126); see methods for further details.
(2) Data were extracted from figure 1 (p.126); see methods for further details.
(3) Data were extracted from figure 1 (p.126); see methods for further details.
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Analysis 2.4. Comparison 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE, Outcome 4
Global outcome: 1a. General - Need for additional measures.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE
Outcome: 4 Global outcome: 1a. General - Need for additional measures
Study or subgroup Risperidone Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Need for seclusion room
Walther 2014 0/14 1/15 100.0 % 0.36 [ 0.02, 8.07 ]
Subtotal (95% CI) 14 15 100.0 % 0.36 [ 0.02, 8.07 ]
Total events: 0 (Risperidone), 1 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
2 Use of restraints
Walther 2014 4/14 3/15 100.0 % 1.43 [ 0.39, 5.28 ]
Subtotal (95% CI) 14 15 100.0 % 1.43 [ 0.39, 5.28 ]
Total events: 4 (Risperidone), 3 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42), I2 =0.0%
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Analysis 2.5. Comparison 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE, Outcome 5
Global outcome: 1b. General - Need for additional medication (skewed data).
Global outcome: 1b. General - Need for additional medication (skewed data)
Study Intervention Mean
(total mg of diazepam needed
during the entire study per pa-
tient)
SD N
Walther 2014 Risperidone 92.9 86.8 14
Walther 2014 Olanzapine 114.0 79.5 15
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Analysis 2.6. Comparison 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE, Outcome 6
Adverse effects: 1a. Specific - Movement disorder - i. Meed for biperiden.
Adverse effects: 1a. Specific - Movement disorder - i. Meed for biperiden
Study Intervention Mean
(total mg of biperiden needed
during the entire study per pa-
tient)
SD N
Walther 2014 Risperidone 4.1 7.3 14
Walther 2014 Olanzapine 0.7 2.6 15
Analysis 2.7. Comparison 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE, Outcome 7
Adverse effects: 1b. Specific - Movement disorder - ii. Average scores (skewed data).
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE
Outcome: 7 Adverse effects: 1b. Specific - Movement disorder - ii. Average scores (skewed data)
Study or subgroup Risperidone Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score (BARS, high = worse)
Walther 2014 14 0.3 (1.1) 15 0.1 (0.5) 100.0 % 0.20 [ -0.43, 0.83 ]
Subtotal (95% CI) 14 15 100.0 % 0.20 [ -0.43, 0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
2 Endpoint score (SAS, high = worse)
Walther 2014 14 3 (3.7) 15 1.2 (2.9) 100.0 % 1.80 [ -0.63, 4.23 ]
Subtotal (95% CI) 14 15 100.0 % 1.80 [ -0.63, 4.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 1.56, df = 1 (P = 0.21), I2 =36%
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Analysis 2.8. Comparison 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE, Outcome 8
Leaving the study early.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 2 RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE
Outcome: 8 Leaving the study early
Study or subgroup Risperidone Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lack of efficacy
Walther 2014 4/14 2/15 100.0 % 2.14 [ 0.46, 9.93 ]
Subtotal (95% CI) 14 15 100.0 % 2.14 [ 0.46, 9.93 ]
Total events: 4 (Risperidone), 2 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE, Outcome 1
Specific behaviour: 1. Aggression - Average scores - i. Over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome: 1 Specific behaviour: 1. Aggression - Average scores - i. Over 24 hours
Study or subgroup Risperidone Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 2 weeks (MOAS, high = worse)
Dai 2012 20 10.9 (2.81) 20 9.1 (2.33) 100.0 % 1.80 [ 0.20, 3.40 ]
Subtotal (95% CI) 20 20 100.0 % 1.80 [ 0.20, 3.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
2 Endpoint score at 4 weeks (MOAS, high = worse)
Dai 2012 20 8.45 (2.31) 20 7.55 (1.99) 100.0 % 0.90 [ -0.44, 2.24 ]
Subtotal (95% CI) 20 20 100.0 % 0.90 [ -0.44, 2.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
3 Endpoint score at 6 weeks (MOAS, high = worse)
Dai 2012 20 6.55 (1.57) 20 5.85 (1.63) 100.0 % 0.70 [ -0.29, 1.69 ]
Subtotal (95% CI) 20 20 100.0 % 0.70 [ -0.29, 1.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
4 Endpoint score at 8 weeks (MOAS, high = worse)
Dai 2012 20 4.1 (1.21) 20 3.55 (1.79) 100.0 % 0.55 [ -0.40, 1.50 ]
Subtotal (95% CI) 20 20 100.0 % 0.55 [ -0.40, 1.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Chi2 = 1.82, df = 3 (P = 0.61), I2 =0.0%
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Analysis 3.2. Comparison 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE, Outcome 2
Mental state: 1a. No change in general mental state.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome: 2 Mental state: 1a. No change in general mental state
Study or subgroup Risperidone Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No response at 8 weeks (≤ 25% reduction at PANSS score)
Dai 2012 2/20 2/20 100.0 % 1.00 [ 0.16, 6.42 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.16, 6.42 ]
Total events: 2 (Risperidone), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours risperidone Favours quetiapine
91Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation) (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.3. Comparison 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE, Outcome 3
Mental state: 1b. Change in general mental state.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome: 3 Mental state: 1b. Change in general mental state
Study or subgroup Risperidone Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Clinical response at 8 weeks (25 - 50% reduction at PANSS score)
Dai 2012 (1) 4/20 3/20 100.0 % 1.33 [ 0.34, 5.21 ]
Subtotal (95% CI) 20 20 100.0 % 1.33 [ 0.34, 5.21 ]
Total events: 4 (Risperidone), 3 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
2 Clinical response at 8 weeks (50 - 75% reduction at PANSS score)
Dai 2012 (2) 7/20 8/20 100.0 % 0.88 [ 0.39, 1.95 ]
Subtotal (95% CI) 20 20 100.0 % 0.88 [ 0.39, 1.95 ]
Total events: 7 (Risperidone), 8 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
3 Clinical response at 8 weeks (≥ 75% reduction at PANSS score)
Dai 2012 (3) 7/20 7/20 100.0 % 1.00 [ 0.43, 2.33 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.43, 2.33 ]
Total events: 7 (Risperidone), 7 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.27, df = 2 (P = 0.87), I2 =0.0%
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Favours quetiapine Favours risperidone
(1) Axis labels have been switched in order to improve readability.
(2) Axis labels have been switched in order to improve readability.
(3) Axis labels have been switched in order to improve readability.
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Analysis 3.4. Comparison 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE, Outcome 4
Mental state: 1c. Average scores - i. Over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome: 4 Mental state: 1c. Average scores - i. Over 24 hours
Study or subgroup Risperidone Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 2 weeks (PANSS, high = worse)
Dai 2012 20 87.3 (6.7) 20 84.9 (7.93) 100.0 % 2.40 [ -2.15, 6.95 ]
Subtotal (95% CI) 20 20 100.0 % 2.40 [ -2.15, 6.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
2 Endpoint score at 4 weeks (PANSS, high = worse)
Dai 2012 20 76.9 (7.05) 20 74.95 (9.04) 100.0 % 1.95 [ -3.07, 6.97 ]
Subtotal (95% CI) 20 20 100.0 % 1.95 [ -3.07, 6.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
3 Endpoint score at 6 weeks (PANSS, high = worse)
Dai 2012 20 67.5 (7.36) 20 61.75 (11.11) 100.0 % 5.75 [ -0.09, 11.59 ]
Subtotal (95% CI) 20 20 100.0 % 5.75 [ -0.09, 11.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
4 Endpoint score at 8 weeks (PANSS, high = worse)
Dai 2012 20 52.25 (7.28) 20 48.7 (6.38) 100.0 % 3.55 [ -0.69, 7.79 ]
Subtotal (95% CI) 20 20 100.0 % 3.55 [ -0.69, 7.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
5 Endpoint score at 2 weeks (PANSS positive symptoms sub-scale, high = worse)
Dai 2012 20 27.2 (2.14) 20 26.05 (2.72) 100.0 % 1.15 [ -0.37, 2.67 ]
Subtotal (95% CI) 20 20 100.0 % 1.15 [ -0.37, 2.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
6 Endpoint score at 4 weeks (PANSS positive symptoms sub-scale, high = worse)
Dai 2012 20 23.8 (2.53) 20 22.1 (2.9) 100.0 % 1.70 [ 0.01, 3.39 ]
Subtotal (95% CI) 20 20 100.0 % 1.70 [ 0.01, 3.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
7 Endpoint score at 6 weeks (PANSS positive symptoms sub-scale, high = worse)
Dai 2012 20 19.75 (3.16) 20 17.7 (3.9) 100.0 % 2.05 [ -0.15, 4.25 ]
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(. . . Continued)
Study or subgroup Risperidone Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 20 20 100.0 % 2.05 [ -0.15, 4.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
8 Endpoint score at 8 weeks (PANSS positive symptoms sub-scale, high = worse)
Dai 2012 20 17.55 (3.9) 20 15.3 (4.51) 100.0 % 2.25 [ -0.36, 4.86 ]
Subtotal (95% CI) 20 20 100.0 % 2.25 [ -0.36, 4.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
9 Endpoint score at 2 weeks (PANSS negative symptoms sub-scale, high = worse)
Dai 2012 20 21.4 (1.9) 20 20.1 (2.49) 100.0 % 1.30 [ -0.07, 2.67 ]
Subtotal (95% CI) 20 20 100.0 % 1.30 [ -0.07, 2.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
10 Endpoint score at 4 weeks (PANSS negative symptoms sub-scale, high = worse)
Dai 2012 20 19.01 (1.89) 20 17.7 (2.43) 100.0 % 1.31 [ -0.04, 2.66 ]
Subtotal (95% CI) 20 20 100.0 % 1.31 [ -0.04, 2.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
11 Endpoint score at 6 weeks (PANSS negative symptoms sub-scale, high = worse)
Dai 2012 20 16.55 (2.86) 20 14.85 (3.01) 100.0 % 1.70 [ -0.12, 3.52 ]
Subtotal (95% CI) 20 20 100.0 % 1.70 [ -0.12, 3.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
12 Endpoint score at 8 weeks (PANSS negative symptoms sub-scale, high = worse)
Dai 2012 20 15.1 (3.21) 20 13.05 (3.59) 100.0 % 2.05 [ -0.06, 4.16 ]
Subtotal (95% CI) 20 20 100.0 % 2.05 [ -0.06, 4.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
13 Endpoint score at 2 weeks (PANSS general psychopathology sub-scale, high = worse)
Dai 2012 20 37.5 (4.25) 20 39.25 (5.31) 100.0 % -1.75 [ -4.73, 1.23 ]
Subtotal (95% CI) 20 20 100.0 % -1.75 [ -4.73, 1.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
14 Endpoint score at 4 weeks (PANSS general psychopathology sub-scale, high = worse)
Dai 2012 20 33.45 (4.4) 20 34.05 (5.62) 100.0 % -0.60 [ -3.73, 2.53 ]
Subtotal (95% CI) 20 20 100.0 % -0.60 [ -3.73, 2.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
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(. . . Continued)
Study or subgroup Risperidone Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
15 Endpoint score at 6 weeks (PANSS general psychopathology sub-scale, high = worse)
Dai 2012 20 30.04 (4.12) 20 29.03 (5.16) 100.0 % 1.01 [ -1.88, 3.90 ]
Subtotal (95% CI) 20 20 100.0 % 1.01 [ -1.88, 3.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
16 Endpoint score at 8 weeks (PANSS general psychopathology sub-scale, high = worse)
Dai 2012 20 27.5 (4.15) 20 26.13 (4.46) 100.0 % 1.37 [ -1.30, 4.04 ]
Subtotal (95% CI) 20 20 100.0 % 1.37 [ -1.30, 4.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 10.74, df = 15 (P = 0.77), I2 =0.0%
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Analysis 3.5. Comparison 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE, Outcome 5
Adverse effects: 1a. Specific - Anticholinergic.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome: 5 Adverse effects: 1a. Specific - Anticholinergic
Study or subgroup Risperidone Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Blurred vision over 24 hours
Dai 2012 2/20 4/20 100.0 % 0.50 [ 0.10, 2.43 ]
Subtotal (95% CI) 20 20 100.0 % 0.50 [ 0.10, 2.43 ]
Total events: 2 (Risperidone), 4 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE, Outcome 6
Adverse effects: 1b. Specific - Arousal.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome: 6 Adverse effects: 1b. Specific - Arousal
Study or subgroup Risperidone Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Somnolence over 24 hours
Dai 2012 3/20 5/20 100.0 % 0.60 [ 0.17, 2.18 ]
Subtotal (95% CI) 20 20 100.0 % 0.60 [ 0.17, 2.18 ]
Total events: 3 (Risperidone), 5 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE, Outcome 7
Adverse effects: 1c. Specific - Cardiovascular.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome: 7 Adverse effects: 1c. Specific - Cardiovascular
Study or subgroup Risperidone Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tachycardia over 24 hours
Dai 2012 4/20 1/20 100.0 % 4.00 [ 0.49, 32.72 ]
Subtotal (95% CI) 20 20 100.0 % 4.00 [ 0.49, 32.72 ]
Total events: 4 (Risperidone), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE, Outcome 8
Adverse effects: 1d. Specific - Gastrointestinal.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome: 8 Adverse effects: 1d. Specific - Gastrointestinal
Study or subgroup Risperidone Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea and vomiting over 24 hours
Dai 2012 1/20 1/20 100.0 % 1.00 [ 0.07, 14.90 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.07, 14.90 ]
Total events: 1 (Risperidone), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE, Outcome 9
Adverse effects: 1e. Specific - Movement disorders.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome: 9 Adverse effects: 1e. Specific - Movement disorders
Study or subgroup Risperidone Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Akathisia over 24 hours
Dai 2012 5/20 3/20 100.0 % 1.67 [ 0.46, 6.06 ]
Subtotal (95% CI) 20 20 100.0 % 1.67 [ 0.46, 6.06 ]
Total events: 5 (Risperidone), 3 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
2 Hypermyotonia over 24 hours
Dai 2012 7/20 1/20 100.0 % 7.00 [ 0.95, 51.80 ]
Subtotal (95% CI) 20 20 100.0 % 7.00 [ 0.95, 51.80 ]
Total events: 7 (Risperidone), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.057)
Test for subgroup differences: Chi2 = 1.40, df = 1 (P = 0.24), I2 =28%
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Analysis 3.10. Comparison 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE, Outcome 10
Adverse effects: 1f. Specific - Miscellaneous.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 3 RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE
Outcome: 10 Adverse effects: 1f. Specific - Miscellaneous
Study or subgroup Risperidone Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Headache over 24 hours
Dai 2012 2/20 2/20 100.0 % 1.00 [ 0.16, 6.42 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.16, 6.42 ]
Total events: 2 (Risperidone), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Liver Function Tests (LFTs) elevation over 24 hours
Dai 2012 1/20 1/20 100.0 % 1.00 [ 0.07, 14.90 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.07, 14.90 ]
Total events: 1 (Risperidone), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Weight gain over 24 hours
Dai 2012 4/20 1/20 100.0 % 4.00 [ 0.49, 32.72 ]
Subtotal (95% CI) 20 20 100.0 % 4.00 [ 0.49, 32.72 ]
Total events: 4 (Risperidone), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
4 Agitation over 24 hours
Dai 2012 7/20 2/20 100.0 % 3.50 [ 0.83, 14.83 ]
Subtotal (95% CI) 20 20 100.0 % 3.50 [ 0.83, 14.83 ]
Total events: 7 (Risperidone), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.089)
Test for subgroup differences: Chi2 = 1.72, df = 3 (P = 0.63), I2 =0.0%
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Analysis 4.1. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 1 Specific behaviour: 1. Agitation - Average scores - i. over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 1 Specific behaviour: 1. Agitation - Average scores - i. over 24 hours
Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 1 week (PANSS-EC, high = worse)
Wang 2012 33 18.9 (4.5) 35 16.2 (5.1) 100.0 % 2.70 [ 0.42, 4.98 ]
Subtotal (95% CI) 33 35 100.0 % 2.70 [ 0.42, 4.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
2 Endpoint score at 2 weeks (PANSS-EC, high = worse)
Wang 2012 33 14.1 (5.3) 35 11.7 (3.1) 100.0 % 2.40 [ 0.32, 4.48 ]
Subtotal (95% CI) 33 35 100.0 % 2.40 [ 0.32, 4.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
3 Endpoint score at 4 weeks (PANSS-EC, high = worse)
Wang 2012 33 10.8 (4.7) 35 8.4 (2.9) 100.0 % 2.40 [ 0.53, 4.27 ]
Subtotal (95% CI) 33 35 100.0 % 2.40 [ 0.53, 4.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Chi2 = 0.05, df = 2 (P = 0.98), I2 =0.0%
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Analysis 4.2. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 2 Global Outcome: 1. Average scores - i. Over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 2 Global Outcome: 1. Average scores - i. Over 24 hours
Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 1 week (CGI-I, high = worse)
Wang 2012 33 2.6 (0.7) 35 2.8 (1) 100.0 % -0.20 [ -0.61, 0.21 ]
Subtotal (95% CI) 33 35 100.0 % -0.20 [ -0.61, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
2 Endpoint score at 2 weeks (CGI-I, high = worse)
Wang 2012 33 2.4 (1) 35 1.9 (0.8) 100.0 % 0.50 [ 0.07, 0.93 ]
Subtotal (95% CI) 33 35 100.0 % 0.50 [ 0.07, 0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
3 Endpoint score at 4 weeks (CGI-I, high = worse)
Wang 2012 33 2.2 (0.8) 35 1.7 (0.7) 100.0 % 0.50 [ 0.14, 0.86 ]
Subtotal (95% CI) 33 35 100.0 % 0.50 [ 0.14, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.0062)
4 Endpoint score at 1 week (CGI-S, high = worse)
Wang 2012 33 4.2 (0.9) 35 4 (1) 100.0 % 0.20 [ -0.25, 0.65 ]
Subtotal (95% CI) 33 35 100.0 % 0.20 [ -0.25, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
5 Endpoint score at 2 weeks (CGI-S, high = worse)
Wang 2012 33 3.4 (1) 35 2.9 (0.8) 100.0 % 0.50 [ 0.07, 0.93 ]
Subtotal (95% CI) 33 35 100.0 % 0.50 [ 0.07, 0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
6 Endpoint score at 4 weeks (CGI-S, high = worse)
Wang 2012 33 3.2 (0.8) 35 2.7 (0.7) 100.0 % 0.50 [ 0.14, 0.86 ]
Subtotal (95% CI) 33 35 100.0 % 0.50 [ 0.14, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.0062)
Test for subgroup differences: Chi2 = 9.66, df = 5 (P = 0.09), I2 =48%
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Analysis 4.3. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 3 Mental state: 1a. No change in general mental state.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 3 Mental state: 1a. No change in general mental state
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No response at 4 weeks ( < 50% reduction BPRS score)
Wang 2012 10/33 1/35 100.0 % 10.61 [ 1.44, 78.36 ]
Subtotal (95% CI) 33 35 100.0 % 10.61 [ 1.44, 78.36 ]
Total events: 10 (Risperidone), 1 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 4 Mental state: 1b. Change in general mental state.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 4 Mental state: 1b. Change in general mental state
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Clinical response at 4 weeks (50 - 75% reduction at BPRS score)
Wang 2012 (1) 19/33 29/35 100.0 % 0.69 [ 0.50, 0.97 ]
Subtotal (95% CI) 33 35 100.0 % 0.69 [ 0.50, 0.97 ]
Total events: 19 (Risperidone), 29 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
2 Clinical response at 4 weeks (≥ 75% reduction at BPRS score)
Wang 2012 (2) 4/33 5/35 100.0 % 0.85 [ 0.25, 2.89 ]
Subtotal (95% CI) 33 35 100.0 % 0.85 [ 0.25, 2.89 ]
Total events: 4 (Risperidone), 5 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.76), I2 =0.0%
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Analysis 4.5. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 5 Mental state: 1c. Average scores - i. Over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 5 Mental state: 1c. Average scores - i. Over 24 hours
Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 1 week (BPRS, high = worse)
Wang 2012 33 39.7 (8.4) 35 34.5 (9.1) 100.0 % 5.20 [ 1.04, 9.36 ]
Subtotal (95% CI) 33 35 100.0 % 5.20 [ 1.04, 9.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
2 Endpoint score at 2 weeks (BPRS, high = worse)
Wang 2012 33 28.1 (8.6) 35 21.9 (6.9) 100.0 % 6.20 [ 2.48, 9.92 ]
Subtotal (95% CI) 33 35 100.0 % 6.20 [ 2.48, 9.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.27 (P = 0.0011)
3 Endpoint score at 4 weeks (BPRS, high = worse)
Wang 2012 33 19.1 (8.3) 35 13.7 (6.5) 100.0 % 5.40 [ 1.84, 8.96 ]
Subtotal (95% CI) 33 35 100.0 % 5.40 [ 1.84, 8.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0029)
Test for subgroup differences: Chi2 = 0.15, df = 2 (P = 0.93), I2 =0.0%
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Analysis 4.6. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 6 Adverse effects: 1. General - Total number of AEs.
Adverse effects: 1. General - Total number of AEs
Study AEs (n), risperidone patients (n), risperidone AEs (n), combination patients (n), combination
Wang 2012 40 33 47 35
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Analysis 4.7. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 7 Adverse effects: 2a. Specific - Anticholinergic.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 7 Adverse effects: 2a. Specific - Anticholinergic
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Dry mouth over 24 hours
Wang 2012 10/33 5/35 100.0 % 2.12 [ 0.81, 5.55 ]
Subtotal (95% CI) 33 35 100.0 % 2.12 [ 0.81, 5.55 ]
Total events: 10 (Risperidone), 5 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
2 Constipation over 24 hours
Wang 2012 11/33 9/35 100.0 % 1.30 [ 0.62, 2.72 ]
Subtotal (95% CI) 33 35 100.0 % 1.30 [ 0.62, 2.72 ]
Total events: 11 (Risperidone), 9 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.63, df = 1 (P = 0.43), I2 =0.0%
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Analysis 4.8. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 8 Adverse effects: 2b. Specific - Arousal.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 8 Adverse effects: 2b. Specific - Arousal
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Excessive sedation over 24 hours
Wang 2012 0/33 9/35 100.0 % 0.06 [ 0.00, 0.92 ]
Subtotal (95% CI) 33 35 100.0 % 0.06 [ 0.00, 0.92 ]
Total events: 0 (Risperidone), 9 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.044)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 9 Adverse effects: 2c. Specific - Cardiovascular.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 9 Adverse effects: 2c. Specific - Cardiovascular
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tachycardia over 24 hours
Wang 2012 7/33 6/35 100.0 % 1.24 [ 0.46, 3.30 ]
Subtotal (95% CI) 33 35 100.0 % 1.24 [ 0.46, 3.30 ]
Total events: 7 (Risperidone), 6 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 4.10. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 10 Adverse effects: 2d. Specific - Gastrointestinal.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 10 Adverse effects: 2d. Specific - Gastrointestinal
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea over 24 hours
Wang 2012 2/33 1/35 100.0 % 2.12 [ 0.20, 22.31 ]
Subtotal (95% CI) 33 35 100.0 % 2.12 [ 0.20, 22.31 ]
Total events: 2 (Risperidone), 1 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 4.11. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 11 Adverse effects: 2e. Specific - Movement disorders.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 11 Adverse effects: 2e. Specific - Movement disorders
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 EPS over 24 hours
Wang 2012 6/33 4/35 100.0 % 1.59 [ 0.49, 5.14 ]
Subtotal (95% CI) 33 35 100.0 % 1.59 [ 0.49, 5.14 ]
Total events: 6 (Risperidone), 4 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
2 Tremor over 24 hours
Wang 2012 4/33 5/35 100.0 % 0.85 [ 0.25, 2.89 ]
Subtotal (95% CI) 33 35 100.0 % 0.85 [ 0.25, 2.89 ]
Total events: 4 (Risperidone), 5 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Chi2 = 0.53, df = 1 (P = 0.47), I2 =0.0%
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Analysis 4.12. Comparison 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE,
Outcome 12 Adverse effects: 2f. Specific - Miscellaneous.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 4 RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE
Outcome: 12 Adverse effects: 2f. Specific - Miscellaneous
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Headache over 24 hours
Wang 2012 0/33 7/35 100.0 % 0.07 [ 0.00, 1.19 ]
Subtotal (95% CI) 33 35 100.0 % 0.07 [ 0.00, 1.19 ]
Total events: 0 (Risperidone), 7 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
2 Skin rash over 24 hours
Wang 2012 0/33 1/35 100.0 % 0.35 [ 0.01, 8.37 ]
Subtotal (95% CI) 33 35 100.0 % 0.35 [ 0.01, 8.37 ]
Total events: 0 (Risperidone), 1 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.55, df = 1 (P = 0.46), I2 =0.0%
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Analysis 5.1. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 1 Specific behaviour: 1. Agitation - average scores - i. over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 1 Specific behaviour: 1. Agitation - average scores - i. over 24 hours
Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 3 days (PANSS-EC, high = worse)
Zhou 2013 27 20.24 (5.64) 27 20.35 (5.11) 100.0 % -0.11 [ -2.98, 2.76 ]
Subtotal (95% CI) 27 27 100.0 % -0.11 [ -2.98, 2.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 Endpoint score at 5 days (PANSS-EC, high = worse)
Zhou 2013 27 18.33 (5.32) 27 12.86 (5.28) 100.0 % 5.47 [ 2.64, 8.30 ]
Subtotal (95% CI) 27 27 100.0 % 5.47 [ 2.64, 8.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.79 (P = 0.00015)
3 Endpoint score at 7 days (PANSS-EC, high = worse)
Zhou 2013 27 16.42 (5.36) 27 11.31 (4.32) 100.0 % 5.11 [ 2.51, 7.71 ]
Subtotal (95% CI) 27 27 100.0 % 5.11 [ 2.51, 7.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.86 (P = 0.00011)
4 Endpoint score at 2 weeks (PANSS-EC, high = worse)
Jin 2013 31 11.21 (2.01) 32 11.12 (2.01) 100.0 % 0.09 [ -0.90, 1.08 ]
Subtotal (95% CI) 31 32 100.0 % 0.09 [ -0.90, 1.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
5 Endpoint score at 4 weeks (PANSS-EC, high = worse)
Jin 2013 31 9.15 (1.98) 32 8.98 (2.16) 100.0 % 0.17 [ -0.85, 1.19 ]
Subtotal (95% CI) 31 32 100.0 % 0.17 [ -0.85, 1.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 24.80, df = 4 (P = 0.00), I2 =84%
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Analysis 5.2. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 2 Specific behaviour: 1. Aggression - Average scores - i. over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 2 Specific behaviour: 1. Aggression - Average scores - i. over 24 hours
Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 3 days (MOAS, high = worse)
Zhou 2013 27 7.42 (2.33) 27 6.35 (2.42) 100.0 % 1.07 [ -0.20, 2.34 ]
Subtotal (95% CI) 27 27 100.0 % 1.07 [ -0.20, 2.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.098)
2 Endpoint score at 5 days (MOAS, high = worse)
Zhou 2013 27 6.24 (2.18) 27 5.86 (2.37) 100.0 % 0.38 [ -0.83, 1.59 ]
Subtotal (95% CI) 27 27 100.0 % 0.38 [ -0.83, 1.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 Endpoint score at 7 days (MOAS, high = worse)
Zhou 2013 27 6.56 (2.47) 27 3.24 (2.22) 100.0 % 3.32 [ 2.07, 4.57 ]
Subtotal (95% CI) 27 27 100.0 % 3.32 [ 2.07, 4.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.19 (P < 0.00001)
4 Endpoint score at 2 weeks (MOAS, high = worse)
Li 2013 30 8 (2.4) 30 7.4 (2.6) 50.4 % 0.60 [ -0.67, 1.87 ]
Wang 2013 34 6.94 (2.73) 34 5.28 (2.64) 49.6 % 1.66 [ 0.38, 2.94 ]
Subtotal (95% CI) 64 64 100.0 % 1.13 [ 0.23, 2.02 ]
Heterogeneity: Chi2 = 1.34, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 2.45 (P = 0.014)
5 Endpoint score at 4 weeks (MOAS, high = worse)
Li 2013 30 5.6 (2.4) 30 3.8 (2.1) 51.5 % 1.80 [ 0.66, 2.94 ]
Wang 2013 34 5.29 (2.59) 34 3.96 (2.35) 48.5 % 1.33 [ 0.15, 2.51 ]
Subtotal (95% CI) 64 64 100.0 % 1.57 [ 0.75, 2.39 ]
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.76 (P = 0.00017)
6 Endpoint score at 6 weeks (MOAS, high = worse)
Wang 2013 34 3.65 (1.57) 34 2.18 (1.08) 100.0 % 1.47 [ 0.83, 2.11 ]
Subtotal (95% CI) 34 34 100.0 % 1.47 [ 0.83, 2.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.50 (P < 0.00001)
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(. . . Continued)
Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
7 Endpoint score at 8 weeks (MOAS, high = worse)
Li 2013 30 4.1 (2.3) 30 3.1 (2.1) 100.0 % 1.00 [ -0.11, 2.11 ]
Subtotal (95% CI) 30 30 100.0 % 1.00 [ -0.11, 2.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Chi2 = 13.06, df = 6 (P = 0.04), I2 =54%
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Analysis 5.3. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 3 Mental state: 1. No change in general mental state.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 3 Mental state: 1. No change in general mental state
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No clinical response at 8 weeks ( < 30% reduction at PANSS score)
Yao 2010 5/31 3/31 100.0 % 1.67 [ 0.44, 6.38 ]
Subtotal (95% CI) 31 31 100.0 % 1.67 [ 0.44, 6.38 ]
Total events: 5 (Risperidone), 3 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 4 Mental state: 2. Average scores - i. over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 4 Mental state: 2. Average scores - i. over 24 hours
Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 2 weeks (PANSS, high = worse)
Jin 2013 31 80.49 (4.69) 32 75.63 (6.01) 36.2 % 4.86 [ 2.20, 7.52 ]
Li 2013 30 70.1 (5) 30 69.3 (5.1) 39.2 % 0.80 [ -1.76, 3.36 ]
Wang 2013 34 75.7 (8.7) 34 65.8 (9.7) 13.3 % 9.90 [ 5.52, 14.28 ]
Yao 2010 31 79.13 (9.45) 31 78.34 (9.67) 11.3 % 0.79 [ -3.97, 5.55 ]
Subtotal (95% CI) 126 127 100.0 % 3.48 [ 1.88, 5.08 ]
Heterogeneity: Chi2 = 14.74, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 4.27 (P = 0.000020)
2 Sub-group analysis: Endpoint score at 2 weeks (PANSS, high = worse)
Jin 2013 31 80.49 (4.69) 32 75.63 (6.01) 41.8 % 4.86 [ 2.20, 7.52 ]
Li 2013 30 70.1 (5) 30 69.3 (5.1) 45.2 % 0.80 [ -1.76, 3.36 ]
Yao 2010 31 79.13 (9.45) 31 78.34 (9.67) 13.0 % 0.79 [ -3.97, 5.55 ]
Subtotal (95% CI) 92 93 100.0 % 2.50 [ 0.78, 4.21 ]
Heterogeneity: Chi2 = 5.23, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 2.85 (P = 0.0044)
3 Endpoint score at 4 weeks (PANSS, high = worse)
Jin 2013 31 70.04 (4.23) 32 63.51 (8.62) 24.0 % 6.53 [ 3.19, 9.87 ]
Li 2013 30 56.4 (4.9) 30 53.1 (4.4) 48.1 % 3.30 [ 0.94, 5.66 ]
Wang 2013 34 64.8 (8.6) 34 53.8 (9.6) 14.2 % 11.00 [ 6.67, 15.33 ]
Yao 2010 31 61.68 (9.07) 31 56.37 (8.62) 13.8 % 5.31 [ 0.91, 9.71 ]
Subtotal (95% CI) 126 127 100.0 % 5.45 [ 3.81, 7.08 ]
Heterogeneity: Chi2 = 9.91, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 6.53 (P < 0.00001)
4 Sub-group analysis: Endpoint score at 4 weeks (PANSS, high = worse)
Jin 2013 31 70.04 (4.23) 32 63.51 (8.62) 27.9 % 6.53 [ 3.19, 9.87 ]
Li 2013 30 56.4 (4.9) 30 53.1 (4.4) 56.0 % 3.30 [ 0.94, 5.66 ]
Yao 2010 31 61.68 (9.07) 31 56.37 (8.62) 16.0 % 5.31 [ 0.91, 9.71 ]
Subtotal (95% CI) 92 93 100.0 % 4.52 [ 2.76, 6.29 ]
Heterogeneity: Chi2 = 2.55, df = 2 (P = 0.28); I2 =21%
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Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 5.03 (P < 0.00001)
5 Endpoint score at 6 weeks (PANSS, high = worse)
Wang 2013 34 49.2 (7.9) 34 34.5 (7.6) 45.1 % 14.70 [ 11.02, 18.38 ]
Yao 2010 31 57.08 (6.87) 31 51.13 (6.54) 54.9 % 5.95 [ 2.61, 9.29 ]
Subtotal (95% CI) 65 65 100.0 % 9.90 [ 7.42, 12.37 ]
Heterogeneity: Chi2 = 11.89, df = 1 (P = 0.00056); I2 =92%
Test for overall effect: Z = 7.84 (P < 0.00001)
6 Endpoint score at 8 weeks (PANSS, high = worse)
Li 2013 30 49.4 (4.2) 30 44.6 (4.3) 63.3 % 4.80 [ 2.65, 6.95 ]
Yao 2010 31 53.21 (5.71) 31 45.61 (5.63) 36.7 % 7.60 [ 4.78, 10.42 ]
Subtotal (95% CI) 61 61 100.0 % 5.83 [ 4.12, 7.54 ]
Heterogeneity: Chi2 = 2.39, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 6.68 (P < 0.00001)
7 Endpoint score at 2 weeks (PANSS positive symptoms sub-scale, high = worse)
Jin 2013 31 27.89 (3.69) 32 25.69 (3.92) 22.2 % 2.20 [ 0.32, 4.08 ]
Li 2013 30 20.2 (2.3) 30 20.5 (1.9) 68.8 % -0.30 [ -1.37, 0.77 ]
Wang 2013 34 24.4 (6.2) 34 20.4 (6.2) 9.0 % 4.00 [ 1.05, 6.95 ]
Subtotal (95% CI) 95 96 100.0 % 0.64 [ -0.24, 1.53 ]
Heterogeneity: Chi2 = 10.62, df = 2 (P = 0.005); I2 =81%
Test for overall effect: Z = 1.42 (P = 0.15)
8 Endpoint score at 4 weeks (PANSS positive symptoms sub-scale, high = worse)
Jin 2013 31 24.8 (3.68) 32 19.79 (3.98) 22.1 % 5.01 [ 3.12, 6.90 ]
Li 2013 30 17.1 (2) 30 15.2 (2.2) 69.8 % 1.90 [ 0.84, 2.96 ]
Wang 2013 34 19.6 (6.7) 34 15.7 (6.4) 8.1 % 3.90 [ 0.79, 7.01 ]
Subtotal (95% CI) 95 96 100.0 % 2.75 [ 1.86, 3.64 ]
Heterogeneity: Chi2 = 8.46, df = 2 (P = 0.01); I2 =76%
Test for overall effect: Z = 6.06 (P < 0.00001)
9 Endpoint score at 6 weeks (PANSS positive symptoms sub-scale, high = worse)
Wang 2013 34 13.8 (6.5) 34 9.4 (6.1) 100.0 % 4.40 [ 1.40, 7.40 ]
Subtotal (95% CI) 34 34 100.0 % 4.40 [ 1.40, 7.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0040)
10 Endpoint score at 8 weeks (PANSS positive symptoms sub-scale, high = worse)
Li 2013 30 14.4 (2.2) 30 12.7 (1.7) 100.0 % 1.70 [ 0.71, 2.69 ]
Subtotal (95% CI) 30 30 100.0 % 1.70 [ 0.71, 2.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.00081)
11 Endpoint score at 2 weeks (PANSS negative symptoms sub-scale, high = worse)
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Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Li 2013 30 20.8 (1.8) 30 20.7 (1.7) 94.0 % 0.10 [ -0.79, 0.99 ]
Wang 2013 34 26.1 (7.8) 34 22.9 (6.9) 6.0 % 3.20 [ -0.30, 6.70 ]
Subtotal (95% CI) 64 64 100.0 % 0.29 [ -0.57, 1.15 ]
Heterogeneity: Chi2 = 2.83, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.65 (P = 0.51)
12 Endpoint score at 4 weeks (PANSS negative symptoms sub-scale, high = worse)
Li 2013 30 17.3 (2.9) 30 16.5 (3) 86.9 % 0.80 [ -0.69, 2.29 ]
Wang 2013 34 21.4 (8) 34 17.3 (8.2) 13.1 % 4.10 [ 0.25, 7.95 ]
Subtotal (95% CI) 64 64 100.0 % 1.23 [ -0.16, 2.62 ]
Heterogeneity: Chi2 = 2.45, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 1.73 (P = 0.083)
13 Endpoint score at 6 weeks (PANSS negative symptoms sub-scale, high = worse)
Wang 2013 34 15.4 (5.7) 34 11.6 (5.8) 100.0 % 3.80 [ 1.07, 6.53 ]
Subtotal (95% CI) 34 34 100.0 % 3.80 [ 1.07, 6.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0064)
14 Endpoint score at 8 weeks (PANSS negative symptoms sub-scale, high = worse)
Li 2013 30 15 (2.5) 30 13.7 (2.7) 100.0 % 1.30 [ -0.02, 2.62 ]
Subtotal (95% CI) 30 30 100.0 % 1.30 [ -0.02, 2.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.053)
15 Endpoint score at 2 weeks (PANSS general psychopathology sub-scale, high = worse)
Li 2013 30 30 (2) 30 29.5 (2.4) 80.3 % 0.50 [ -0.62, 1.62 ]
Wang 2013 34 25.2 (4.9) 34 22.5 (4.6) 19.7 % 2.70 [ 0.44, 4.96 ]
Subtotal (95% CI) 64 64 100.0 % 0.93 [ -0.07, 1.93 ]
Heterogeneity: Chi2 = 2.93, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 1.82 (P = 0.068)
16 Endpoint score at 4 weeks (PANSS general psychopathology sub-scale, high = worse)
Li 2013 30 22.4 (2.3) 30 21.6 (2.4) 84.7 % 0.80 [ -0.39, 1.99 ]
Wang 2013 34 23.8 (6.8) 34 20.8 (4.8) 15.3 % 3.00 [ 0.20, 5.80 ]
Subtotal (95% CI) 64 64 100.0 % 1.14 [ 0.04, 2.23 ]
Heterogeneity: Chi2 = 2.01, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 2.04 (P = 0.042)
17 Endpoint score at 6 weeks (PANSS general psychopathology sub-scale, high = worse)
Wang 2013 34 20 (4.6) 34 13.5 (5.6) 100.0 % 6.50 [ 4.06, 8.94 ]
Subtotal (95% CI) 34 34 100.0 % 6.50 [ 4.06, 8.94 ]
Heterogeneity: not applicable
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Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 5.23 (P < 0.00001)
18 Endpoint score at 8 weeks (PANSS general psychopathology sub-scale, high = worse)
Li 2013 30 20 (2.2) 30 18.4 (2.4) 100.0 % 1.60 [ 0.43, 2.77 ]
Subtotal (95% CI) 30 30 100.0 % 1.60 [ 0.43, 2.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0071)
Test for subgroup differences: Chi2 = 140.95, df = 17 (P = 0.00), I2 =88%
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Analysis 5.5. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 5 Adverse effects: 1a. General - Total number of AEs.
Adverse effects: 1a. General - Total number of AEs
Study AEs (n), risperidone patients (n), risperidone AEs (n), combination patients (n), combination
Wang 2012 16 27 20 27
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Analysis 5.6. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 6 Adverse effects: 1b. General - Serious.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 6 Adverse effects: 1b. General - Serious
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 myocardial ischaemia (at 8 weeks)
Yao 2010 2/31 1/31 100.0 % 2.00 [ 0.19, 20.93 ]
Subtotal (95% CI) 31 31 100.0 % 2.00 [ 0.19, 20.93 ]
Total events: 2 (Risperidone), 1 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 7 Adverse effects: 2a. Specific - Anticholinergic.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 7 Adverse effects: 2a. Specific - Anticholinergic
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Blurred vision over 24 hours
Wang 2013 4/34 3/34 42.9 % 1.33 [ 0.32, 5.51 ]
Zhou 2013 3/27 4/27 57.1 % 0.75 [ 0.19, 3.04 ]
Subtotal (95% CI) 61 61 100.0 % 1.00 [ 0.37, 2.68 ]
Total events: 7 (Risperidone), 7 (Combination)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 Dry mouth over 24 hours
Jin 2013 10/31 2/30 22.5 % 4.84 [ 1.15, 20.28 ]
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(. . . Continued)
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wang 2013 5/34 7/34 77.5 % 0.71 [ 0.25, 2.03 ]
Subtotal (95% CI) 65 64 100.0 % 1.64 [ 0.76, 3.54 ]
Total events: 15 (Risperidone), 9 (Combination)
Heterogeneity: Chi2 = 4.63, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 0.60, df = 1 (P = 0.44), I2 =0.0%
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Analysis 5.8. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 8 Adverse effects: 2b. Specific - Arousal.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 8 Adverse effects: 2b. Specific - Arousal
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Insomnia over 24 hours
Zhou 2013 2/27 1/27 100.0 % 2.00 [ 0.19, 20.77 ]
Subtotal (95% CI) 27 27 100.0 % 2.00 [ 0.19, 20.77 ]
Total events: 2 (Risperidone), 1 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 Somnolence over 24 hours
Jin 2013 9/31 8/30 53.7 % 1.09 [ 0.48, 2.45 ]
Li 2013 4/30 7/30 46.3 % 0.57 [ 0.19, 1.75 ]
Subtotal (95% CI) 61 60 100.0 % 0.85 [ 0.44, 1.63 ]
Total events: 13 (Risperidone), 15 (Combination)
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
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Analysis 5.9. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 9 Adverse effects: 2c. Specific - Cardiovascular.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 9 Adverse effects: 2c. Specific - Cardiovascular
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Decreased blood pressure over 24 hours
Wang 2013 3/34 4/34 100.0 % 0.75 [ 0.18, 3.10 ]
Subtotal (95% CI) 34 34 100.0 % 0.75 [ 0.18, 3.10 ]
Total events: 3 (Risperidone), 4 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
2 Tachycardia over 24 hours
Jin 2013 12/31 3/30 19.0 % 3.87 [ 1.21, 12.36 ]
Li 2013 2/30 3/30 18.7 % 0.67 [ 0.12, 3.71 ]
Wang 2013 6/34 5/34 31.2 % 1.20 [ 0.40, 3.56 ]
Yao 2010 4/31 5/31 31.2 % 0.80 [ 0.24, 2.70 ]
Subtotal (95% CI) 126 125 100.0 % 1.48 [ 0.83, 2.67 ]
Total events: 24 (Risperidone), 16 (Combination)
Heterogeneity: Chi2 = 4.59, df = 3 (P = 0.20); I2 =35%
Test for overall effect: Z = 1.32 (P = 0.19)
3 T-wave changes in ECG over 24 hours
Zhou 2013 2/27 1/27 100.0 % 2.00 [ 0.19, 20.77 ]
Subtotal (95% CI) 27 27 100.0 % 2.00 [ 0.19, 20.77 ]
Total events: 2 (Risperidone), 1 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 0.86, df = 2 (P = 0.65), I2 =0.0%
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Analysis 5.10. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 10 Adverse effects: 2d. Specific - Gastrointestinal.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 10 Adverse effects: 2d. Specific - Gastrointestinal
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Constipation over 24 hours
Jin 2013 13/31 8/30 33.7 % 1.57 [ 0.76, 3.24 ]
Li 2013 9/30 12/30 49.7 % 0.75 [ 0.37, 1.51 ]
Wang 2013 5/34 4/34 16.6 % 1.25 [ 0.37, 4.26 ]
Subtotal (95% CI) 95 94 100.0 % 1.11 [ 0.70, 1.76 ]
Total events: 27 (Risperidone), 24 (Combination)
Heterogeneity: Chi2 = 2.13, df = 2 (P = 0.34); I2 =6%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Nausea over 24 hours
Wang 2013 5/34 7/34 70.0 % 0.71 [ 0.25, 2.03 ]
Zhou 2013 2/27 3/27 30.0 % 0.67 [ 0.12, 3.68 ]
Subtotal (95% CI) 61 61 100.0 % 0.70 [ 0.29, 1.71 ]
Total events: 7 (Risperidone), 10 (Combination)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Chi2 = 0.81, df = 1 (P = 0.37), I2 =0.0%
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Analysis 5.11. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 11 Adverse effects: 2e. Specific - Movement disorders.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 11 Adverse effects: 2e. Specific - Movement disorders
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 EPS over 24 hours
Jin 2013 17/31 4/30 25.3 % 4.11 [ 1.56, 10.81 ]
Li 2013 5/30 12/30 74.7 % 0.42 [ 0.17, 1.04 ]
Subtotal (95% CI) 61 60 100.0 % 1.35 [ 0.76, 2.39 ]
Total events: 22 (Risperidone), 16 (Combination)
Heterogeneity: Chi2 = 11.48, df = 1 (P = 0.00070); I2 =91%
Test for overall effect: Z = 1.04 (P = 0.30)
2 Akathisia over 24 hours
Wang 2013 3/34 4/34 50.0 % 0.75 [ 0.18, 3.10 ]
Zhou 2013 3/27 4/27 50.0 % 0.75 [ 0.19, 3.04 ]
Subtotal (95% CI) 61 61 100.0 % 0.75 [ 0.28, 2.03 ]
Total events: 6 (Risperidone), 8 (Combination)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
3 Tremor over 24 hours
Wang 2013 6/34 5/34 100.0 % 1.20 [ 0.40, 3.56 ]
Subtotal (95% CI) 34 34 100.0 % 1.20 [ 0.40, 3.56 ]
Total events: 6 (Risperidone), 5 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 1.01, df = 2 (P = 0.60), I2 =0.0%
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Analysis 5.12. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 12 Adverse effects: 2f. Specific - Movement disorders - Average scores - i. Over 24 hours.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 12 Adverse effects: 2f. Specific - Movement disorders - Average scores - i. Over 24 hours
Study or subgroup Risperidone Combination
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endpoint score at 3 days (TESS, high = worse)
Zhou 2013 27 4.42 (2.56) 27 4.46 (2.34) 100.0 % -0.04 [ -1.35, 1.27 ]
Subtotal (95% CI) 27 27 100.0 % -0.04 [ -1.35, 1.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
2 Endpoint score at 5 days (TESS, high = worse)
Zhou 2013 27 4.25 (2.29) 27 4.36 (3.06) 100.0 % -0.11 [ -1.55, 1.33 ]
Subtotal (95% CI) 27 27 100.0 % -0.11 [ -1.55, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
3 Endpoint score at 7 days (TESS, high = worse)
Zhou 2013 27 5.32 (2.46) 27 5.83 (2.66) 100.0 % -0.51 [ -1.88, 0.86 ]
Subtotal (95% CI) 27 27 100.0 % -0.51 [ -1.88, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Chi2 = 0.27, df = 2 (P = 0.87), I2 =0.0%
-2 -1 0 1 2
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Analysis 5.13. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 13 Adverse effects: 2g. Specific - Miscellaneous.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 13 Adverse effects: 2g. Specific - Miscellaneous
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Headache over 24 hours
Jin 2013 6/31 3/30 15.2 % 1.94 [ 0.53, 7.04 ]
Li 2013 4/30 6/30 29.9 % 0.67 [ 0.21, 2.13 ]
Wang 2013 6/34 7/34 34.9 % 0.86 [ 0.32, 2.29 ]
Zhou 2013 3/27 4/27 20.0 % 0.75 [ 0.19, 3.04 ]
Subtotal (95% CI) 122 121 100.0 % 0.94 [ 0.53, 1.68 ]
Total events: 19 (Risperidone), 20 (Combination)
Heterogeneity: Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
2 Weight gain over 24 hours
Li 2013 6/30 4/30 100.0 % 1.50 [ 0.47, 4.78 ]
Subtotal (95% CI) 30 30 100.0 % 1.50 [ 0.47, 4.78 ]
Total events: 6 (Risperidone), 4 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
3 Oedema over 24 hours
Jin 2013 0/31 1/32 100.0 % 0.34 [ 0.01, 8.13 ]
Subtotal (95% CI) 31 32 100.0 % 0.34 [ 0.01, 8.13 ]
Total events: 0 (Risperidone), 1 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
4 Leukopenia over 24 hours
Jin 2013 0/31 1/32 100.0 % 0.34 [ 0.01, 8.13 ]
Subtotal (95% CI) 31 32 100.0 % 0.34 [ 0.01, 8.13 ]
Total events: 0 (Risperidone), 1 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
5 Liver Function Tests (LFTs) elevation over 24 hours
Yao 2010 2/31 2/31 40.0 % 1.00 [ 0.15, 6.66 ]
Zhou 2013 1/27 3/27 60.0 % 0.33 [ 0.04, 3.01 ]
Subtotal (95% CI) 58 58 100.0 % 0.60 [ 0.15, 2.40 ]
Total events: 3 (Risperidone), 5 (Combination)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 1.80, df = 4 (P = 0.77), I2 =0.0%
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Analysis 5.14. Comparison 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID,
Outcome 14 Leaving the study early.
Review: Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
Comparison: 5 RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID
Outcome: 14 Leaving the study early
Study or subgroup Risperidone Combination Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 For any reason
Jin 2013 0/31 2/32 100.0 % 0.21 [ 0.01, 4.13 ]
Subtotal (95% CI) 31 32 100.0 % 0.21 [ 0.01, 4.13 ]
Total events: 0 (Risperidone), 2 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
2 Due to adverse effects
Jin 2013 0/31 2/32 100.0 % 0.21 [ 0.01, 4.13 ]
Subtotal (95% CI) 31 32 100.0 % 0.21 [ 0.01, 4.13 ]
Total events: 0 (Risperidone), 2 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Linked reviews
Focus of review Reference
Completed and maintained reviews
Aripiprazole (intramuscular) for psychosis-induced aggression or
agitation (rapid tranquillisation)
Ostinelli 2018
Benzodiazepines for psychosis-induced aggression or agitation Zaman 2017
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Table 1. Linked reviews (Continued)
Chlorpromazine for psychosis-induced aggression or agitation Ahmed 2010
Containment strategies for people with serious mental illness Muralidharan 2006
De-escalation techniques for psychosis-induced aggression or ag-
itation
Du 2017
Droperidol for psychosis-induced aggression or agitation Khokhar 2016
Haloperidol for psychosis-induced aggression or agitation (rapid
tranquillisation)
Ostinelli 2017
Haloperidol plus promethazine for psychosis-induced aggression Huf 2016
Olanzapine IM or velotab for acutely disturbed/agitated people
with suspected serious mental illnesses
Belgamwar 2005
Zuclopenthixol acetate for acute schizophrenia and similar serious
mental illnesses
Jayakody 2012
Reviews in the process of being completed
Loxapine inhaler for psychosis-induced aggression Vangala 2012
Quetiapine for psychosis-induced aggression Wilkie 2012
Table 2. Suggested design for a trial
Methods Allocation: randomised, clearly described and concealed.
Blindness: double, described and tested.
Duration: 2 weeks.
Participants Diagnosis: thought to be psychosis.
N = 300*.
Age: any.
Sex: both.
History: acutely ill, aggressive and/or agitated.
Interventions 1. Risperidone: dose flexible within recommended limits. N = 150.
2. Comparison: dose flexible within recommended limits. N = 150
Outcomes All outcomes are grouped by time: by 30 minutes, up to two hours, up to four hours, up to 24 hours, and over 24
hours. First outcome of interest could be as early as 20 minutes
Tranquillisation or asleep - tranquil; asleep.
Repeated need for tranquillisation - needing additional injections
Specific behaviours - self-harm, including suicide, injury to others
Global outcomes - patient satisfaction; use of restraint or seclusion
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Table 2. Suggested design for a trial (Continued)
Service outcomes - length of hospitalisation; readmission rate
Mental state - effect of medication on mental state.
Adverse effects - medication significant side effects.
Leaving the study early - detailed reasons provided.
Quality of life outcomes.
Economic outcomes.
Notes * Enough power to be able to identify a difference of ~20% between groups for primary outcome with adequate
degree of certainty
H I S T O R Y
Protocol first published: Issue 11, 2011
Review first published: Issue 4, 2018
Date Event Description
12 April 2017 Amended Search re-run and 14 Studies were added to Studies awaiting classification section of the review
19 June 2015 Amended Search re-run and two studies (three references) were added to ’Studies awaiting assessment’ section
of the review
1 November 2013 Amended Search re-run inNovember 2013, and 56 studies were added to ’Studies awaiting assessment’ section
of the review
1 December 2011 Amended Original search in December 2011.
C O N T R I B U T I O N S O F A U T H O R S
Edoardo G Ostinelli - screened and retrieved papers (2017 search, checking again studies from previous searches) against eligibility
criteria, appraised quality of papers, extracted data from papers, entered data into RevMan and analysed data, interpreted data and took
the lead in writing the review.
Mohsin Hussein - screened and retrieved papers (2017 search, checking again studies from previous searches) against eligibility criteria,
appraised quality of papers, extracted data from papers, entered data into RevMan and analysed data, interpreted data and helped in
writing the review.
Uzair Ahmed - (2011 and 2013 searches) screened and retrieved papers against eligibility criteria, extracted data from papers, helped
writing the protocol and review.
Fair-ur Rehman - (2011 and 2013 searches) screened and retrieved papers against eligibility criteria, extracted data from papers, helped
writing the protocol and review.
Miramontes - extracted data from papers, helped writing the review (2015 search).
Clive E Adams - helped writing and provided advice for the protocol and all review versions.
126Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation) (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D E C L A R A T I O N S O F I N T E R E S T
Edoardo G Ostinelli: none known.
Mohsin Hussein: none known.
Uzair Ahmed: none known.
Faiz-ur Rehman: none known.
Krista Miramontes: none known.
Clive E Adams: none known.
S O U R C E S O F S U P P O R T
Internal sources
• Università degli Studi di Milano, Milan, Italy.
Employs lead author Edoardo G Ostinelli.
• Queens Medical Centre, The University of Nottingham, UK.
Employs review author Mohsin Hussein.
• Rotherham, Doncaster and South Humber NHS Foundation Trust, Doncaster, UK.
Employed review author Uzair Ahmed at the time of writing the review.
• Buxton Health Centre, Buxton, UK.
Employed review author Faiz-ur Rehman at time of writing review.
• Cochrane Schizophrenia Group, The University of Nottingham, UK.
Employs review author Clive E Adams.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As the latest searches were conducted some time after protocol publication, we used the latest Cochrane methods for each search and
updated the methods section with the Cochrane Schizophrenia Methods template.
In addition, in order to conform this systematic review to the family of ’rapid tranquillisation’ ones, the ’methods’ section was amended
as follows.
Title amendment
Title is now Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation), the previous title was Risperidone for
psychosis induced aggression or agitation (rapid tranquillisation)
Types of interventions
The ’risperidone in combination with other drugs’ potential comparisons were not taken in consideration, in order to have ’risperidone
alone’ as a common comparator.
Types of outcome measures - primary outcomes
The primary outcome ’not tranquil or asleep’ has been specified with a relevant time point indication: ’by up to 30 minutes’.
Types of outcome measures - secondary outcomes
A list of secondary outcomes within the ’tranquillisation or asleep’ subgroup was added.
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Data extraction and management - extraction
A reference for data extraction from figures was added.
Data extraction and management - ’Summary of findings’ table
The list of included outcomes was improved and listed within the ’type of outcome measures’ section.
Data synthesis
We preferred to use a fixed-effect model; please note that this change was done before data extraction and studies analyses.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Aggression [∗drug effects; psychology]; Antipsychotic Agents [adverse effects; ∗therapeutic use]; Carbamazepine
[analogs & derivatives; therapeutic use]; Psychomotor Agitation [∗drug therapy]; Psychotic Disorders [∗complications; drug therapy;
psychology]; Quetiapine Fumarate [therapeutic use]; Randomized Controlled Trials as Topic; Risperidone [adverse effects; ∗therapeutic
use]; Tranquilizing Agents [therapeutic use]; Valproic Acid [therapeutic use]
MeSH check words
Humans
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